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Abstract 
Background 
Venous insufficiency is very common and causes significant quality of life (QoL) 
impairment.  Conventional open surgery featuring junction ligation, stripping of 
the axial vein and phlebectomy is known to offer significant benefits over 
conservative management; resulting in improved QoL.  Additionally this treatment 
has been shown to be highly cost-effective.  Despite these advantages, surgery is 
associated with significant post-operative morbidity; in the form of pain and 
immobility, even in the absence of complications.  Additionally, in the long term; 
high recurrence rates have marred these promising early results, eventually 
returning patients to their pre-operative state.  Unsurprisingly recurrence is 
unpopular with patients and patient satisfaction has been observed to be 
disappointingly low. 
At the end of the 20th century, new minimally invasive endovenous interventions 
were developed.  Rapidly gaining popularity; it was hoped that they could address 
some of the limitations of surgery.  Following initial cases series; the endothermal 
technique of endovenous laser ablation (EVLA) appeared to have the highest 
technical efficacy with a good safety record. 
Objectives 
Three studies were performed with the aim of perfecting the ablative procedure 
and evaluating it against the gold standard of conventional surgery.   
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Study 1 was designed to establish the optimal management of saphenous 
tributaries and perforators following ablation of the saphenous axis.  
Study 2 was designed to directly compare the outcomes of EVLA with surgery to 
establish whether EVLA can match the effectiveness of surgery, whilst addressing 
its limitations. 
Study 3 was designed to explore the association between the magnitude of energy 
delivered during EVLA, procedural safety and periprocedural morbidity; in the 
context of evidence suggesting lower recanalisation rates following more 
aggressive use of laser energy. 
Methods 
Studies 1 and 2 were randomised clinical trials.  Participants had primary, 
symptomatic, unilateral venous insufficiency, with isolated saphenofemoral 
junction incompetence, leading to reflux into the great saphenous vein (GSV).  
Study 1 randomised 50 patients to EVLA alone (Control) or EVLA with concomitant 
ambulatory phlebectomies (EVLTAP).  Study 2 randomised 280 patients equally 
into groups receiving either surgery or EVLA.  Outcomes were: QoL, Venous 
Clinical Severity Score (VCSS), technical success, requirement for secondary 
procedures, pain scores, time taken to return to normal function, recurrent 
varicose veins on clinical examination, patterns of reflux on duplex ultrasound 
examination, and the effect of recurrence on quality of life.  Assessments were at 
1, 6, 12 and 52 weeks after the procedure.  
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Study 3 used linear and logistic regression models to study the effect of energy 
delivery on outcome. The models controlled for age, gender, BMI, pre-operative 
QoL and vein dimension. The outcomes were QoL, complications, recovery time, 
pain scores and analgesia requirements.  The sample size calculation established 
that 115 patients would be required to detect any significant relationship. 
Results 
Study 1: EVLTAP took longer, but significantly decreased the requirement for 
subsequent interventions.  There was no impairment in immediate post-
procedural pain or QoL with EVLTAP.  Median (IQR) Venous Clinical Severity Score 
(VCSS) at 3 months was lower (better) for EVLTAP than for Control (0 (0-1) versus 2 
(0-2); P < 0.001), with lower (better) disease specific QoL (Aberdeen Varicose Vein 
Questionnaire (AVVQ) scores) at 6 weeks (7.9 (4.1-10.7) versus 13.5 (10.9-18.1); P 
< 0.001) and 3 months (2.0 (0.4-7.7) versus 9.6 (2.2-13.8); P = 0.015).  At 1 year, 
there were no differences in VCSS or AVVQ scores. 
Study 2:  Both groups had significant improvements in VCSS after treatment (P < 
0.001), which resulted in improved disease-specific QoL (AVVQ, P < 0.001) and 
quality-adjusted life year (QALY) gain (P < 0.001).  The pain and disability following 
surgery impaired normal function, with a significant decline in five of eight SF-36 
domains (P < 0.001 to P = 0.029).  Periprocedural QoL was relatively preserved 
following EVLA, leading to a significant difference between the two treatments in 
pain scores (P < 0.001), six of eight SF-36 domains (P = 0.004 to P = 0.049) and 
QALYs (P = 0.003).  As a result, surgical patients took longer to return to work and 
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normal activity (14 versus 3 days; P < 0.001).  Complications were rare.  Initial 
technical success was greater following EVLA: 99.3 versus 92.4% (P = 0.005).  
Surgical failures related mainly to an inability to strip the above-knee GSV.  The 
clinical recurrence rate at 1 year was lower after EVLA:  4.0 versus 20.4% (P < 
0.001).  The number of patients needed to treat with EVLA rather than surgery to 
avoid one recurrence at 1 year was 6.3 (95 per cent confidence interval 4.0 to 
12.5).  12 of 23 surgical recurrences were related to an incompetent below-knee 
GSV and ten to neovascularisation.  Of five recurrences after EVLA, two were 
related to neoreflux in the groin tributaries and one to recanalisation.  Clinical 
recurrence was associated with worse QoL (AVVQ scores) (P < 0.001). 
Study 3:  232 patients were included. The mean (range) age was 50 (18-83) years. 
63% were women. The mean (range) energy delivery was 89.8 (44.5-158.4) Jcm-1.  
There was no significant effect on any outcome related to increasing energy 
delivery. 
Conclusions 
Concomitant phlebectomy with EVLA prolonged the procedure, but reduced the 
need for secondary procedures and significantly improved quality of life and the 
severity of venous disease.  This supports a recommendation that phlebectomy is 
performed routinely in conjunction with EVLA. 
EVLA was as effective as surgery for varicose veins, but importantly had lower 
periprocedural morbidity as evidenced by less negative impact on early post-
intervention QoL and furthermore clinical recurrence rates were also significantly 
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lower than observed following conventional surgery.  This suggests that EVLA with 
phlebectomy is superior to conventional surgery in the management of primary 
superficial venous insufficiency. 
Study 3 clearly confirms that EVLA is a safe procedure and that for the range of 
energies studied, there was no evidence demonstrating an increase in 
complication rates or the periprocedural morbidity of EVLA.  
These findings support the adoption of EVLA and concomitant phlebectomy as the 
gold standard treatment for primary superficial venous insufficiency. 
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Chapter 1 - Introduction 
Opening Statement 
The venous system itself, along with its associated diseases; is by its very nature 
variable and inconsistent.  This chapter draws from over half a century of detailed 
research, but in many regards a clear understanding remains elusive.  The aim of 
this introduction is to discuss the highest quality of evidence available, analysing 
for points of consensus and contradiction, in order to set the scene for three new 
studies.   Each of these studies aims to answer a specific management question, 
with the intention of improving the care received by current and future suffers of 
venous disease.  
 
1.1 The Venous System  
History 
An awareness of the importance of the circulatory system can be traced back as 
early as prehistoric times; where cave paintings of bison and mammoth display an 
indication of the anatomical position of the heart.  A useful target for hunters; 
haemorrhage was quickly linked to death and as time passed, the flow of blood 
became linked to the fundamental concepts of life, spirituality and medicine1.  
The early writing on the circulation, present in the Ebers Papyrus (written around 
1550BC; thought to be a transcription of a documents from around 3400BC), were 
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developed over time by giants such as Hippocrates and Galen, before the 17th 
Century science of William Harvey and Marcelo Malpighi established the basic 
structure of the circulatory system known today.   
The first documented attempts at the treatment of varicose veins also come in the 
Ebers papyrus and noted that surgery upon “leg serpents” can result in fatal 
bleeding.  Ambulatory hook phlebectomy was performed by the Romans in the 
first century and a primitive form of ligation and stripping described by Albucasis 
of Cordova towards the end of the first millennium.  This technique was developed 
and popularised by Friedrich Trendeleburg at the end of the 19th century, where 
saphenous ligation led to around five weeks hospitalisation.  The first varicose vein 
operation to be performed under anaesthetic was done so in Finland in 18972.  
Invagination stripping was introduced and developed by Keller and Mayo 15 years 
later3,4.  With the exception of the introduction of modern anaesthetic techniques, 
the concepts surrounding surgery for superficial venous insufficiency (SVI) 
changed little until the end of the 20th century.   
Sclerotherapy was described by Chassaignac in 1855, but did not become popular 
until the middle of the 20th century and this was relatively short lived, due to high 
recurrence rates and side-effects.  There was a renaissance of this approach with 
the development of foam sclerotherapy at the turn of the 21st century.   
The management of leg ulcers again has its origins in ancient times with bandaging 
known to have been used since at least 3500BC5.  In the fourth century BC, 
Hippocrates recommended regular cleaning, debridement and removal of excess 
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granulation tissue and noted that excess moisture was detrimental.  He also 
observed that incisions made into skin with the changes of chronic venous 
insufficiency may result in ulcer formation.  Celsus is thought to be the first to 
recommend compression of ulcers in the first century and despite many 
subsequent attempts at surgical techniques and topical treatment, nothing 
beyond compression to date has been shown to improve venous ulcer healing 
rates other than the treatment of active infection. 
 
Anatomy and Physiology 
Blood delivers oxygen, nutrients and hormones to the tissues whilst passing 
through the capillary network.  Following this, deoxygenated blood carrying 
metabolites, leaves the capillaries; entering into the systemic venous tree.  The 
peripheral venous system can be divided anatomically into the superficial venous 
system, which is located within the superficial tissues and the deep venous 
system, which typically accompanies the arterial tree, beneath fascial planes, deep 
in the body.  The superficial veins drain into the deep system, either at junctions or 
via fascial perforating veins, and the deep veins then return blood to the right 
atrium of the heart.  Venous anatomy is characteristically variable.  The 
terminology used below is consistent with international consensus6.   
Considering the lower limb, the deep venous system commences with the medial 
and lateral plantar veins in the sole of the foot.  These unite behind the medial 
malleolus to form the posterior tibial vein, which ascends the leg adjacent to the 
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posterior tibial artery.  A similar arrangement is seen with the anterior tibial and 
peroneal veins, which commence as a confluence of the venae comitantes of their 
accompanying nominate artery and also ascend with the arteries until the three 
vessels to unite around the level of the knee to form the popliteal vein, which 
continues to become the superficial femoral vein (SFV), ascending onwards in the 
thigh adjacent to its artery.  The profunda femoris vein commences deep in the 
thigh and accompanies its artery to the groin where it unites in the groin with the 
SFV to become the common femoral vein (CFV) and onwards through the iliac 
veins to the inferior vena cava and then the right atrium of the heart.   
Far more anatomical variations exist within the superficial veins of the lower limb, 
but it usually contains 2 systems or axes.  As the sole of the foot is often placed 
under significant pressure, the majority of the venous drainage of the foot is into 
the dorsal venous arch, running in the subcutaneous tissues over the metatarsal 
heads.  The medial end of this arch drains into the first axis: the great saphenous 
vein (GSV).  This is the longest vein in the body and the most frequently affected 
by superficial insufficiency.  The GSV passes anterior to the medial malleolus and 
ascends the leg accompanied by the saphenous nerve in the superficial tissues 
medial to the tibia, looping posteriorly at the level of the medial condyle of the 
femur and continuing in the medial thigh.  In the groin, it unites with tributaries 
corresponding to the arterial branches of the common femoral artery, before 
piercing the cribiform facia covering the saphenous opening (approximately 3cm 
below and lateral to the pubic tubercle) and terminates by draining into the CFV at 
the saphenofemoral junction (SFJ).  Throughout its course the GSV unites variably 
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with other superficial tributaries.  The anterior (accessory) saphenous vein (ASV) is 
one of the most common.  This is often seen originating around the lateral border 
of the knee, although sometimes originates as low as the lateral end of the dorsal 
venous arch.  Occasionally this vein may also course down the medial aspect of the 
thigh, anterolateral to the GSV following its course.  In this instance its origin is 
typically a confluence of small tributaries around the knee.  There is usually an in-
line GSV axis passing uninterrupted from the foot (in some cases this may be 
hypoplastic), but this pattern of ASV is commonly mistaken for the GSV itself 
(Some surgeons will call this a duplex GSV; a true duplex GSV is rare).  The ASV 
may drain into the GSV in the thigh at any point from the SFJ down, but is typically 
at or near the junction itself.  Another variable tributary of note is the Giacomini 
vein, which is discussed below. 
The small saphenous vein (SSV) originates from the lateral side of the dorsal 
venous arch and accompanies the sural nerve as it passes posterior to the lateral 
malleolus, then upwards in the posterior midline of the leg.  Its termination 
commonly occurs by piercing the fascia of the popliteal fossa to drain into the 
popliteal vein at the saphenopopliteal junction (SPJ), however this junction is 
highly variable and the vein may terminate as low as the mid calf.  The SSV may 
extend cranially beyond the SPJ; in which case it is known as either a cranial 
extension of the SSV which terminates by piercing the fascia in the posterior thigh 
to drain into the deep system or the Giacomini vein which communicates with the 
GSV system occasionally joining the GSV at or about the SFJ.  In some cases, the 
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SSV doesn’t terminate at or below the popliteal fossa (i.e there is no junction with 
the deep venous system), but continues on as described above.    
The purpose of the systemic venous system is primarily to return blood back to the 
heart so that it can be delivered into the pulmonary circulation.  The systemic 
venous system contains approximately 60% of the total blood volume with an 
average pressure of around 5-10 mmHg.  Mechanical factors (discussed below), 
alongside the autonomic nervous and endocrine systems, control the rate at which 
blood is delivered to the right atrium.  Through its effects upon myocardial 
contractility via the Starling mechanism; venous return is one of the factors 
responsible for determining cardiac output.   
The mechanical factors at work are the muscle and respiratory “pumps.”  As most 
venous flow is against gravity; these pumps are necessary to allow successful 
antegrade flow towards the heart.  The peripheral deep veins run in proximity to 
skeletal muscle.  During standing without skeletal muscle activity, venous 
pressures in the legs are determined by the hydrostatic component and capillary 
flow, and they may reach 80 to 90 mm Hg7.  Contraction of these muscles, 
compresses the relatively thin walled veins, resulting in flow within the vessel.  
Even very small leg movements can provide this important pumping action.  
Additionally during inspiration, expansion of the volume of the thorax results in a 
decrease in intra-thoracic pressure, also resulting in antegrade venous flow.  
Competent venous valves ensure that venous blood flows toward the heart, 
thereby emptying the deep and superficial venous systems and reducing venous 
pressure, usually to less than 30 mm Hg7.   
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The success of these mechanisms relies upon the valves found in healthy veins, 
preventing retrograde flow and these valves are variable in number and location.  
There are typically more valves in the lower limb than in the upper limb, which 
seems intuitive as there is a shorter column of blood below the heart upon which 
gravity will act; promoting retrograde flow.  In the superficial system; the GSV has 
a median of 6 valves with a range of 4-25 in its full length8.  85% of people have a 
valve within 2-3cm of the SFJ8.  The SSV  has a median of 7 valves, with a range of 
4-139.  In general the number of valves in the lower limb also tends to decrease 
above the knee and in the deep system; the CFV and external iliac veins have only 
one valve between them in about 63% of cases9, whilst in 17-37% there is no valve 
between the CFV and the heart10-12. 
 
 
1.2 Venous Insufficiency 
Definition 
Venous insufficiency, otherwise known as incompetence or reflux, occurs when 
the veins become diseased, interfering with the normal mechanisms of antegrade 
flow.  This failure of efficient venous return, coupled with turbulent and 
retrograde flow within the vessels results in a relative venous hypertension.   
Venous hypertension promotes the development of a spectrum of clinical 
syndromes from simple varicose veins to ulceration and these syndromes are 
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associated with symptoms, which impair a sufferer’s health related quality of life 
(QoL). 
 
The Scale of the Problem 
Venous disease is one of the most common conditions facing western health care 
systems (See: Prevalence p58).  This high prevalence along with the chronic nature 
of its complications, such as venous ulceration, leads to extremely high costs to 
society.  The direct costs account for 1-3% of the entire healthcare budget13-15.  In 
the USA alone, treatment of venous ulcers costs around $3 billion per year16.  
 
Clinical Features 
Lower limb venous insufficiency causes a relative venous hypertension, which 
through the proposed mechanisms outlined below (see Pathophysiology, p48) 
results in pathological, clinically evident features.  Clinical studies have clearly 
shown this association17-23 and have related the number of incompetent venous 
systems to the clinical severity of disease19,21-23.  
The clinical features of venous insufficiency lie on a spectrum of severity, although 
this spectrum is by no means linear or continuous and clinical features may not be 
cumulative or additive; some patients may present with severe features in the 
absence of lesser findings24.   
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The following clinical features are commonly seen (these definitions are consistent 
with international consensus25): 
 Telangectasia (thread veins, spider veins, and hyphen webs) - These 
represent tiny intradermal venules less than 1mm in diameter 
 Reticular vein – small dilated “bluish” subdermal vein between 1 and 
2.9mm in diameter, usually tortuous, can be difficult to distinguish this 
from a normal subdermal vein in someone white thin transparent skin 
 Varicose vein – subcutaneous dilated vein 3mm in diameter or larger.  
They are frequently elongated and tortuous, with intermittent “blowouts”, 
but are defined by the presence of reflux and may be tubular in 
morphology 
 Corona phlebectatica (malleolar flare) – a fan shaped pattern of 
telangectasia on the ankle or foot.  Thought to be an early sign of advanced 
venous disease 
 Oedema – increased volume of fluid in the skin and soft tissues of the leg.  
Commonly starts distally and moves more proximally with increasing 
venous dysfunction.  Classically this is “pitting oedema”, with firm digital 
pressure leaving an indentation in the soft tissues 
 Eczema – an erythematous dermatitis, often appears minor, although may 
be associated with significant itching and discomfort.  In extreme cases it 
may progress to blistering and weeping 
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 Pigmentation (haemosiderosis) – a brownish discolouration of the skin, 
usually permanent, this is usually seen around the ankle, but is also seen in 
proximity to varicose veins and incompetent perforators 
 Lipodermatosclerosis (LDS) – chronic inflammation and fibrosis of the skin 
and subcutaneous tissues, resulting in a tight, contracted, “woody” leg on 
examination.  Occasionally results in significant contractures of the Achilles 
tendon.  This is a sign of severe chronic venous disease 
 Atrophy blanche – localised areas of atrophic, white skin, often 
surrounded by telangectasia and pigmentation.  Some authors distinguish 
this from the white scarring left by ulceration, others do not.  Either way 
this is a sign of severe chronic venous disease 
 Venous ulcer – full-thickness skin loss, usually around the ankle, which fails 
to heal spontaneously and is propagated by continuing venous 
hypertension and the changes associated with chronic venous disease 
 
Eczema, pigmentation, LDS and atrophy blanche are often referred to as trophic 
skin changes, whilst the presence of oedema, eczema, pigmentation, LDS, atrophy 
blanche and ulceration are usually implied by the use of the term chronic venous 
insufficiency (CVI). 
Typically ulcers start with trivial wounds but tend to be stubborn, chronic wounds; 
difficult to heal and prone to relapse.  In a UK based population study, the median 
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duration of ulceration was 9 months, 20% of ulcers had not healed in 2 years, and 
66 percent of patients had recurrent episodes of ulceration lasting longer than five 
years26.  
The clinical classification systems, alongside the symptoms and QoL impairment 
associated with venous insufficiency, will be discussed later (See: Quality of Life 
Impairment, p40, The Clinical Assessment of Patients with Superficial Venous 
Insufficiency, p79 and Assessing the Quality of life Impairment Associated with 
Superficial Venous Insufficiency, p84). 
 
Patterns of Reflux 
Venous insufficiency may involve the superficial venous system (superficial venous 
insufficiency – SVI), the deep venous system (deep venous insufficiency – DVI) or 
both causing mixed venous insufficiency.   
It is clear that SVI is more common than DVI or mixed insufficiency and that when 
the superficial veins are considered, the GSV is affected in many more cases than 
either the SSV or non-saphenous veins.   
In a study of women with uncomplicated varicose veins27; of 590 limbs, 80% had 
GSV or SSV reflux.  77% had GSV reflux (in 60% this was isolated), 20% had SSV 
reflux (but only 3% were isolated) and 17% had combined reflux.  Additionally non-
saphenous reflux was noted in 20%.  Deep venous reflux was only noted in 2% and 
perforating vein reflux in 23%. 
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This pattern was also demonstrated at a population level in the Bonn vein study22 
(Table 1) and confirmed in a patient population by Myers et al23 (Table 2).  
 
Site of 
Reflux 
No disease 
(n=290) 
Thread 
veins 
(n=1777) 
VV  
(n=432) 
Oedema 
(n=407) 
Trophic 
skin 
changes 
(n=86) 
Ulcer 
(n=22) 
Sy
st
em
 
Su
p
er
fi
ci
al
 
2.4 
(1.0-4.9) 
5.0 
(4.1-6.2) 
49.2 
(44.3-54.1) 
24.1 
(19.9-28.6) 
67.1 
(55.8-77.1) 
72.7 
(49.8-89.3) 
D
ee
p
 
16.6 
(12.5-21.3) 
9.8 
(8.4-11.2) 
18.8 
(15.2-22.8) 
12.3 
(9.3-15.9) 
24.1 
(15.4-34.7) 
54.5 
(32.2-75.6) 
Su
p
er
fi
ci
al
 v
ei
n
 
G
SV
 
2.1 
(0.8-4.4) 
3.4 
(2.6-4.3) 
32.2 
(27.7-36.9) 
16.5 
(13.0-20.6) 
41.7 
(31.0-52.9) 
57.1 
(34.0-78.2) 
SS
V
 0.0 
(0.0-2.5) 
0.6 
(0.3-1.1) 
8.6 
(6.2-11.7) 
3.0 
(1.5-5.1) 
12.9 
(6.6-22.0) 
22.7 
(7.8-45.4) 
D
ee
p
 v
ei
n
 
FV
 13.1 
(9.4-17.5) 
6.3 
(5.2-7.5) 
10.0 
(7.3-13.2) 
6.9 
(4.6-9.8) 
12.8 
(6.6-21.7) 
36.4 
(17.2-59.3) 
P
V
 3.8 
(1.9-6.7) 
3.5 
(2.7-4.5) 
9.7 
(7.1-12.9) 
6.6 
(4.4-9.5) 
12.9 
(6.6-22.0) 
36.4 
(17.2-59.3) 
P
TV
 0.0 
(0.0-1.3) 
0.2 
(0.1-0.6) 
0.5 
(0.1-1.7) 
0.5 
(0.1-1.8) 
3.6 
(0.7-10.1) 
25.0 
(8.7-49.1) 
Table 1: The association between venous insufficiency  and severity of venous disease by venous 
system and individual vein (as a percentage (95%CI))
22
.  These figures are irrespective of the 
coexistence of insufficiency elsewhere. VV – uncomplicated varicose veins, GSV – great 
saphenous vein, SSV – small saphenous vein, FV – femoral vein, PV – popliteal vein, PTV – 
posterior tibial vein 
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Site of Reflux 
Uncomplicated 
VV 
LDS Ulcer 
System 
Superficial only 429 (55%) 27 (39%) 36 (38%) 
Deep only 12 (2%) 5 (7%) 8 (8%) 
Superficial and deep 137 (18%) 24 (34%) 46 (48%) 
Superficial 
vein 
GSV only 327 (58%) 29 (57%) 33 (40%) 
SSV only 104 (18%) 9 (18%) 21 (26%) 
GSV and SSV 135 (24%) 12 (25%) 28 (34%) 
Deep vein 
CFV 95 (61%) 14 (48%) 30 (56%) 
SFV 59 (38%) 11 (38%) 27 (50%) 
PV 79 (51%) 12 (41%) 33 (61%) 
PTV 33 (21%) 12 (41%) 24 (44%) 
Table 2:  The association of venous insufficiency with severity of disease by system and then each 
system by vein
23
 (as number of patients (percentage)).  VV – varicose veins, LDS – 
lipodermatosclerosis, GSV – great saphenous vein, SSV – small saphenous vein, CFV – common 
femoral vein, SFV – superficial femoral vein, PV – popliteal vein, PTV – posterior tibial vein 
 
The methodology of the second study was such that many patients with obvious 
GSV reflux on hand-held Doppler were excluded (as they did not go on to have 
DUS mapping prior to intervention) and therefore the authors believe that the 
true rates of GSV insufficiency will be higher with a smaller proportion attributable 
to the SSV. 
Studies of isolated SVI have unsurprisingly shown the same patterns; with 67-86% 
of patients having GSV insufficiency (48-60% in isolation) and 3-33% having 
isolated SSV insufficiency19,21,27-32.  Currently, there is no explanation for why the 
GSV is affected more commonly than the SSV.  Some authors suggest this may be 
due to the greater number of tributaries draining into the GSV and the higher 
number of valves in the SSV (per unit length; each vein contains a similar number 
of  valves) may be responsible19,33,34. 
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The degree of reflux influences the magnitude of venous hypertension and is 
therefore associated with a worsening in clinical severity.  The Bonn vein study, 
the Edinburgh vein study and Myers et al all demonstrated that increasing 
numbers of insufficient trunks are associated with clinical severity17,22,23.  Increases 
in the diameter of the trunks themselves is also associated with increased 
severity21, as is the length of the incompetent segment within the vein19 (Table 3).   
Reflux in particular segments of vein is especially important as demonstrated by 
the greater association of CVI with below knee GSV insufficiency19 (Table 3) and 
SFJ, SPJ and perforator incompetence21,23.  
 
Extent of reflux Ache Swelling Skin Changes Ulceration 
Above knee only 11 (46%) 8 (33%) 1 (4%) 0 
Below knee only 12 (57%) 13 (62%) 10 (48%) 0 
Full Length 63 (81%) 71 (91%) 42 (58%) 6 (8%) 
Total 86 (70%) 92 (75%) 53 (43%) 6 (5%) 
Table 3: The association of the extent of isolated great saphenous vein reflux with the symptoms 
and signs of venous insufficiency 
 
Previously it was thought that venous ulceration was due to secondary DVI, but a 
meta-analysis of 13 studies of 1153 legs with venous ulceration found isolated SVI 
in 45%, isolated DVI in 12% and 43% had reflux in both, confirming that SVI has an 
important part to play in the pathogenesis35.  This has important implications 
when considering the treatment of venous ulceration, as SVI is eminently 
amenable to treatment (See Interventional Treatment, p115). 
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Quality of Life Impairment  
Venous insufficiency rarely threatens a patient’s life.  The rationale for 
intervention therefore must be with the aim of improving QoL.  Consequently it is 
of paramount importance that the QoL impairment associated with SVI is 
investigated to understand the nature of this association, whether this impairment 
is addressed by intervention, how to select which patients will benefit and 
whether such improvements are robust over time.  
Patients with SVI complain of a range of symptoms; which are often fairly non-
specific and it can be challenging to delineate which of these symptoms are 
related specifically to their venous insufficiency. Similar symptoms are also 
common in the background population who do not have demonstrable 
insufficiency.  This issue was highlighted and rationalised during population level 
studies.  Early work was fairly crude and was undertaken prior to the widespread 
use of validated disease specific QoL analysis in this area.  The focus of such 
studies was to link simple physical symptoms to venous disease, rather than a 
specific quantification of the strength of this association, or the contribution of 
individual elements to the overall morbidity and impact upon a sufferer’s daily life 
and career.  Functional and psychosocial issues were not addressed.  Typically 
venous symptoms are worse when the legs are dependant, particularly when 
standing for long periods and are usually relieved on elevation.  This clearly has 
occupational implications. 
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The Edinburgh vein study studied patients randomly drawn from the general 
population36.  They found that symptoms typically associated with venous disease 
were common, increased with age and were significantly more prevalent in 
women.  For example 44.9% of women with no evidence of varicose veins 
complained of aching legs.  Nonetheless, symptoms were shown to be more 
common with worsening degrees of varicose veins, particularly aching, heaviness 
and itching.  The strength of this association was weak, particularly in men and the 
authors concluded that history taking alone was no enough to gauge who would 
and would not benefit from treatment.  This analysis relied upon very simple 
questionnaire outcomes; there was no detailed enquiry of the QoL impairment 
and no validated QoL assessment scores were used.  Some of the patients without 
clinically obvious varicose veins may have had early subclinical disease with 
underlying insufficiency which had not yet manifested itself in varicose veins.  
Another population based study found a stronger association and was able to 
quantify this; varicose veins were an independent risk factor for “venous 
symptoms” OR 2.37 (1.19-4.72) – men and 2.11 (1.43-3.13) – women37.  The 
extent of actual reflux seen on DUS has also been linked to the proportion of 
patients reporting symptoms (Table 3, p39)19. 
Women are significantly more likely to report symptoms than men (51.3% of 
women compared with 20.4% of men)37; which has also been noted on QoL 
modelling, where women reported a greater disease specific QoL impairment than 
men, controlling for the clinical severity of disease and other demographic and 
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anatomical factors38.   This is perhaps the motivation behind women presenting 
earlier and in greater numbers, for treatment. 
Validated instruments designed to study QoL have been developed and have 
offered much more insight into the nature of the QoL impairment associated with 
venous disease.  The instruments themselves will be discussed in detail in a later 
section (See Assessing the Quality of life Impairment Associated with Superficial 
Venous Insufficiency p84).  Detailed study using such instruments has 
demonstrated not just the physical symptoms and disability, but also the 
emotional impact; leading in some cases to depression and social isolation, 
particularly in advanced disease39-41. 
Large studies have linked venous disease to a marked deterioration in QoL, which 
becomes more profound with increasing severity42,43.  A QoL modelling study of 
561 patients44 clearly demonstrated that increasing severity of disease had a 
greater impact upon a range of QoL measures (Figure 1 - Figure 7) (For details of 
these outcome measures and CEAP clinical grading see The CEAP Classification p80 
and Assessing the Quality of life Impairment Associated with Superficial Venous 
Insufficiency p84)  
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Figure 1: Aberdeen Varicose Vein Questionnaire (AVVQ) scores by Clinical aEtiologic Anatomic 
Pathophysiologic (CEAP) clinical grade. *P < 0.001, †P = 0.006 (intergroup Mann–Whitney U 
testing with Bonferroni correction).  Higher AVVQ scores represent worse disease specific QoL
44
. 
 
Figure 2: Physical function scores by Clinical aEtiologic Anatomic Pathophysiologic (CEAP) clinical 
grade. Lower physical function scores represent worse QoL
44
. 
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Figure 3: Role limitation due to physical disability scores by Clinical aEtiologic Anatomic 
Pathophysiologic (CEAP) clinical grade. Lower role-physical scores represent worse QoL
44
. 
 
 
 
Figure 4: Bodily pain scores by Clinical aEtiologic Anatomic Pathophysiologic (CEAP) clinical 
grade. Lower bodily pain scores represent worse QoL
44
. 
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Figure 5: General health scores by Clinical aEtiologic Anatomic Pathophysiologic (CEAP) clinical 
grade. Lower general health scores represent worse QoL
44
. 
 
 
Figure 6: Vitality scores by Clinical aEtiologic Anatomic Pathophysiologic (CEAP) clinical grade. 
Lower vitality scores represent worse QoL
44
. 
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Figure 7: Euroqol index (QALY) scores by Clinical aEtiologic Anatomic Pathophysiologic (CEAP) 
clinical grade. Lower EQ5D scores represent worse QoL
44
. 
 
Disease specific QoL measurement (in this case with the AVVQ) as the name 
implies, is the most sensitive to the direct QoL impairment associated with the 
disease itself.  It is interesting to note that even with a sample size this large, there 
was no appreciable difference between patients with uncomplicated varicose 
veins (C2) and those with skin changes short of ulceration (C3 & C4).  This was an 
important finding, as it decouples objective clinical severity from the impairment 
in QoL resulting from these grades of disease.  Another study found similar results 
and also discovered that QoL impairment could not be predicted from 
haemodynamic outcomes such as venous refill times45.  This leads to the 
conclusion that patients cannot be selected for intervention based upon any 
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clinician observed outcome in common use currently, but the decision must be 
made based upon the patient reported symptoms and their consequent 
impairment of health related QoL. 
When considering the generic scores, the QoL impairment was observed in 
predominantly physical (rather than psychological) domains.  Cosmetic concern is 
most closely associated with mental health46, however this domain was not 
primarily affected in this and other studies46-48.  This domain was unaffected in this 
study.  With regard to index utility scores (EQ5D), a patient with uncomplicated 
varicose veins will experience a loss of 0.7 (95% CI 0.3 to 1.2) QALYs over 10 
years (undiscounted) compared with someone in full health, if left untreated.  This 
rises to 1.0 (0.5 to 1.6) QALYs with skin changes and 2.0 (0.5 to 3.6) QALYs with 
venous ulceration.  These results are of a clinically significant magnitude49.  The 
REACTIV trial50 demonstrated a 1-year improvement in EQ-5D scores of 0.1 
following surgery, suggesting that the estimated morbidity observed in the 
present analysis was indeed reversible.  To contextualize these results, patients 
with symptomatic disease can have bodily pain scores comparable to those of 
reference patients with recent acute myocardial infarction; whilst those patients 
with venous ulceration can suffer physical function and role limitation comparable 
to those in patients with congestive cardiac failure or chronic obstructive 
pulmonary disease51.  Such profound QoL impairment has also be noted by other 
authors52 and provides a clear mandate for the development and application of 
interventions to address this suffering and increase the health and well-being of 
the population. 
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Pathophysiology 
A normal venous system depends on the integrity of the valves, vein wall and the 
haemodynamics of venous blood flow. These components are interdependent and 
the disruption of one affects the integrity of the others53. 
Insufficiency is the result of valvular dysfunction permitting retrograde venous 
flow in the leg.  The aetiology may be congenital or secondary to thrombosis, but 
the vast majority of cases have no clear underlying cause and are said to be 
primary (at least 80% of cases54).  As disease severity increases, the aetiology and 
the pathophysiology become increasingly multifactorial, for instance in venous 
ulcer disease, the association of previous DVT may be as high as 32%35.   
Congenital causes include Klippel-Trenaunay syndrome (manifesting as varicose 
veins, limb hypertrophy and dermal capillary haemangioma).  Such patients have a 
range of venous abnormalities including atresia, agenesis, valvular incompetence 
and venous aneurysms.  Klippel-Trenaunay syndrome, along with other congenital 
disorders associated with venous insufficiency is rare55-57. 
Whilst insufficiency is the most common cause of venous dysfunction, venous 
obstruction may also exist in isolation or in conjunction with it.  Obstruction may 
be mechanical or functional (in the case of muscle pump failure).  True mechanical 
obstruction is very rare, being involved in less than 0.2% of cases23. 
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The Pathogenesis of Primary Venous Insufficiency 
The descending theory is the classical hypothesis of the pathogenesis of primary 
venous insufficiency.  This constitutes a mechanical failure of the junctional 
valvular structure, thought to be caused by back pressure acting on a background 
of years of battling against gravity in a bipedal gait, perhaps exacerbated by 
increased intra-abdominal pressure, secondary to constipation, pregnancy or 
chronic cough.  After the proximal valves fail, increasing pressure is then 
propagated down the vein’s axis causing dilatation and degradation of the vein 
and subsequent valves, which fail one after another.  This appears to explain the 
most commonly seen patterns of SVI and is supported by pathological evidence of 
absence, deformity and distortion of the valves at a macroscopic level58,59, in 
addition to structural changes and inflammatory infiltration60,61 at a cellular level.    
The descending theory however, fails to explain some inconsistencies in the 
patterns of reflux observed.  Although it is common to see incompetence at the 
SFJ with reflux going down the GSV, it is also common to observe contradictory 
patterns20,62: 
 Varicose veins with no incompetence in the trunk, junction or perforator 
 Axial incompetence and dilatation below competent valves   
In 1 study, 24% of 139 limbs with SVI had saphenous vein trunk or tributary reflux 
in the absence of an incompetent junction or perforator63.  In the Bonn vein study; 
a large population based epidemiological study, around half of those with 
uncomplicated varicose veins had no trunk insufficiency demonstrated22.  If left, 
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such patterns can be seen to progress proximally as well as distally30.  The concept 
of insufficiency starting low in the leg and propagating proximally is known as the 
ascending theory of venous insufficiency.     
This alternate theory cannot be explained by the proposed mechanism of a 
primary mechanical failure of the junctional valve and recent research has started 
to uncover a different, more intricate mechanism in action.   
The acute effects of increased venous pressure have been studied in animal 
models.  In rats, production of an arteriovenous fistula between the femoral artery 
and vein abruptly increased the pressure in the femoral vein to approximately 90 
mm Hg.  Although the valves were stretched immediately by the increased 
pressure, reflux did not occur until at least two days later and then increased with 
time in association with features of progressive inflammation.  This process 
culminated in morphologic changes in the valves; there were reductions in leaflet 
height and width, and some valves disappeared.  This suggests that valves can 
tolerate high pressures for limited periods, but when there is prolonged pressure-
induced inflammation, valve remodelling, loss and reflux occur64-66. 
Inflammation plays a key role in the pathogenesis of primary venous insufficiency.  
Rather than being a secondary change, it is possible that this may be a significant 
driver of the process.   
A vicious cycle exists (Figure 8): inflammation results in structural changes in the 
valves and the veins wall; weakening them.  This in turn causes incompetence, 
precipitating venous hypertension, which then drives further inflammation.  This 
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cycle can be initiated at any point in the venous system, but is often multifocal, 
with gradual propagation over time.   
 
 
 
Figure 8: The Vicious Cycle of the pathophysiology of primary venous insufficiency 
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Inflammation and Degradation of the Venous Structure  
Prolonged high pressure on the venous endothelium causes an imbalance in its 
endogenous humoral control of venous tone, resulting in relaxation67-70.  Over 
distension also causes endothelial cells to release inflammatory mediators and 
growth factors62,69,71,72.  Mast cells, macrophages and leukocytes are attracted to 
these areas of inflammation64-66,73-75, releasing superoxide anions and proteases 
which act to break down the extracellular matrix62,72, undermining the structural 
integrity of the vein wall.  The growth factors initiate remodelling of the structure 
of the vein wall62,69,72,76, which becomes stiffer and less elastic due to smooth 
muscle cell proliferation, collagen imbalance77 (more type I, less type III) and a 
reduction in the elastin content of the media78-82.  This is compounded by 
fragmentation of the collagen and elastic laminae82-87.  The smooth muscle cells 
themselves are also dysfunctional, with impaired contractile function, 
dedifferentiation and structural disorganisation88,89.  These processes may be 
mediated by dysfunctional apoptosis53 and it is this patchy distribution of 
stiffened, inelastic media alternating with structurally compromised, fragmented 
media, prone to distension, which gives varicose veins their classical appearance. 
Further damage to the extracellular matrix is mediated by matrix 
metalloproteinases (MMPs).  In health, the structural matrix of the vein is 
modelled by the competing actions of MMPs and their tissue inhibitors 
(TIMPs)68,69,90,91.  MMPs break down the constituents of the extracellular 
matrix68,91 and reduce venous tone92.  Normal homeostasis depends on balancing 
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the actions of MMPs and TIMPs, but inflammation and vein wall tension92-94 
causes imbalance of this mechanism, resulting in varicose veins64-66,91. 
 
Triggering the Cycle 
It is unclear what factors are responsible for the initiation of the pathological cycle 
of venous insufficiency, but it is possible that venous stasis and hypertension 
results in venous wall hypoxia, mechanical stress and changes in shear stress and 
mechanical load62,72.  
Venous stasis has 2 elements; increasing pressure and absence of normal flow.  
When a rat mesenteric venule was experimentally occluded, the effects of 
increased pressure could be separated from the effects of reduced flow by 
comparing regions on either side of the occlusion; flow was essentially zero at 
both sites, but only the upstream site had high pressure.  Leukocyte rolling, 
adhesion, and migration, as well as micro-haemorrhage and cell death, were all 
increased at the high-pressure site95, indicating that it may be pressure rather than 
absence of flow acting as an initiator. 
Venous valves are operated by pressure96.  Venous flow is normally phasic, and 
whilst a person is standing, valves open and close approximately 20 times per 
minute.  When the leaflets are fully open, they do not touch the sinus wall, causing 
flow to separate into an antegrade jet and a vortical flow into the sinus pocket 
behind the valve cusp.  This vortical flow prevents stasis in the pocket and exerts a 
shear stress upon all surfaces of the valve97.  Valve closure occurs when the 
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pressure caused by the vortical flow exceeds the pressure on the luminal side of 
the valve leaflet because of the antegrade flow.  This ensures that minimal reflux 
occurs and endothelial surfaces are not generally exposed to reverse blood flow.  
Pulsatile, laminar shear stress in the endothelium causes the release of factors 
that reduce inflammation and the formation of reactive free radicals.  By contrast, 
low or zero shear stress, caused by disturbed, turbulent or retrograde flow 
promotes inflammation and thrombosis98-101.  These processes also operate in the 
arterial systems, where they may underlie the observation that atherosclerotic 
lesions occur preferentially in regions of low or reversing shear stress102,103. 
It is not known for sure what triggers initiate the inflammatory events in venous 
valves and walls, but plausible mechanisms are now known.  Prolonged pooling of 
blood causes distension of lower limb veins.  This initiates inflammation and 
distorts venous valves, allowing leakage and exposing endothelial cells to flow 
reversal.  Venous stasis, even in the absence of reflux, produces regions of low or 
zero shear stress, whereas subsequent structural changes and irregularities in 
vessel walls may induce regions of disturbed and even turbulent flow.  All of these 
events can initiate and propagate inflammatory reactions described above.  
Overall, it appears that inflammatory processes involving leukocyte-endothelial 
interactions and triggered largely in response to abnormal venous flow are 
important in causing the adverse changes within venous valves and vein walls.  
The extent and rate of progression of the different changes will depend on the 
interplay of many factors, producing wide variation among patients. 
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The Pathogenesis of Chronic Venous Insufficiency  
The venous hypertension associated with CVI results in the oedema and skin 
changes which are apparent clinically.  Higher post-exercise venous pressure is 
associated with a greater severity of skin damage104.  A study of 236 limbs found 
that post-exercise venous pressures of less than 30 mm Hg are not associated with 
venous ulceration, whereas 100% of those with pressures of more than 90mm Hg 
had venous ulcers105. 
Venous hypertension increases the capillary hydrostatic pressure causing an 
imbalance in the net hydrostatic pressure across the capillary wall.  This increased 
net filtration pressure causes increased movement of protein-free plasma into the 
interstitium, resulting in oedema. 
There is greater uncertainty regarding the mechanisms behind trophic skin 
changes and two main hypotheses exist: the fibrin cuff and leukocyte trapping 
with inflammation: 
 
The Fibrin Cuff Hypothesis: Increased venous pressure transmitted to the 
capillaries results in elongation and widening of the pores between endothelial 
cells106, allowing the exudation of fibrinogen into the tissues107.  This, along with 
defective fibrinolysis108 causes fibrin cuffs to form around the capillaries.  These 
cuffs are then purported to interfere with gas exchange, resulting in tissue 
ischaemia and cell death109,110. 
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The Leukocyte Trapping Hypothesis:  A more contemporary hypothesis is centred 
on inflammation and can be traced back to the observation that the blood 
returning from feet that have been passively dependent for 40 to 60 minutes is 
depleted of leukocytes, especially in patients with chronic venous disease111,112.  
This finding suggests that leukocytes accumulate in the leg under conditions of 
high venous pressure.  It is likely that this is largely due to leukocyte adhesion to 
the capillary endothelium mediated by decreased shear force113 and up-regulation 
of adhesion molecules in response to venous hypertension114-116.  Evidence for this 
theory shows that in the presence of venous hypertension, levels of adhesion 
molecules on circulating leukocytes decreases, reflecting the trapping of these 
cells in the microcirculation.  Simultaneously, plasma levels of soluble adhesion 
molecules increases, demonstrating the shedding of these molecules from 
leukocyte surfaces during leukocyte-endothelial adhesion114,115.  Following 
trapping in the capillaries, the leukocytes then migrate into the tissues and are 
activated, initiating an intense inflammatory reaction, thought to be responsible 
for the skin changes117-120. 
During inflammation, tissue injury is mediated by increased expression and activity 
of MMPs (especially MMP-2) in LDS121 and in ulcers122,123.  In contrast, levels of 
TIMP-2 are lower in these conditions121,122, resulting in unrestrained MMP activity 
breaking down the extracellular matrix.  This process promotes ulcer formation 
and impairs healing. 
Shoab et al124 found that plasma levels of vascular endothelial growth factor 
(VEGF) are increased in patients with chronic venous disease, compared to 
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controls during venous hypertension induced by 30 minutes of standing and are 
higher in patients with CVI than those with uncomplicated varicose veins125.  VEGF 
is thought to cause morphological changes in LDS, making the skin capillaries 
elongated and tortuous and inducing proliferation of the capillary endothelium in 
more advanced cases126.  VEGF also increases microvascular permeability127.  
Pappas et al128 discovered elevated levels of active TGF-β1 in skin taken from the 
lower calf of patients with CVI, compared to skin from their thigh region or skin 
from the calves of controls.  This fibrogenic cytokine; stimulates collagen 
production by dermal fibroblasts, culminating in dermal fibrosis128.  Altered 
collagen synthesis by dermal fibroblasts in apparently healthy areas of skin in 
patients with varicose veins has also been reported129. 
Skin pigmentation is a product of capillary hyper-permeability; with extravasation 
of red cells leading to elevated levels of ferritin and ferric iron trapped inside 
phagocytes in affected skin130,131.  Rather than being a benign cosmetic problem, 
this process may cause oxidative stress, MMP activation, and the development of 
a microenvironment that exacerbates tissue damage and delays healing132.  
Supporting this view; the haemochromatosis C282Y mutation is associated with an 
increase in the risk of ulceration by a factor of nearly seven in patients with 
chronic venous disease133. 
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Epidemiology 
The only population based follow-up study to date, estimates the incidence of 
varicose veins to be 39 per 1000 years in men and 52 per 1000 years in women 
(between the ages of 40 and 89)134.  However, the chronic nature of venous 
disease escalates the prevalence; making it one of the most common ailments 
seen in developed countries.  Some aspects of venous disease, such as thread 
veins are so common that they are considered by many to be “normal”.   
 
Prevalence 
Much of the epidemiological data is old and estimates of the prevalence of clinical 
disease and the significance vary widely135 (Table 4).  There are a range of possible 
explanations for this:  There are methodological differences in the studies, with 
some using self-reporting of disease status, others clinical examination and some 
imaging investigations such as duplex ultrasound (DUS) (See: Assessing Anatomical 
and Haemodynamic Dysfunction, p100).  Early studies did not benefit from 
standardised classification systems such as the CEAP and venous clinical severity 
score (VCSS) (See: The Clinical Assessment of Patients with Superficial Venous 
Insufficiency, p79 ) and there was consequent disagreement regarding 
definitions135,136.  Additionally there were differences in sample selection 
methodology; with some using samples drawn from the general population and 
others using patient or occupational groups.  There were inconsistencies in the age 
and gender distributions, which can have a marked effect, when not corrected for 
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as these are independent associative factors in their own right (See below).  It is 
also plausible that a proportion of these differences may also be due to genuine 
geographical and ethnic differences in prevalence, along with lifestyle changes 
over the many years of research. 
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Year 
  
Country 
  
Sample 
Size 
Prevalence (%) 
Male Female 
1942 USA 536 40.7 73.2 
1958 Denmark 1684 18.4 38.0 
1966 Bohemia 15060 6.6 14.1 
1969 
England 504 
 
32.1 
Egypt 467 
 
5.8 
1970 New Zealand 232 25.0 42.0 
1972 
N. India 354 6.8 
 S. India 323 25.1 
 1973 USA 6389 12.9 25.9 
1973 Switzerland 610 
 
29.0 
1974 Switzerland 4376 57.0 68.0 
1975 New Guinea 728 5.0 0.1 
1975 
Tokelau Island 286 2.9 0.8 
Cook Island 
377 2.1 4.0 
417 15.6 14.9 
New Zealand 
721 33.4 43.7 
356 19.6 37.8 
1977 Tanzania 1259 6.1 5.0 
1978 Switzerland 4529 56.0 55.0 
1981 France 7425 26.2 
 1981 Czechoslovakia 696 
 
60.5 
1981 Israel 4802 10.4 29.5 
1986 Brazil 1755 37.9 50.9 
1988 Sicily 1122 19.3 46.2 
1989 Germany 2821 14.5 29.0 
1990 Japan 541 
 
45.0 
1992 England 1338 17.4 31.6 
1993 Finland 5568 18.0 42.0 
1994 Turkey 856 34.5 38.3 
1995 Finland 8000 6.8 24.6 
1998 Italy 1319 17.0 35.2 
1999 Scotland 1566 39.7 32.2 
2000 Croatia 1324 18.9 34.6 
2003 USA 2211 15.0 27.7 
2008 Germany / Lithuania 3072 31.4 
Table 4: Summary of studies of the estimated prevalence of varicose veins 
 
61 
 
In order to obtain reliable estimates for societal prevalence, samples must be 
taken without bias, from the general population.  Three high quality population 
based epidemiological studies, involving expert clinical assessment have been 
performed in recent years:   
The Edinburgh vein study18 selected an age stratified random sample from 12 
general practice registers.  There was a response rate of 54% giving a sample size 
of 1556.  It was found that minor stigmata of venous disease are incredibly 
common with 80% of subjects having evidence of thread veins.  Adjusting for age, 
39.7% of men and 32.3% of women had varicose veins, and 9.4% of men and 6.6% 
of women had evidence of CVI. 
French population study37  randomly drew household phone numbers from four 
geographical areas of France for inclusion in a study on Reynaud’s phenomenon.  
Each household was invited to enrol aiming for a target sample size of 2000.  In a 
subsequent offshoot study; 835 of these patients were examined for the presence 
of venous disease and analysis of risk factors.  30.1% of men and 50.5% of women 
were reported to have varicose veins, whilst 5.4% of men and 2.8% of women had 
evidence of CVI on clinical examination. 
Finally the Bonn vein study22 was set in Germany and Latvia.  Subjects were 
randomly selected from population registries.  The response rate was 59% and 
3072 people were examined.  90.4% had some clinical evidence of venous 
insufficiency; (59% - thread veins, 14.3% - varicose veins, 13.5% - oedema, 2.9% - 
trophic skin changes, 0.7% - ulcers). 
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All such studies carry the same possible biases in that response rates tend to be 
fairly low (not reported in the French study), leaving uncertainties around the 
degree to which this data can be generalised to the whole population.  There is no 
way of knowing that there were no significant differences between the study 
population and the 41-46% of people choosing not to participate.  Clearly with 
such a great proportion, even small differences will have a significant effect upon 
the estimated population value following extrapolation.  Additionally if it is 
assumed that venous disease is progressive; when populations with different 
health care systems are studied, the relative timeliness, availability and quality of 
treatment may have an impact upon prevalence many years into the future. 
Despite these issues; on the whole, the quality of these studies was high and many 
working within this field accept that the majority of the population carry minor 
evidence of venous disease, around a third suffer from varicose veins, 5-10% have 
trophic skin changes and around 1% suffer with venous ulcer disease137,138. 
 
Risk Factors and Associations 
Many potential risk and / or associative factors have been identified and studied 
over the years and all have their proposed pathophysiological basis.  Overall, as 
with the other epidemiological evidence, much of the data is very old, involving 
highly selected groups and fails to control for other potential confounding factors, 
such as age139-141, which has a strong association with venous insufficiency. 
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Age 
There is strong evidence that the prevalence and severity of venous disease 
increases with age18,21,134,140-150.  Both the Edinburgh18,140,144 and Bonn vein 
studies22 establish a clear link between the prevalence of SVI and increasing age 
(Table 5). 
Unsurprisingly this increase in pathological reflux, results in an increase in both the 
prevalence of varicose veins (Table 6) and CVI (Table 7).   
Some of the best data on risk factor modelling comes from the Tampere varicose 
vein study in Finland.  Questionnaires were sent to all 40, 50 and 60 year old 
people in a city and 5568 people responded (response rate 75% men and 86% 
women)147.  Both this data and that of the French population study37 was used to 
perform multiple logistic regression analyses to estimate the independent effect of 
risk factors upon clinical disease (Table 8 - Table 10).  Both studies confirm the 
significant association of age and clinical venous disease. 
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Table 5: The prevalence (as a percentage (95%CI)) of venous reflux >0.5s on DUS by age, gender 
and venous segment
22
.  GSV – Great saphenous vein, SSV – Small saphenous vein, SFV – 
Superficial femoral vein, PV – Popliteal vein, PTV – Posterior tibial vein.  Figures in bold indicate a 
statistically significant difference between men and women (α≤0.050) 
 
Age 18-24  25-34  35-44  45-54  55-64  
Male 20.0 15.5 36.1 42.0 61.4 
Female 5.3 13.9 22.6 41.9 50.5 
Total 11.5 14.6 28.8 41.9 55.7 
Table 6: The prevalence of saphenous varicose veins (as a percentage) by age and gender in the 
Edinburgh vein study
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Age 17-39 40-59 60-80 
Venous System 
Male 
(n=446) 
Female 
(n=567) 
Male 
(n=479) 
Female 
(n=649) 
Male 
(n=397) 
Female 
(n=478) 
Su
p
er
fi
ci
al
 
GSV 
Proximal 
Thigh 
9.6 
(7.1-12.8) 
10.3 
(7.9-13.1) 
12.8 
(9.9-16.1) 
14.0 
(11.4-16.9) 
13.0 
(9.8-16.7) 
27.1 
(23.1-31.3) 
GSV 
Distal 
Thigh 
3.2 
(1.7-5.2) 
6.7 
(4.8-9.1) 
10.9 
(8.3-14.1) 
13.9 
(11.3-16.8) 
14.3 
(11.0-18.2) 
27.2 
(23.2-31.5) 
SSV 
2.2 
(1.1-4.1) 
1.1 
(0.4-2.3) 
2.9 
(1.6-4.9) 
3.3 
(2.0-4.9) 
5.6 
(3.5-8.3) 
6.7 
(4.7-9.4) 
Overall 
12.6 
(9.6-16.0) 
12.6 
(10.0-15.6) 
17.6 
(14.3-21.3) 
21.8 
(18.7-25.2) 
23.7 
(19.5-28.2) 
39.1 
(34.7-43.7) 
D
ee
p
 
SFV 
18.6 
(15.1-22.5) 
13.4 
(10.7-16.5) 
14.0 
(11.0-17.1) 
7.6 
(5.7-9.9) 
11.1 
(8.2-14.6) 
13.3 
(10.3-16.6) 
PV 
9.5 
(6.9-12.6) 
4.8 
(3.2-6.9) 
10.9 
(8.2-14.0) 
6.6 
(4.8-8.8) 
12.9 
(9.7-16.6) 
10.7 
(8.1-13.8) 
PTV 
0.4 
(0.1-1.6) 
0.2 
(0-1.0) 
0.6 
(0.1-1.8) 
0.6 
(0.2-1.6) 
2.0 
(0.9-4.0) 
0.8 
(0.2-2.2) 
Overall 
26.1 
(22.1-30.5) 
17.9 
(14.8-21.3) 
22.4 
(18.7-26.4) 
13.9 
(11.3-16.8) 
20.7 
(16.8-25.0) 
22.3 
(18.6-26.3) 
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Age 18-24  25-34  35-44  45-54  55-64  
Male 0.0 0.0 2.53  
(0.69-6.28) 
7.73  
(4.31-12.74) 
25.25  
(19.25-31.62) 
Female 1.32  
(0.03-7.11) 
1.25  
(0.15-4.44) 
3.76  
(1.48-7.48) 
7.93  
(4.87-12.52) 
12.27  
(8.17-17.20) 
Table 7: The prevalence of chronic venous insufficiency (as a percentage (95% CI)) by age and 
gender in the Edinburgh vein study
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Risk Factor OR (95% CI) 
Female 2.3 (1.8-2.9) 
Age (years)* 50 2.2 (1.9-2.6) 
  60 2.8 (2.4-3.3) 
Weight (Kg) >65 (F), >80 (M) 1.2 (1.1-1.4) 
Height (m) >1.65 (F), >1.75 (M) 1.4 (1.1-1.6) 
Mainly standing posture at work 1.6 (1.4-1.8) 
FH (1st degree relative) 4.9 (4.2-5.7) 
Parity 1 1.2 (1.0-1.6) 
  2 1.7 (1.3-2.1) 
  3 1.9 (1.4-2.5) 
  4+ 2.7 (1.9-3.9) 
Table 8: Independent Odds ratios (95%CI) for the association of proposed risk factors with 
varicose veins
147
.  *The baseline age comparator is 40 years 
 
 
Despite this association with age; venous dysfunction has been demonstrated to 
commence early in life, for example; 2.5% of 518 school children aged 10-12 were 
found to have saphenous incompetence on ultrasound, increasing to 12.3% after 2 
years and 19.8% by the age 18-20.  This in turn was associated with 2.5% having 
visible varicose veins by 14-16 and 8.3% by the age of 18-20151.  
 
 
66 
 
Risk Factor 
Men Women 
Varicose veins 
Age* 1.05 (1.02-1.07) 1.04 (1.02-1.05) 
FH 3.53 (1.91-6.54) 3.47 (2.38-5.07) 
Exercise+ 1.97 (1.08-3.61) NS 
Previous Pregnancy NA 1.98 (1.20-3.25) 
Height >1.65m NS 1.32 (1.08-1.62) 
 
Chronic Venous Insufficiency 
Age* 1.08 (1.04-1.13) 
FH 2.81 (1.03-7.71) 
Table 9: Independent Odds ratios (95%CI) for the association of proposed risk factors with 
varicose veins and chronic venous insufficiency
37
. Controlling for activity, socioeconomic status, 
Body mass index, history of thromboembolic disease, geographical area, smoking status, alcohol 
consumption, level of education and oestrogen therapy in women. FH – Family history of a first 
degree relative, NS – no significant relationship, NA – not applicable. * - Odds ratio per year of 
age, + less than once per week 
 
 
Risk factor 
Proportion of Variance Explained (%) 
Men Women 
Age 50 years 23 12 
Age 60 years 21 18 
FH 38 31 
Weight* 12 12 
Height+ 12 4 
Standing at work 12 15 
Parity NA 24 
Table 10: The proportion of variance (as a percentage) in the prevalence of varicose veins 
explained by risk factor
147
.  (Derived from the multiple logistic regression models detailed in 
Table 8) 
 
There is also evidence that aside from the prevalence of venous dysfunction in 
general, the severity of venous disease increases with age140, indeed; venous 
ulcers are uncommon below the age of 60, but their prevalence then increases 
with age152-154.   
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Scott et al141 performed a case control study in an outpatient clinic setting.  This 
compared 222 patients with varicose veins or CVI against 113 “general surgery 
patients” with no clinical evidence of venous disease.  A multivariate logistic 
regression analysis was subsequently performed (Table 11).  The results should be 
interpreted with caution; as the chosen controls are likely to be significantly 
different from the general population.  This resulted in some discrepancies, such 
as the apparent “protective effect” of age in the development of varicose veins.  
However, when patients with varicose veins are compared with those suffering 
CVI, it is apparent that age is a risk factor in progression from uncomplicated to 
complicated disease. 
This association of worsening disease severity with age seems to support the 
theory of the progressive overall deterioration in clinical condition of people with 
unaddressed venous incompetence over time.  
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Risk Factor OR (95%CI) 
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Age 0.96 (0.93-0.99)* 
Female Gender 5.00 (2.20-12.50) 
History Phlebitis/DVT 6.30 (1.80-22.30) 
“Family History VV” 21.50 (10.00-46.30) 
    
 
C
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ed
 w
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h
 
co
n
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ls
 
Age 1.06 (1.03-1.09)* 
Male Gender 2.90 (1.30-6.40) 
BMI 1.06 (1.01-1.10)+ 
History Phlebitis/DVT 25.70 (7.60-86.50) 
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V
 
Age 1.07 (1.04-1.10)* 
Male Gender 8.00 (3.50-18.30) 
BMI 1.07 (1.01-1.13)+ 
Table 11: Independent Odds ratios (95%CI) for the association of proposed risk factors comparing 
controls with varicose veins and chronic venous insufficiency
141
.   DVT – Deep vein thrombosis, VV 
– varicose veins, BMI – Body mass index. * - Per year, + - Per Kgm
-2
 
 
 
Gender/Pregnancy 
It is a widely held belief, that venous insufficiency is more common in women than 
men.  It is certainly true that women present more often for treatment142,145-
148,150,155,156 and there is evidence from population based studies that the 
prevalence of varicose veins is indeed higher21,22,37,143,147, however on closer 
inspection of the evidence; a complicated relationship with gender becomes 
apparent. 
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Firstly considering the findings of insufficiency upon venous duplex imaging: 
Women were observed to have a higher prevalence of SVI in the Bonn vein 
study22, but it is men who appear to have the highest prevalence of DVI (Table 12).  
In the Edinburgh vein study men also had higher rates of DVI, but there was no 
significant difference in the superficial venous duplex findings between genders18. 
 
Venous System Male (n=1694) Female (n=1322) 
Su
p
er
fi
ci
al
 
GSV Proximal Thigh 11.8 (10.1-13.6) 16.4 (14.7-18.3) 
GSV Distal Thigh 9.3 (7.8-11.0) 15.1 (13.5-17.0) 
SSV 3.5 (2.6-4.6) 3.5 (2.7-4.5) 
Overall 17.7 (15.7-19.9) 23.5 (21.5-25.7) 
D
ee
p
 
SFV 14.7 (12.8-16.7) 11.1 (9.7-12.7) 
PV 11.0 (9.4-12.8) 7.2 (6.0-8.5) 
PTV 1.0 (0.5-1.7) 0.5 (0.2-1.0) 
Overall 23.1 (20.9-25.5) 17.6 (15.8-19.5) 
Table 12: The prevalence (as a percentage (95%CI)) of venous reflux >0.5s on DUS by gender and 
venous segment in the Bonn Vein Study
22
.  GSV – Great saphenous vein, SSV – Small saphenous 
vein, SFV – Superficial femoral vein, PV – Popliteal vein, PTV – Posterior tibial vein.  Figures in 
bold indicate a statistically significant difference between men and women (α≤0.050) 
 
These deep venous findings are based upon a definition of pathological reflux 
lasting more than 0.5 seconds; however, many believe that reverse flow of less 
than 1 second in deep veins, particularly in men; is physiological and that a cut off 
below this will erroneously label veins as incompetent (See Assessing Anatomical 
and Haemodynamic Dysfunction, p100).  These gender-related differences in the 
70 
 
deep veins become less prominent when a cut off of 1 second is used, however, 
some difference is still evident and men judged to have no clinical evidence of 
venous disease have similar reflux durations to those seen in women.   
There is disagreement in the literature as to whether women or men have a higher 
prevalence of varicose veins.   Most studies find this to be higher in 
women21,22,37,143,147 (Table 8), but the Edinburgh vein study showed the opposite18 
(See: Prevalence, p58).  What does seem clear is that a greater proportion of men 
suffer with CVI18,21,37,141,143 and male gender may be a risk factor for progression 
from varicose veins to CVI (Table 11)141.  It is uncertain as to whether this 
increased risk of CVI is an indication of a greater tendency to have venous disease 
treated at an earlier stage in women or differing pathophysiology between men 
and women, (perhaps seen in the differences in DVI rates discussed above). 
Age may have a part to play in the disagreement in varicose vein prevalence:  
Table 5 (p64) shows that there is no significant difference in the prevalence of SVI 
between men and women in those under the age of 60 years.  Table 6 and Table 7 
(p64-65) echo this; showing significant divergence in the prevalence of varicose 
veins and CVI after 55 years.  Prevalence therefore increases with age in both 
genders, but this may be at a greater rate in women, causing a gradual divergence 
between the rates seen in men and women.  
With higher rates of SVI seen in women, it seems probable that the prevalence of 
varicose veins will be higher and interestingly the pattern of the varicosities may 
be different.  The French population study37 supported the evidence that overall, 
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varicosities are more common in women (See Prevalence, p58), however these 
followed a different distributional pattern.  Both sexes had the same proportion of 
varicose veins coming from saphenous axial incompetence, but women had 
significantly more non-saphenous varicosities (Table 13).  
 
Table 13: The prevalence of varicose veins (as a percentage) by gender and distribution
37
. GSV – 
great saphenous vein, SSV – Small saphenous vein. Figures in bold indicate a statistically 
significant difference between men and women (α≤0.050) 
 
Women are significantly more likely to report symptoms than men (51.3% of 
women compared with 20.4% of men)37; which has also been noted on QoL 
modelling, where women reported a greater disease specific QoL impairment than 
men, controlling for the clinical severity of disease and other demographic and 
anatomical factors38.   This is perhaps the motivation behind women presenting 
earlier and in greater numbers, for treatment. 
Another interesting observation is that varicose veins from both saphenous and 
non-saphenous origins are associated similarly with the presence of symptoms 
(Saphenous - 70.1%, non-saphenous - 63.7% - women.  Saphenous - 36.4%, non-
saphenous - 34.0% - men), however saphenous varicosities had greater association 
with trophic skin changes (Saphenous 13.4%, non-saphenous 4.2%)37. 
 Source Women Men 
GSV and main tributaries 14.8 14.3 
SSV 4.8 3.4 
Non-Saphenous 26.9 8.7 
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To further complicate things, when CVI is looked at in detail, further 
inconsistencies are observed.  Despite the higher rates of trophic skin changes in 
men, venous ulceration is 2 to 3 times more common in women140.  This has not 
been satisfactorily explained, but may indicate differing pathological mechanisms 
or additional factors are involved.  
 
Pregnancy is a proposed explanation for the increased incidence of varicose veins 
in women, with multiparity being associated with a greater prevalence than 
nulliparity37,142,146,147,157-162  (Table 8 - Table 10, p65-66).  There is even evidence of 
a “dose response” with incidence increasing with the number of full term 
pregnancies147,148,150,155,158,160,163.  This is not a unanimous view however and some 
of these studies may be biased by a failure to control for age139,140.   
There are several proposed mechanisms to explain the association of venous 
incompetence and pregnancy.  The most obvious is that the increase in intra 
abdominal pressure associated with the enlarging uterus impedes venous 
return164,165, however this is debateable as varicose veins often develop prior to 
significant uterine enlargement135, suggesting that other factors are important.  
There is also clinical evidence that weight gain is not an independent risk factor for 
varicose veins in pregnancy158. 
During early pregnancy there is a significant increase in blood volume due to 
plasma expansion placing an increased strain upon the capacitance of the venous 
system166.  In addition to the increased demands upon the venous system, the 
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hormonal changes associated with pregnancy have a likely role.  Relaxin causes 
softening of connective tissues.  The primary function of this is in preparing the 
pelvic structures for delivery, but it also, works alongside oestrogen to mediate 
vasodilatation; which in turn results in increased venous stasis and valvular 
dysfunction167-171.  Another hormone; progesterone, is known to weaken the 
structural integrity of blood vessels167,169,171,172.  Concentrations of both oestrogen 
and progesterone increase rapidly in early pregnancy, but both are produced 
through a woman’s reproductive life and it may be that even low levels have a 
cumulative deleterious effect upon venous integrity. 
A further possible explanation of the increasing gender divergence with age is that 
there may be a differential weakness of the muscle pump with aging, due to the 
more rapid drop off in musculoskeletal mass in females. 
 
Heredity 
It is difficult to establish the role of genetics in venous insufficiency as venous 
disease is so common and most studies rely upon questionnaires to establish 
family histories rather than the independent objective verification of pedigrees.  
Subjects with venous disease are often more likely to be aware of others in the 
family, than those unaffected135.  There is also some evidence that the number of 
reported “false positives” of a family history may be higher in those with venous 
disease173.  
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Accepting this, there appears to be reasonable evidence of a hereditary 
association with both varicose veins and CVI (Table 8 - Table 10, p65-66) 
37,134,141,142,145,147,174,175.  Two large population based risk factor studies found that a 
family history of a first degree relative with venous insufficiency was the most 
powerful risk factor for developing the disease, increasing the risk by 
approximately 3.5 to 5 times37,147 (Table 8 & Table 9).  Given the high rates of 
prevalence of venous insufficiency; it may be more correctly stated that an 
absence of family history is highly protective.   
A detailed study of heritability was performed in Germany.  2701 patients with 
venous disease were recruited and a questionnaire based pedigree likelihood 
approach was applied.  The heritability or proportion of phenotypic variance 
attributable to genetic inheritance was calculated to be around 17% and was 
stable throughout the clinical disease spectrum175. 
Hirai et al146 studied 541 Japanese women, finding 42% of those with varicose 
veins had a positive family history compared with just 14% of women without 
disease.  Importantly; this difference decreased with age, suggesting that genetic 
factors may be involved in the early development of disease. 
There are known congenital syndromes associated with venous disease, but to 
date, no genotypes have been convincingly associated with the heritability of 
primary venous insufficiency53. 
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Geography/Race 
Once again, there is little contemporary data on this.  Venous disease is not a 
research or health priority in the developing world as it cannot compete with 
other more pressing health and social issues in these areas.  Previous work has 
suggested that venous insufficiency is less common in the developing world than 
in Europe and North America and it was suggested that this was mainly due to 
lifestyle issues176-178.  Although there is little clear evidence, mechanisms such as 
reduced constipation; secondary to a high fibre diet, toilet habit, less time spent 
standing and less tight undergarments have been suggested, alongside the 
possibility of a genetic ethnic link162. 
A classic study compared 358 female cotton workers in the north of England with 
467 of their counterparts in Egypt149.  The prevalence of venous disease was 
higher in England (32% v 6%), when controlling for age. 
Differences are noted between continents, even following immigration.  In a 
community study in Jerusalem, Abramson et al142 found a lower prevalence of 
varicose veins in immigrants from North Africa (13.2% - men, 30.2% - women) 
compared with immigrants from Europe and America (26.9% - men, 48.8% - 
women) and from other parts of Asia (22.4% - men, 39.7% - women).  However, a 
more recent paper studied UK Asian men as they attended a Mosque in 
Birmingham, finding similar rates of varicose veins and CVI as reported in the 
white British population179. 
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The most detailed study to date on ethnicity within an immigrant population 
consisted of 2211 current and retired university employees in San Diego143.  The 
cohort was broken down into non-Hispanic white (58%), Hispanic (15%), African 
Americans (14%) and Asians (12%).  There were no differences in the prevalence 
of varicose veins, trophic skin changes or venous ulcers.  Hispanics were less likely 
to have oedema (OR 0.29), and Asians were less likely to have SVI on DUS (OR 
0.65).   
Beaglehole et al155 studied 2301 people in New Zealand and the Pacific islands 
(Table 14).  In New Zealand the western settlers (Pakeha) had a lower prevalence 
of varicose veins than the native Maori.  There was an even a larger difference 
between the Rarotonga and the Pukapuka in the Cook Islands.  As island 
communities tend to display greater genetic diversity between each other than 
those living on the great land masses, perhaps this gives more evidence as to the 
impact of genetic factors upon venous insufficiency.  
 
Location  People Male Female 
New Zealand 
Maori 33.4 43.7 
Pakeha 19.6 37.8 
Cook 
Islands 
Rarotonga 15.6 14.9 
Pukapuka 2.1 4.0 
Tokelau Island 2.9 0.8 
Table 14: The age standardised prevalence (as a percentage) of varicose veins by people and 
location in the South Pacific
155
. 
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Differences have also been noted within continents; Guberan et al180 found the 
prevalence of varicosities was significantly lower among women from Southern 
Europe (Italy and Spain) than among women from Switzerland, France, and other 
Central European countries. 
Other detailed studies have failed to attribute any significance to geographical 
variations within countries22,37. 
 
Body Mass Index 
Evidence on the significance of body mass index is mixed and much of it is very 
weak.  Amongst the most convincing evidence is seen in the Bonn vein study22, 
which found an increase in the prevalence of SVI associated with a BMI of greater 
than 30.  Other studies also support a link22,141,142,150,155,161,163, which may only be 
relevant in women134,144,157.  The reason for this differential relationship is 
speculation, but may be mediated by an increase in bioavailable circulating 
oestrogens in obese women135.  Further studies have failed to identify any 
link139,146,159,160,180.  Interestingly, obese women are more likely to report varicose 
veins181. It is possible that obesity may worsen the clinical severity or symptoms 
rather than having a direct effect upon prevalence, or perhaps obesity causes leg 
symptoms which are mistaken as venous in origin.   
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Lifestyle 
Although lifestyle risk factors have long been blamed for variation in prevalence, 
there is little high quality evidence to support their role.  Lifestyle factors are 
difficult to investigate as many studies rely on self reported data, which is difficult 
for the investigators to verify.   
There is some support for the view that periods of protracted standing 
predisposes to venous insufficiency134,142,144,150,159,163,182.  The Edinburgh vein study 
found that sitting at work is protective in women (OR 0.75 (0.57-0.99))139.  This 
appears to be corroborated by the Israeli and Framingham epidemiological 
studies134,142 again mainly in women.   
Constipation has been suggested as a potential cause, with a loaded colon 
compressing the pelvic veins and the effect of straining at stool on intra abdominal 
pressure as suggested mechanisms176.  There is currently little supportive evidence 
for this hypothesis and detailed analysis in the Edinburgh vein study failed to 
demonstrate an association139. 
The evidence to support any association between varicosities and other lifestyle 
factors such as social class, education, tight undergarments, toilet posture, chair 
sitting, oral contraceptives, hormone replacement therapy and smoking is also 
lacking37,135,144,162. 
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1.3 The Management of Superficial Venous 
Insufficiency 
Assessment 
The Clinical Assessment of Patients with Superficial Venous 
Insufficiency 
It is clearly important to be able to objectively evaluate the clinical severity of 
disease suffered by a patient in a manner which is standardised across the 
literature.  As discussed earlier, many of the early studies into venous disease 
were hampered by a lack of consensus upon how to grade and classify its diverse 
spectrum.  This was addressed in 1994 by an international ad hoc committee at 
the American Venous Forum annual meeting.  The result was the CEAP 
classification system published in 1996 and revised in 200425,183.   
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The CEAP Classification 
The C is for clinical severity and runs from 0 to 6.  Each clinical subgroup may be 
followed by the subscript A (asymptomatic) or S (symptomatic).  E is for aEtiologic 
and divided into the 3 main aetiological mechanisms.  A is for anatomic, detailing 
which veins are involved and finally P is pathologic, representing the 
pathophysiological mechanism underlying the disease.   
Figure 9 provides a detailed breakdown of the classification system. 
 
Clinical C0 No visible / palpable signs of venous disease 
  C1 Telangectasia or reticular veins 
  C2  Varicose veins 
  C3 Oedema 
  C4a Pigmentation or eczema 
  C4b Lipodermatosclerosis or atrophy blanche 
  C5 Healed venous ulcer 
  C6 Active venous ulcer  
aEtiologic Ec Congenital 
  Ep Primary 
  Es Secondary (post-thrombotic) 
  En No venous cause 
Anatomy As Superficial Veins 
  Ap Perforator veins 
  Ad Deep veins 
  An No venous cause 
Pathology Pr Reflux / insufficiency 
  Po Obstruction 
  Pn No venous pathophysiology 
Figure 9: The revised CEAP classification
25
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Clearly full CEAP evaluation requires the use of objective clinical observation in 
conjunction with imaging and physiological assessment.  Whilst the CEAP system 
offers descriptive precision; some criticise that it becomes too precise and 
complex in some cases; furthermore it is a poor outcome for clinical interventional 
studies for several reasons.  There is no indication as to the severity within each of 
the clinical classes.  A single 1cm long varicosity of 3mm diameter scores the same 
as severe tortuous veins covering 90% of the leg’s surface area.  This makes the C2 
relatively resistant to change and in practise C4 is highly resistant to change and 
C5 permanent.  This inherent resistance to clinically significant improvements 
makes this instrument insensitive to the variation observed in interventional 
studies184-187. 
 
The Venous Clinical Severity Score 
In a bid to produce a clinical severity classification system which is responsive to 
changes a further ad-hoc committee of the American Venous Forum produced the 
Venous Clinical Severity Score (VCSS), which was designed to supplement the CEAP 
and provide a method for serial assessment184,186,188.  It was also designed to give 
additional weight to more severe manifestations of chronic venous disease (CEAP 
clinical class 4 and class 6).  The VCSS has been shown to withstand differences in 
intra-observer and inter-observer reproducibility and to be responsive to 
change185. 
Figure 10 provides a detailed breakdown of the classification system. 
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The VCSS is not without its critics however with some criticising the inclusion of a 
observer assessed valuation of pain and discomfort and the use of compression 
therapy.  The quality of life impairment associated with venous disease is clearly a 
critical issue; but one best left to assessment using validated patient reported 
quality of life assessment instruments, which will be discussed later.  The use of 
compression is a multifactorial issue, relating to clinician, patient and societal 
preference as much as to the control of symptoms.  In clinical studies, this is 
clearly open to bias as this factor is eminently under investigator control and 
differing compression practices may result in very different VCSS outcomes for 
clinically similar patients. 
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Component 
Score 
0 1 2 3 
Pain (or discomfort of 
presumed venous origin) 
None 
Occasional, 
not restricting 
ADL 
Daily, 
interfering 
with ADL 
Daily, limiting 
most or 
preventing ADL 
Varicose veins (≥3mm) None 
Few, 
scattered, 
corona 
phlebectatica 
Confined to 
thigh or calf 
Involves thigh 
and calf 
Oedema (of presumed 
venous origin) 
None 
Limited to 
foot and 
ankle 
Extends 
above ankle, 
below knee 
Extends to 
knee and 
above 
Skin pigmentation (of 
presumed venous origin) 
None or 
focal over a 
varicose vein 
Peri-malleolar 
Diffuse over 
lower third 
calf 
Wider 
distribution 
above lower 
third calf 
Inflammation None Peri-malleolar 
Diffuse over 
lower third 
calf 
Wider 
distribution 
above lower 
third calf 
Induration (including  
lipodermatosclerosis 
and atrophy blanche)  
None Peri-malleolar 
Diffuse over 
lower third 
calf 
Wider 
distribution 
above lower 
third calf 
Active ulcer(s) 0 1 2 >2 
Active ulcer duration NA <3 months 
3 months - 1 
year 
>1 year 
Active ulcer diameter NA <2cm 2-6cm >6cm 
Use of compression 
therapy 
None Intermittent Most days Every day 
Figure 10:  The Venous Clinical Severity Score
188
. ADL – activities of daily living 
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Assessing the Quality of life Impairment Associated with Superficial 
Venous Insufficiency 
Venous insufficiency does not significantly alter the length of life, but can have a 
profound impact upon the quality of that life (See Quality of Life Impairment, p40).  
Therefore the principle aim of any treatment is the improvement of a patient’s 
QoL.  In the UK, the National Institute for Health and Clinical Excellence (NICE) 
recommends the consideration of treatment for varicose veins that impact on 
QoL189, irrespective of the coexistence of complications.  This makes patient 
centred QoL assessment the primary outcome for any study on venous 
insufficiency and as such; must be studied in detail.  Accurate information 
regarding the QoL value of the health states associated with venous disease is also 
essential for cost–utility analysis, the keystone of economic evaluation in the 
context of health technology assessment190.  In the UK, QoL analysis has evolved 
from this research role and it is now compulsory in the NHS to measure QoL 
before and after venous interventions191,192. 
Broadly speaking there are two categories of QoL instrument; those specific to a 
given disease and generic systems assessing the QoL impairment from any 
condition. 
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Disease Specific Quality of Life Assessment 
At the time this research was commenced, most was known about the 
performance characteristics of the Aberdeen varicose vein questionnaire (AVVQ). 
This is a disease-specific instrument that measures the QoL impairment associated 
directly with venous disease and is the most widely used and stringently validated 
instrument in this role47.  Disease specific measures have potential advantages 
over generic instruments47: 
 It may be more sensitive to small yet clinically significant changes in health 
status   
 It may have greater power to discriminate between patients whose health 
is only mildly affected by their varicose veins   
 The questions will be familiar to patients, and the resulting questionnaire 
will be acceptable and present them with few difficulties 
 
The questionnaire was based on questions commonly used in the clinical 
assessment of patients with varicose veins, as indicated by a review of the clinical 
literature.  An “expert panel” of two consultant surgeons was convened to assess 
the content validity (whether the questions are representative of the disease).  
Each question was then independently scored by the surgeons.  0 was the score 
for responses considered to be normal and the other responses were given a score 
in proportion to what is believed to be the associated morbidity.  The two sets of 
scores were then averaged and rescaled to yield total scores between 0 and 100; 0 
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is reserved for patients with no features or evidence of venous disease and 100 for 
patients ticking the most severe response to each question.  A patient focus group 
was used to assess the wording of the questions for comprehension and 
ambiguity.  Factor analysis was used to identify any questions which did not 
contribute significantly to the overall score.  Such questions were removed; along 
with any where greater than 80% of respondents gave the same answer or gave all 
responses to a question; as these questions did not add to the questionnaire’s 
ability to discriminate between different levels of morbidity.  Finally the 
questionnaire was validated by a sample of patients and the general population.  It 
was found that variation in the AVVQ was associated with variation in previously 
validated generic instruments such as the Short Form 36 (SF-36®; Medical 
Outcomes Trust, Waltham, Massachusetts, USA)47.  
 
Question 1 of the questionnaire invites the subject to draw the distribution of 
their varicose veins on an unmarked diagram of the front and rear aspects of the 
legs.  The investigator then uses an acetate overlay with a grid pattern to score the 
number of affected segments (Figure 11). 
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Figure 11: Scoring grid for question 1 of the Aberdeen varicose vein questionnaire
47
 
 
The remaining 14 questions are in a tick box format (Figure 12).   
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Figure 12: Questions 2-15 of the Aberdeen varicose veins questionnaire
47
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For an instrument to be used as a measure of health outcome, it needs to be 
reliable (reproducible), valid (tests what it purports to measure), responsive 
(sensitive enough to recognise small but significant differences), and practical 
(ease of administration)51,193,194.  An external validation study48 alongside a further 
study by the original author46 confirmed that the AVVQ fulfilled these criteria and 
as intended; is more responsive than generic instruments.  The AVVQ has since 
become an extremely popular outcome measure, although is not without its 
criticisms:  from the very beginning it was not designed to be patient centred and 
was developed according to the views of experts rather than patient preferences.  
Consequently; there appears to be some cross over with the VCSS, including an 
assessment of clinical severity and the inclusion of compression treatment, both 
may be questionable features.  Despite this, validation studies are favourable and 
a comparison with subsequent systems involving a more patient-centred approach 
in development, found similar results45 and perhaps the performance 
characteristics of the AVVQ are superior.  Furthermore an estimation of clinical 
severity by the patient themselves is important, irrespective of the actual severity; 
as it displays that patient’s perceptions, as does their decision to comply with 
compression therapy. 
In summary therefore, the AVVQ gives a measure of the patient perceived 
morbidity in association with their venous disease.  It is an outcome measure 
which is sensitive to small, but meaningful changes in QoL and therefore can be 
used to show the effectiveness of treatment and the significance of disease 
recurrence.  Other disease specific instruments exist such as the VEINES-Sym195, 
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CIVIQ 2196 and SQOR-V197, but the AVVQ remains the most popular in the UK and 
USA and has undergone the most stringent validation to date.  
It is recommended that a disease-specific measure should be used in conjunction 
with a generic instrument46,51,198-200; disease-specific measures may be relatively 
insensitive to the morbidity associated with invasive procedures48 and are difficult 
to map on to index utility scores, precluding detailed economic evaluation.  
 
Generic Quality of Life Assessment 
Health Profile 
The generic SF-36 instrument201,202 was born of the Medical Outcomes Survey and 
the RAND health insurance experiment203,204 (Figure 13).  The aim was to produce 
a standardised, comprehensive, psychometrically sound, practical instrument, 
which could replace long and time consuming health surveys, which prevailed up 
to this point; reducing the burden of research on both patients and research team.  
This has become the most widely used generic instrument in the world today205.  It 
produces a comprehensive profile of eight domains covering the range of physical 
and psychological well-being: physical function, role limitation due to physical 
disability (role – physical), bodily pain, general health perception, vitality, social 
function, role limitation due to emotional problems (role – emotional) and mental 
health.  Item scores for 36 questions are coded, summed and transformed on to a 
scale from 0 (worst health) to 100 (best health) in each domain.  SF-36 has been 
extensively shown to be both valid and reliable46,47,193,206-209, and used in many 
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patient groups, including those with venous insufficiency.  Its global popularity has 
resulted in its being translated into 130 languages and norm based scores 
produced for a range of populations based upon population responses, making it a 
patient centred questionnaire. 
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Figure 13: The Short Form 36 Questionnaire (UK V2) 
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Index utility 
Patient preference or utility scoring allows the production of a single generic index 
utility score, representing a patient’s health status on a continuous interval scale 
from 0 to 1, where 0 represents dead or unconscious and 1; full health.  With 
some scales; utilities of below 0 are possible for states such as intractable pain and 
disability, considered “worse than death.”  This index is used in the calculation of 
the quality adjusted life year (QALY) and this common currency is the bedrock of 
health utility analysis.  This single common unit potentially allows the meaningful 
optimisation of the allocation of health resources, ensuring that these resources 
are invested in such a way as to maximise the health gained from healthcare 
programmes; addressing the full spectrum of human disease and disability. 
In this context, the concept of an interval utility is applied to the measurement of 
patient or societal preference.  That is the measurement of which health states are 
preferred to others, and by how much.  The interval or the numerical difference 
relates to the magnitude of the difference in preference. 
The philosophy of utility in this context was revolutionised in 1941 with the work 
of von Neumann and Morgenstern on a model of rational decision making under 
uncertainty; the expected utility theory210-212, providing the framework of modern 
decision theory used in business, government, engineering and healthcare.    
There are several methods of measuring utility.  The most simple is a visual 
analogue scale, where subjects are invited to place a cross representing their 
preference for a give state between two defined points; at a distance which 
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reflects the difference in preference.  This technique is rarely used in isolation as it 
often fails to produce a representative interval scale213-217.  The optimum methods 
for evaluating health preference are the time trade off (TTO) and the standard 
gamble (SG). 
 
The Standard Gamble  
The SG is the classical method for measuring utility and does so under conditions 
of uncertainty (similar to real life situations)218.  If a health state is preferred to 
death then a subject is asked to choose between two options.  Option 1 is to 
continue in the health state to be valued and option 2 has two possible outcomes: 
restoration to full health for life (with a probability p) or instant death (probability 
1-p).  p is then varied until the subject is indifferent between the two options.  The 
utility estimate is then equivalent to p (Figure 14). 
 
 
Figure 14: The Standard Gamble 
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The Time Trade Off 
A drawback of the SG is that many people struggle to relate to the concept of 
probabilities.  The TTO was designed to be conceptually simple and easy to 
administer219.  A subject is asked to choose between option 1 living in the health 
state to be valued for life or option 2 where they are restored to full health, but 
with a given reduction in the length of life.  The time they are willing to “trade off” 
is varied until they are indifferent between the two options.  The utility estimate is 
the proportion of life to be traded (Figure 15). Some argue that the lack of 
uncertainty associated with this technique makes it unrealistic. 
 
 
Figure 15: The Time Trade Off 
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Utility Measurement Instruments 
Although these methods are the underlying theory behind utility measurement, it 
is time consuming to employ them and many studies utilise “off the shelf”, pre-
scored multi-attribute instruments.   
The EuroQol (EQ5D™; EuroQol Group, Rotterdam, The Netherlands) was 
developed by a multidisciplinary group of researchers from five European 
centres220 (Figure 16).  It is an index scale, mapping three available responses to 
five questions onto a utility scale with 245 possible states.  The UK weights were 
derived from TTO responses from 3000 adults from the general population221, with 
statistical modelling.  The EQ5D has been shown to be valid220,222,223 and is the 
recommended utility measure for cost utility analysis in the UK190.  It is also a 
popular system world-wide with 150 languages available.  The EQ5D also includes 
a 100 point visual analogue scale, from “worst imaginable health state” to the 
“best imaginable health state”.  
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Mobility  
I have no problems in walking about 
I have some problems in walking about 
I am confined to bed 
 
Self-Care  
I have no problems with self-care 
I have some problems washing or dressing myself 
I am unable to wash or dress myself 
 
Usual Activities (e.g. work, study, housework, family or  
leisure activities)  
I have no problems with performing my usual activities 
I have some problems with performing my usual activities 
I am unable to perform my usual activities 
 
Pain/Discomfort 
I have no pain or discomfort 
I have moderate pain or discomfort 
I have extreme pain or discomfort 
 
Anxiety/Depression  
I am not anxious or depressed 
I am moderately anxious or depressed 
I am extremely anxious or depressed 
 
Figure 16: The EuroQol Time Trade Off Questionnaire 
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Another recently developed index utility score is the SF-6D224,225.  This can be 
derived from responses to the SF-36 or the shorter SF-12 health profile.  The UK 
weights were derived from SG responses from 836 adults, again with statistical 
modelling to produce 18,000 health states.  A benefit of this instrument is that it 
can be calculated from the results of previous studies not featuring dedicated 
utility assessment.  Relatively little is known about the performance characteristics 
when compared with the EQ5D. 
 
Assessing Anatomical and Haemodynamic Dysfunction 
Duplex Ultrasound 
Duplex ultrasound (DUS) has become the gold standard investigation of venous 
disease below the inguinal ligament, giving both morphological and 
haemodynamic information of the lower limb veins226.  DUS uses two different 
principles of ultrasonic interrogation to derive this data.   
B-mode – An ultrasound transducer makes use of the unique properties of 
piezoelectric crystals.  As an electric current is passed through a crystal, it changes 
shape, producing a sound pulse (a short duration sound wave), also; if a sound 
pulse strikes a crystal, a small electric current is produced.  This enables a 
transducer to emit and detect sound pulses.  
Different densities of human tissue resist the transmission of sound waves to 
different degrees (called acoustic impedance).  When a sound pulse is travelling 
through tissue, as it hits substances of differing acoustic impedance a proportion is 
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reflected back and a proportion of the sound energy may be transmitted onwards.  
The proportion which is reflected is proportional to the difference in impedance at 
the interface.  If there is a large discrepancy such as an air-tissue or tissue-bone 
interface, all of the energy in the sound pulse will be reflected. 
Reflected sound pulses are detected by the transducer.  The ultrasound device 
uses the time from emission of the pulse to reception of its echo to calculate the 
distance from the transducer the reflective interface was, using the assumption 
that sound travels at the average velocity of 1540ms-1 in human tissue.  This point 
is plotted in two dimensions on a screen with a dot.  The brightness of the dot 
indicates the magnitude of the energy reflected back in the echo (which is a 
function of the discrepancy of the acoustic impedance at the interface).  These 
dots are drawn simultaneously in real time to give a moving anatomical image of 
the tissue undergoing insonation.   
Areas where there is little difference in impedance appear black (such as within a 
homogenous tissue such as fat).  Heterogeneous tissue, containing elements of 
differing density (such as muscle) return occasional low magnitude echoes, which 
may appear speckled.  Interfaces between two tissues of differing density result in 
bright lines and if the difference in impedance is great; these lines will be very 
bright and there will be shadows beneath (blackout - as all the sound energy is 
reflected and none transmitted).  Figure 17 is an example of a B-mode image. 
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Figure 17: The right saphenofemoral junction (SFJ) in transverse section. CFA – Common femoral 
artery, CFV – Common femoral vein, GSV – Great saphenous vein 
 
  
Doppler – B-mode anatomical information can be combined with information 
gained by Doppler interrogation of the tissues.  This scientific principle was 
described by Christian Doppler in 1842 as an explanation of why light from stars 
may appear red, even though it is known that the light produced by 
thermonuclear fusion appears white (as it contains all of the wavelengths of visible 
light).  The theory states that as the distance between an observer and an emitter 
of a wave increases, the wavelength perceived by the observer will become longer 
and visa versa.  The magnitude of this change in wavelength (the Doppler shift) is 
proportional to the velocity of the emitter relative to the observer and its effect 
CFA 
CFV 
SFJ 
GSV 
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can be classically experienced as something loud and fast passes by, such as an 
ambulance, resulting in a significant change in tone as it drives by.  
Using this principle an ultrasound device can superimpose information regarding 
the velocity and direction of blood flow onto the B-mode image.  The direction and 
the magnitude of the velocity are represented by colours.  This is called colour 
Doppler.  Additionally, a more accurate estimation of the velocity and direction of 
blood flow over time can be charted on a graph.  This is called spectral Doppler.  
This is so accurate that it can detect the range of velocities and directions seen 
within a unit area, clearly displaying the difference between smooth laminar and 
turbulent flow.  Figure 18 is an example of a colour duplex image and Figure 19 is 
an example of spectral Doppler. 
 
104 
 
 
Figure 18: Duplex ultrasound: colour Doppler is superimposed upon the B-mode image.  This 
demonstrates gross incompetence of the saphenofemoral junction with reverse flow passing 
towards the transducer (which is aiming slightly antegrade), from the GSV back into the CFV 
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Figure 19: Pulse wave spectral Doppler demonstrating saphenofemoral incompetence (in 
longitudinal section).  Augmentation has resulted in antegrade flow - AF, followed by 
approximately 2.5 seconds of retrograde flow – RF (reflux) 
 
 
 
 
 
 
CFV 
GSV 
SFJ 
RF AF 
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Together the use of B-mode and Doppler ultrasound gives a detailed assessment 
of both the anatomy and the physiology of the venous tree and is therefore the 
most frequently used investigation.  DUS results are commonly found as outcomes 
in the literature and a consensus paper has been published aiming to standardise 
the technique227. 
 
One area of controversy within DUS interpretation is the reflux duration required 
to label a vein segment incompetent.  Whilst a cut off of greater than 0.5 seconds 
may be appropriate for the definition of SVI, such a short duration may overcall 
insufficiency within the deep veins.  Two large studies found that there was little 
difference in prevalence of SVI using a cut off of 0.5 seconds when compared with 
a cut off of 1 second17,18,22.  However the same parameters gave significantly 
different results for the prevalence of DVI with rates two to four times higher 
using the threshold of 0.5 seconds.  When considering an association with clinically 
evident venous disease; a reflux duration of 0.5 seconds had a specificity of 87.9% 
whereas and increase to 1 second improved this to 95.7%18.  As a result the clinical 
guidelines of the Society of Vascular Surgery and the American Venous Forum 
recommend a threshold reflux duration of 1 second in the SFV and PV and 0.5 
seconds in all other vein segments in the leg199. 
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More traditional methods of evaluation include clinical examination using 
Trendelenburg tourniquet testing and hand-held continuous wave Doppler (HHD).  
Given the anatomical and pathophysiological factors discussed above, it is 
unsurprising that both have been shown to be unreliable228, and in today’s world 
of image guided minimally invasive interventions; these are inadequate.  Even 
when employing traditional surgical techniques; the use of HHD is associated with 
a failure to detect 24%-33% of refluxing sites overall228,229 and only has 44% 
sensitivity at the SPJ230.  As a consequence; an RCT demonstrated higher 
recurrence rates in a group preoperatively assessed clinically and with HHD 
compared with a group assessed with DUS231.  DUS is recommended as the first 
diagnostic test for all patients with suspected CVD199,227,232.  
 
Plethysmography 
Plethysmography is another non-invasive investigation, involving the 
measurement of a change in leg volume and hence helps to quantify the extent of 
venous dysfunction in the evaluation of calf muscle pump function, global venous 
reflux, and venous outflow obstruction233-236.  This has been used to monitor 
venous functional changes and assess physiologic outcome of surgical 
treatments234; but its place within the research and clinical landscapes is 
uncertain.  Its use has been suggested in the management of patients with CVD 
when no reflux or obstruction is determined upon DUS, as it may suggest outflow 
obstruction or calf muscle pump dysfunction199. 
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Venogram and Invasive Investigations 
Computed tomography (CT) and magnetic resonance (MR) venography may be 
used in the investigation of venous disease proximal to the inguinal ligament, or in 
the evaluation of complex arteriovenous malformations199.  Significant disease 
above the leg includes pelvic venous obstruction, iliac vein stenosis, May-Thurner 
syndrome (compression of the left common iliac vein by the right common iliac 
artery), nutcracker syndrome (compression of the left renal vein between the 
aorta and the superior mesenteric artery), gonadal vein incompetence and pelvic 
venous congestion syndrome.  Invasive contrast venography is occasionally used in 
this role, if the local expertise or availability precludes the use of cross sectional 
imaging.  However, this technique is usually reserved for use during endovenous 
or open procedures on the deep veins, such as angioplasty and stenting.  
Intravascular ultrasound may replace this as a diagnostic and surveillance tool in 
the future and may provide additional information when compared with contrast 
venography237. 
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The Treatment of Venous Insufficiency 
Conservative Treatment  
The principle conservative treatment measure used for venous insufficiency is the 
use of compression.  Compression seeks to combat the relative venous 
hypertension and promote the antegrade flow of blood from the leg, improving 
calf muscle function and decreasing reflux238,239.  There is little doubt as to the 
benefits of compression, even in uncomplicated disease, but uncertainty exists 
around the required degrees of compression and studies of compression are, on 
the whole, less meticulous than those studying interventions.  It does seem that 
compliance with compression is the key issue dictating benefit and this is higher 
with lower degrees of compression.  Whilst this may bias the results of studies, 
perhaps the message is that in disease short of ulceration, lower grades of 
compression may strike the optimal balance between compliance and clinical 
benefit, offering the best results. 
Imaging has shown that compression therapy needs to narrow the veins of 
patients with venous disorders to achieve a haemodynamic effect; initial 
narrowing occurs with a median pressure of between 30 and 40 mm Hg in the 
sitting and standing positions240 although Grade II compression (18-24 mmHg) 
appears to have favourable clinical results and higher compliance (as discussed 
below), suggesting benefits at the tissue level.  
A systematic review241 found the evidence base for the use of compression 
treatment in uncomplicated varicose veins to be poor quality and in common with 
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clinical practice, compliance with compression treatment may have attenuated 
the effect.  There is evidence supporting an improvement in symptoms, with 
maximal relief from Grade II to III (25-35 mmHg) compression242.  There was no 
convincing evidence that compression has any effect upon disease progression. 
There is further evidence for the benefits of compression for CVI; another meta-
analysis looked specifically at the levels of compression and found that patients 
with varicose veins and CVI see an improvement in symptoms and swelling with 
compression of 10-20mm Hg over no compression, but there was no evidence 
found to support a benefit of using higher pressures in this patient group243.  The 
authors acknowledge that the evidence is generally poor in quality and it seems 
unlikely that the benefits from higher compression seen in uncomplicated disease 
will not be seen in CVI. 
There is little doubt that compression has a significant role to play in the 
treatment of venous ulceration.  A Cochrane systematic review found evidence 
that compression increases healing rates and found multiple component dressings 
with an elastic layer give the best results244.  This was confirmed by a European 
working group, who also found evidence that compression reduces ulcer 
recurrence245. 
Compression only offers any benefits whilst it is in place246 and it is therefore not 
without its problems.  The main drawback was alluded to earlier: non-compliance.  
Non-compliance rates may be very high.  For instance 53-63% of patients are non-
compliant with compression after one year247,248.  In a cohort study by Mayberry et 
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al249, ulcer healing with local care and compression was 97% in compliant patients, 
but fell to 55% in non-compliant patients.  Ulcer recurrence was 16% in compliant 
patients and 100% in non-compliant patients.  Poor compliance may be due to 
socioeconomic factors (particularly outside of the UK NHS)247, poor patient 
education250, discomfort (with lower compression pressures better tolerated)251 
and concerns regarding cosmesis.  This may be compounded in the elderly by 
difficulties with putting on compression garments.  One study found that 15% 
were unable to apply them and 26% needed considerable help252.  
Care must be taken in the presence of arterial disease and incorrectly measured or 
applied garments may cause skin and soft tissue damage, which is rare; but has 
been reported in the literature253. 
 
Adjuncts to Compression Therapy 
There is an absence of evidence supporting lifestyle changes such as weight loss or 
leg elevation at rest, and a systematic review and meta-analysis has found no 
supportive evidence for any specific additional dressings on venous ulcers over 
compression254, many of which are highly costly.  For example Michaels et al255 
demonstrated no evidence of efficacy of silver donating dressings when compared 
with simple non-adherent dressings.  The 3 month healing rate was 59.6% for 
silver and 56.7% for control dressings. Similarly there was no difference in 
recurrence rates 11.6% for the silver and 14.4 for the control dressings.  These 
expensive dressings were therefore certainly not cost effective, with an 
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incremental cost-effectiveness ratio of £489,250, when compared to control 
dressings, certainly well above the commonly used UK threshold of £20,000 per 
QALY.  
 
Comparison of Compression Treatment with Surgery 
There is clear and compelling evidence of the benefits of interventional treatment 
for SVI when compared with compression therapy.  The REACTIV trial50 was at the 
time; the most detailed interventional trial undertaken for the treatment of 
venous disease, recruiting in total 1009 patients.  246 patients were randomised 
to receive either conservative management or surgery.  Conservative treatment 
included lifestyle advice relating to exercise, leg elevation, management of weight 
and diet, and the use of compression hosiery.  In the surgical arm, patients 
received the same lifestyle advice but also underwent high ligation, stripping, and 
phlebectomies.  The surgical group saw an improvement in QoL over 2 years with 
an estimated QALY gain (95%CI) of 0.083 (0.005-0.160) using SF-6D and 0.130 
(0.016-0.250) using EQ5D over those receiving compression alone.  The authors 
then used a Markov economic model to simulate the costs and consequences of 
the 2 approaches over a 10 year horizon.  This estimated the incremental cost 
effectiveness ratio to be £1936 per QALY, making surgical treatment highly cost 
effective when compared to conservative measures alone. 
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The REACTIV study had shown that surgery aiming to address SVI improved the 
anatomical extent of disease, symptoms and QoL.  The ESCHAR study256 aimed to 
elicit whether intervention had any favourable effect in the treatment of ulcers.   
500 patients with active or recently healed venous ulcers were randomised to 
compression treatment alone or compression combined with surgical treatment.  
75% received high ligation, stripping, and phlebectomies; under a general 
anaesthetic (GA), but 25% were judged unsuitable for GA and underwent high 
saphenous vein ligation alone under a local anaesthetic (LA).  There was no 
difference in ulcer healing at 6 months (65% versus 65%), however 1 year 
recurrence rates were significantly lower in the surgical arm (12% versus 28%, 
hazard (95% CI) -2.76 (-1.78 to -4.27) and this difference persisted to at least 4 
years257.  Critics of this study suggest that the significant delays prior to surgery 
and the inclusion of healed ulcers in the analysis (decreasing the power) were 
responsible for the failure to show a benefit in healing rates.  Another study of 
surgery for venous ulcers, suggests that in the absence of DVI, compression may 
be unnecessary in the healing of ulcers, demonstrating the power of the 
correction of SVI258. 
 
Compression therapy, through reducing venous hypertension; is a powerful tool to 
combat venous disease, but it cannot replace the benefits of interventions 
correcting venous insufficiency; hence addressing the underlying pathological 
cause of venous hypertension itself. 
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Medical Treatment 
Medical treatments for venous insufficiency are not in common use worldwide; 
however there is emerging evidence that drugs aiming to modulate the 
pathophysiology of skin changes associated with CVI may offer some benefits. 
A range of Cochrane reviews have studied this area.  One such review studied 44 
trials involving 4413 participants using rutosides, hidrosmine, diosmine, calcium 
dobesilate, centella asiatica, French maritime pine bark extract, aminaftone and 
grape seed extract.  Overall there was significant heterogeneity within the studies, 
but there were improvements observed on meta-analysis in oedema RR (95%CI) 
0.72 (0.65 - 0.81) and trophic disorders RR 0.88 (0.83 - 0.94)259.  Horse chestnut 
seed extract also has some early evidence that it may improve the symptoms, 
including pain and itching and also the oedema of CVI260. 
Medical treatment may have greater benefits in the treatment of venous ulcers.  A 
meta-analysis of 12 trials involving 864 participants found pentoxifylline with 
compression is more effective than placebo and compression in ulcer healing RR 
1.56 (1.14 - 2.13) and pentoxifylline without compression is more effective than 
placebo or no treatment RR 2.25 (1.49 - 3.39).  However GI side effects were 
common and this may impact upon compliance and QoL261.  Micronized purified 
flavonoid fraction (MPFF) has similarly been shown to be of benefit.  The mean 
ulcer healing time was 16 weeks in patients treated with MPFF plus compression 
compared with 21 weeks in patients with compression alone, resulting in a 32% 
increase in the chance of ulcer healing within 6 months 0.32 (0.03-0.70)262. 
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Whilst these early results show promise, the evidence base is in its infancy and 
doesn’t support widespread clinical use259.  Large RCTs are required to confirm the 
clinical efficacy, QoL improvement and cost effectiveness associated with these 
treatments.  
 
Interventional Treatment  
Surgical intervention for SVI has been clearly shown to offer benefits over 
conservative management over the spectrum of venous disease and is also highly 
cost-effective50,256 (See: Comparison of Compression Treatment with Surgery, 
p112).  However there has been a revolution in the management of SVI, with an 
explosion of new and revised techniques hoping to offer benefits over 
conventional surgery.  These relatively new, minimally invasive endothermal 
ablative techniques are gaining in popularity. At the time this programme of 
investigation was initiated, endovenous laser ablation (EVLA) had become the 
front runner in the endovenous revolution263.  However, conventional surgery 
remains the most common intervention for SVI in the UK264,265, and is widely 
considered to be the gold standard. 
The mainstay of treatment for DVI is compression, however it has been shown 
that if SVI is addressed, this has favourable haemodynamic consequences on the 
deep system also; reducing the incidence of DVI266.  Surgical interventions have 
been attempted to directly treat DVI and a Cochrane review found three small 
RCTs detailing the treatment of primary DVI which indicated that there may be 
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some improvement in ambulatory venous pressure, but pressures remained 
pathologically high.  The quality of evidence is not sufficient to support any 
positive recommendations at this time267 and further discussion will concentrate 
on intervention for SVI. 
 
Open Surgery 
Conventional Open Surgery 
The classical technique of high ligation of the SFJ, stripping of the GSV and 
phlebectomy under general anaesthetic has been the standard of care of varicose 
vein treatment for around a century.  The procedure is described in detail below 
(See p154).  The benefits of this treatment, particularly the gain in QoL and its cost 
effectiveness compared to conservative management are well established from 
large RCTs50,256 (See: Comparison of Compression Treatment with Surgery, p112).  
These benefits in QoL are significant and even in uncomplicated disease are 
consistent with those seen after other surgical procedures shown to result in 
significant QoL improvements such as laparoscopic cholecystectomy268-270.  
Improvements are also durable with benefits lasting until at least 10 years271. 
Some patients however see little benefit and this is likely to be secondary to poor 
patient selection.  “Venous symptoms” are by their very nature vague and may not 
be secondary to the coincidental existence of venous insufficiency (See: Quality of 
Life Impairment p40).  A trial of compression therapy may be helpful as a pre-
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operative selection method in cases of doubt over the aetiology of symptoms. 
Lurie et al found that patients who improved after conservative therapy were 
more than 15 times more likely to have an improvement in their symptoms at 1 
month RR (95% CI) 15.6 (4.3-56.5), and 21 times higher at 1 year after surgery 21.3 
(4.7-96.9), compared with those who had no improvement with compression272. 
 
The Limitations of Conventional Surgery 
Short Term 
Surgery is not without its drawbacks; in common with all invasive techniques the 
procedure itself carries some morbidity, resulting in impaired QoL in the early 
post-operative period.  Naturally perioperative complications may exacerbate and 
extend this phenomenon.  Compression therapy post-operatively is thought to 
promote a more rapid recovery, by reducing haemorrhage, oedema, haematoma 
and pain, but an RCT of 220 post-surgical patients found no benefit in wearing 
compression stockings for greater than 1 week with respect to postoperative pain, 
number of complications, time to return to work, or patient satisfaction for up to 
12 weeks after surgery273. 
In good hands, conventional surgery on the whole, is both safe and effective.  
However, despite this being classified as “clean surgery”; significant rates of 
wound complications, mostly groin infection are described in 1.5% to 16%274-278.  
Normal wound healing is less likely in current smokers adjusted OR (95% CI) 0.5 
(0.3-0.9) and with increasing BMI OR 0.92 (0.87-0.97 per unitary increase)279.  
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Mekako et al performed an RCT with 443 patients (600 legs) undergoing groin 
surgery for varicose veins; the risk of wound infections and wound-related 
complications was reduced with use of a single dose of perioperative antibiotic 
prophylaxis from 18.2 to 9.9%.  A single dose of co-amoxyclav at induction 
therefore increases the likelihood of normal wound healing OR 2.21 (1.32-
3.60)279.  Haematomas may also be fairly common and have been described in up 
to 33%280, even with the use of post-operative compression.   
In the UK, the commonest single cause of litigation following surgery is alleged 
injury to cutaneous sensory, specifically the saphenous and sural, nerves281.  These 
injuries are associated with pain, paraesthesia and anaesthesia.  The rate of 
saphenous nerve injury is partially dependent upon the length of GSV stripping 
undertaken.  The close anatomical relationship between the GSV and the 
saphenous nerve below the knee282,283 has been shown to increase the rates of 
injury if stripping is continued down below the knee.  An RCT of full length 
stripping compared with stripping to the knee found a nerve injury rate of 39% 
versus 7%284.  However some have pointed out that as the long term results of 
stripping to the knee are worse; the length of GSV stripping should be dictated by 
the length of refluxing vein and not concerns over injury to the saphenous 
nerve285-287.  Full-length stripping remains controversial.   
Following intervention for SSV reflux, sural nerve injury is described at a rate of 2% 
to 4%, whereas common peroneal nerve injury occurred in 4.7% in one series and 
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in 6.7% in another series288.  It is unclear as to what proportion of these injuries 
can be ascribed to the popliteal fossa dissection and to the act of stripping283. 
Adjunctive procedures, such as phlebectomy and perforator treatments are 
associated with nerve injury, but there is little reliable data to quantify this and 
this is clearly compounded by the extent to which such procedures are required. 
Thromboembolic complications were previously thought to be very low275, 
however detailed modern follow-up with DUS has found that the incidence of 
post-operative deep vein thrombosis (DVT) could be as high as 5%, although the 
majority are asymptomatic and confined to the calf veins with no subsequent 
propagation or clinical evidence of pulmonary embolism (PE)289.  The risk of 
clinically significant PE remains around 0.2–0.5%275.  Around half of observed DVTs 
resolved without evidence of DVI at 1 year289. 
Injury to the major vascular structure are very rare (incidence 0.002%-0.300%), but 
consequences may be disastrous290. 
Long Term 
Long-term results following conventional surgical treatment are marred by 
significant recurrence rates.  Quoted rates are as high as 30% at 1 year, 40% at 2 
years and up to 66% beyond 10 years291-297; this has been linked to poor patient 
satisfaction271,298.  Patients requesting re-intervention for symptomatic recurrence 
are less common, but approximately 15–20% of varicose vein procedures are 
performed for recurrence265,299,300. 
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Recurrence may be due to technically inadequate surgery, the growth of new 
incompetent vessels within old scar tissue (neovascularisation), significant 
unaddressed reflux in the below knee GSV or perforators and disease progression. 
 
Innovations in Open Surgical Technique 
Many new innovations have been attempted, aiming to re-invent and re-
invigorate the technique of open surgery with a hope of addressing its limitations.  
This evolution has seen diminishing groin incision size and stripping towards a 
small puncture wound at the knee, made possible by the PIN stripper.  The 
following section covers innovations which have deviated significantly from the 
principles of what is considered conventional surgery. 
 
Junction Ligation without Stripping  
Whether this technique under local anaesthesia minimises peri-procedural 
morbidity is a moot point, as recurrence rates are inflated when an incompetent 
GSV is left in situ.  An RCT randomising 100 patients to ligation and stripping and 
ligation alone found that reoperation was required in 6% and 21% respectively 
(relative risk (95% CI) 0.28 (0.13-0.59)) by 5 years292. 
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Techniques Aiming to Reduce Neovascularisation 
Neovascularisation has been defined as the presence of multiple new small 
tortuous veins in anatomic proximity to a previous venous intervention301.  
Neovascularisation is a significant, though poorly understood cause of recurrence 
at sites which have previously undergone technically adequate surgery296,302. 
Attempts at over-sewing the junction with non-absorbable suture have shown 
conflicting results, with one RCT in support (31 and 45 patients per group)303 and 
another larger study showing no difference (double the sample size) when 
compared with transfixion with absorbable suture304 and this has been 
subsequently confirmed by other studies305.  Closure of the cribiform fascia 
however may help, reducing the rates of neovascularisation from 14.8% to 6.7% at 
1 year306. 
Conflicting results were also shown for the practice of using prosthetic patches as 
barriers to neovascularisation, which may also result in an increase in 
complications291,306-309. 
 
Loco-regional Anaesthesia 
Although not in common use in the UK and USA, European centres have 
experience in performing open ligation, stripping and avulsions without the use of 
general anaesthesia310.  This is a potentially attractive option; potentially reducing 
the morbidity of the procedure.  There are no detailed studies comparing open 
surgery with and without general anaesthesia.  A retrospective study has failed to 
122 
 
see any difference in simple pain scores311, but there is some evidence of potential 
benefit seen when comparing this approach with minimally invasive endovenous 
techniques312.  The benefits of local anaesthetic surgery may however be 
attenuated by the frequent requirement of intravenous sedation313. 
 
Cryostripping 
The aim of cryostripping is to reduce the morbidity associated with stripping the 
GSV.  A probe is passed down the GSV from the groin to the level of the knee.  
Freezing of the vein is then performed at this point using liquid nitrogen and the 
vein stripped by invagination back towards the groin314.  This technique is said to 
reduce the haemorrhage within the saphenous tunnel and avoid a separate 
incision at the knee, although with modern PIN strippers this is little more than a 
small stab wound, similar to those for the phlebectomy element of the procedure.  
An RCT of 160 patients randomised to cryostripping and standard stripping found 
a reduction in bruising, but no difference was seen in pain or in QoL.  This study 
however was not powered to detect small to medium differences in generic QoL 
and no peri-procedural QoL analysis was used, only visual analogue pain scores315.  
Cryostripping; when combined with a local anaesthetic procedure may offer the 
optimum reduction in morbidity possible, whilst retaining the principle of ligation 
and stripping, though this is yet to be conclusively established.  
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Preservation of the Great Saphenous Vein 
Two techniques are described aiming for conservative surgical management with 
preservation of the GSV.  The underlying premise of this approach is the ascending 
theory of venous insufficiency (See The Pathogenesis of Primary Venous 
Insufficiency p49) and they rely on the assumption that the interruption of reflux 
from the distal tributaries will restore competency to the superficial and deep 
venous trunks.  
The first is the ASVAL technique (ambulatory selective vein ablation under local 
anaesthesia), involving ambulatory phlebectomy of all varicose tributaries, with 
preservation of the GSV and SSV irrespective of their competence316.  A case series 
of patients with very early disease (many asymptomatic) has shown 
haemodynamic improvement; with 66% of previously refluxing veins (greater than 
0.5 seconds) reverting to competence (less than 0.5 seconds reflux) at 4 years.  
This was accompanied by some symptomatic improvement, but even treating such 
early disease; 11.5% of patients had suffered recurrence by 4 years316.  There are 
no comparative studies to date. 
The second approach is the CHIVA technique (conservative haemodynamic 
ambulatory venous surgery).  The principle is to decrease the superficial venous 
pressure.  The actual treatment is tailored to the anatomical pattern of 
incompetent veins.  Venous ligations are then performed in specific locations, 
maintaining superficial venous drainage, though sometimes using reverse 
flow317,318.  For example; a frequently used technique includes proximal ligation of 
the incompetent saphenous vein; ligation, division, and avulsion of the 
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incompetent varicose tributaries; and maintaining patency of the saphenous 
trunk, the competent saphenous tributaries, and saphenous venous drainage to 
the deep system through the so-called re-entry perforators319.  Another RCT 
presented further details of the technique in six different patterns of SVI320.  Two 
RCTs have compared CHIVA with conventional ligation and stripping.  The first 
randomised 75 patients per group and found lower recurrence at 10 years 
following CHIVA (18% and 35%, OR (95% CI) 2.2 (1.0-5.0))319.  The second 
randomised 167 patients to CHIVA and 167 patients each, to two ligation and 
stripping groups (clinical assessment and DUS assessment).  Again at 5 years, the 
CHIVA group had two to two and a half times less recurrence320.  Other authors 
have failed to reproduce these results321.  A final study compares CHIVA to 
compression treatment in venous ulcer disease with 47 in each group.  Ulcer 
healing was more rapid and recurrence rates were significantly lower following 
CHIVA (9% compared with 38%)322.  There is therefore some evidence of efficacy, 
however the lack of detailed QoL analysis prevents meaningful conclusion over the 
effectiveness of this treatment to address the QoL impairments associated with 
the disease, or whether this technique reduces the morbidity of intervention.  
Furthermore, many doubt whether this complex, operator dependant technique, 
will offer similar results outside of the hands of a small number of enthusiasts199 
and to date this has not seen widespread adoption. 
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Minimally Invasive Techniques 
Endothermal Ablation  
Endothermal ablative techniques involve the percutaneous introduction of a 
catheter into the target vein under ultrasound guidance.  The vein is then 
surrounded with tumescent local anaesthetic.  This results in pain relief, but also 
performs several other important functions.  It compresses the vein onto the 
catheter allowing the concentrated application of heat via the catheter directly 
onto the venous endothelium, minimising any blood in between.  Blood flow may 
cool the catheter or clot around it, attenuating its effect upon the vein wall itself.  
The tumescent also displaces other structures, such as the nerves and deep veins 
away from the target vein by hydro-dissection, isolating the vein from its 
surrounding tissue.  Finally the tumescent acts as a heat sink; preventing thermal 
energy from propagating and further protecting the surrounding soft tissues.  The 
use of tumescent anaesthesia therefore results in decreased morbidity323 and 
increased efficacy324-326.  Thermal energy is subsequently delivered to the vein 
obliterating its structure.  The treated vein then heals, leaving behind only a cord 
like structure of scar tissue. 
Thermal energy may be delivered in a range of ways.  Endovenous laser ablation 
(EVLA) uses laser energy, radiofrequency ablation uses electrical current, which 
may be passes directly through the vein wall itself (direct radiofrequency ablation 
– RFA) or through a metal coil, which emits thermal energy towards the vein wall 
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(indirect RFA).  Finally a device licensed in continental Europe emits bursts of 
steam.  
 
Endovenous Laser Ablation 
Endovenous Laser Ablation (EVLA) utilises the delivery of laser energy into the vein 
via an optical fibre.  LASER (Light Amplification by the Stimulated Emission of 
Radiation) produces a collimated (low divergent) “beam” of photons whose waves 
are coherent (in-phase) allowing a very intense and accurate delivery of energy, 
which can be mono-chromic (the same “colour” or wavelength) (Figure 20).   
 
 
Figure 20: LASER – A narrow “beam” of photons, emitted “in phase” and of a single wavelength 
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This electromagnetic radiation is then absorbed and converted into thermal 
energy.  Shorter wavelengths (810, 940 and 980nm) are absorbed primarily by the 
haemoglobin in erythrocytes, whereas longer wavelengths (1319, 1320 and 
1470nm) by intra and extracellular water327.  Therefore, rather than hampering 
the transfer of thermal energy to the vein wall, experimental studies have 
suggested that it is the blood itself that acts as the transfer medium328.  Rapid 
heating of the blood (700-1300oC) creates steam329; this alongside some direct 
heating of the vein wall causes collagen contraction and denudation of 
endothelium.  The result is a non-thrombotic occlusion due to vein wall thickening, 
luminal contraction and fibrosis of the vein326.   
Laser energy was first used in the treatment of SVI in 1999 by Boné and in 2001, 
the first case series was published330,331.  By the time the studies detailed in this 
thesis were undertaken, the evidence for EVLA comprised of only case series.  
These confirmed that EVLA had a high initial and medium term technical efficacy.  
These studies were later subjected to a random effects meta-analysis, estimating 
that at 3 months 92.9% and at 5 years 95.4% of patients had an absence of reflux 
on DUS examination332.  This data however was heterogeneous in many respects 
and was following an unreported proportion of secondary procedures.  None of 
these early studies attempted to measure QoL following intervention. 
EVLA has been shown to have a good safety record, although the procedure is not 
completely free from morbidity.  Inflammation of the sclerosed vein and incisions 
related to any concomitant treatment are associated with pain and bruising.  In a 
meta-analysis, some bruising was seen in up to 52.2% of cases333 although the 
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significance of this is debated.  Significant complications are very rare, in meta-
analysis and large series, paraesthesia is seen in around 1.7-2.7%, and deep vein 
thrombosis (DVT) rates are low at 0.3%-0.6%333-335.  An occasional case of 
pulmonary embolus (PE) has been described327,336, along with arteriovenous 
fistulae337,338, skin burn334 and misplaced catheter339, but these are incredibly rare.  
There has been much debate regarding the relative merits of different laser 
wavelengths.  It has been suggested that longer wavelengths may be more 
“gentle” and associated with fewer adverse effects, however there is little 
evidence to unequivocally support this and no studies have shown any significant 
difference in validated QoL measures324,340-343.  What is clear is that as each 
wavelength has a different absorption pattern; the evidence base for one 
wavelength cannot be simply applied to another.  The morbidity, complications 
and efficacy may be very different.  For instance; an early study using a 1,064nm 
laser described skin burns in 5% and a paraesthesia rate of 38%344.  This was 
thought to be due to greater tissue penetration at longer wavelengths; but 
fortunately this has not been seen using other longer wavelengths.  Work looking 
at different wavelengths, frequently varies the energy delivery also.  Mathematical 
modelling suggests that lower energy delivery is required at longer wavelengths in 
order to induce full thickness venous damage345 and It is therefore possible that 
the optimal energy per unit vein required to achieve a durable closure with 
minimal morbidity may also be different.  Studies are required to identify this 
“sweet spot” for each wavelength utilised, before any conclusions may be made 
regarding the optimal wavelength. 
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At least two EVLA device manufacturers have devised fibres designed to evenly 
distribute the laser energy around the surface of the vein.  Biolitec® manufacture 
the ELVeS® radial fibre and Angiodynamics® have the NeverTouch® gold-tip laser 
fibre.  The theory behind this concept is based on the observation that bare-tip 
fibres result in multiple vein perforations346.  This is suggested to result in blood 
leaking from the vessel; resulting in pain and bruising.  To date there is little 
evidence to support either the theory, or these fibres, which are more expensive 
that the standard bare tip fibres.  There may even be some evidence that they may 
attenuate the treatment effect347.  The one obvious benefit is that they are visibly 
clear on DUS imaging, making fibre placement easier for less experienced 
surgeons. 
 
Radiofrequency Ablation  
Radiofrequency ablation (RFA) was introduced in 1998.  This technique is similar 
conceptually to EVLA.  The first device in wide use was the Closure® system.  This 
was a bipolar system; passing a current between two electrodes, with the vein 
wall closing the circuit.  The vein wall was then heated by this current and a 
temperature of around 85-90oC was used to coagulate the vein wall as in EVLA.  
However blood between the catheter and the vein wall, attenuated its effect, 
sometimes even clotting around the catheter tip.  This system was later 
abandoned due to disappointing failure rates and slow withdrawal speeds, 
compounded by a requirement to occasionally remove the catheter to clean blood 
clot from the end.  Many of the early procedures were performed under a GA 
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without tumescent; which may have been partly to blame for its failings.  The 
manufacturer subsequently developed a more sophisticated indirect RFA system 
VNUS® ClosureFast®.  This catheter has a 7cm long electrically insulated coil at its 
tip.  This is heated by the passage of an electric current through it.  The device 
accurately maintains a temperature of exactly 120oC for a treatment cycle of 20 
seconds.  This is then withdrawn in a segmental fashion until the entire vein has 
been treated.  This system has similar withdrawal rates as for EVLA348 and when 
used with tumescent anaesthesia doesn’t become caked with thrombus like the 
previous catheter.    
Early results with the ClosureFast® system appear much better than for the old 
direct system, with 3 month success rates of 99.6% and 96.9% at 1 year; longer 
term follow-up is awaited349. 
In the largest series to date (252 veins); complications include painful induration in 
32.3% (although reported pain scores were low), paraesthesia in 3.4% and no 
DVTs349.  
A second RFA system has also been released: the Olympus® Celon RFITT®.  This 
system is similar to the original RFA system, although its manufacturers claim that 
results are much better.  There is little evidence regarding this system.   A single 
small study reported an occlusion rate of 95% at 10 days350, the results of further 
studies are awaited. 
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Steam Ablation 
A third technique has recently been introduced in Europe, but is not available in 
the UK or USA yet.  This technique uses superheated steam to apply thermal 
energy to the vein, hoping to result in the same occlusive changes as seen with the 
other endothermal techniques.  Early experiences appear promising, but there is 
little evidence to date to allow a clear appraisal of its merits in clinical practise351.   
 
Sclerotherapy 
Sclerotherapy is the use of a chemical agent to occlude incompetent veins by the 
initiation of a chemical thrombophlebitis, followed by endoluminal fibrosis.  This is 
the oldest of the minimally invasive techniques; having been first described in 
principle by Chassaignac in 1855.  Liquid sclerotherapy is mainly used to obliterate 
thread veins and telangectasia (for improved cosmesis), but high recanalisation 
and recurrence rates352,353 have limited its popularity in main axis or tributary 
incompetence.  Renewed interest has resulted from superior results following the 
mixture of sclerosant and gas to form a foam and injecting this under DUS 
guidance354-356.  The proposed mechanism underlying this improved performance 
is that the foam displaces the blood inside the vein, allowing a greater 
concentration of sclerosant to be in contact with the vein wall for a longer time.  
This improves the likelihood of initiation and the subsequent intensity of induced 
phlebitis in the target vein.  A further benefit is that far less sclerosant is required, 
reducing the potential for subsequent side effects and complications. 
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Several different sclerosants have been used including glycerine and hypertonic 
saline, but it is the detergents, including sodium tetradecyl sulphate and 
polidocanol, which have become the most popular.  These agents dissolve the 
endothelial cell membrane and denature the surface proteins.  
Enthusiasts of foam sclerotherapy have seen good results, with successful 
occlusion rates around 80% to 5 years357-359.  A meta-analysis found success rates 
of 82.1% at 3 months and 73.5% at 5 years332. 
Minor complications such as matting and pigmentation are relatively common, 
with an incidence of 17.8% in a systematic review360.  More serious complications 
including, skin necrosis, neurological complications, anaphylaxis and 
thromboembolism are rare360, but potentially catastrophic.  A recent systematic 
review of 10,819 patients found that 0.9% suffered from neurological 
complications, including 0.3% migraine, 0.1% stroke and 0.1% transient ischaemic 
attack (TIA)361.  Half of the strokes and TIAs were in association with a right to left 
cardiac shunt and it may be that this abnormality is more commonly seen in 
association with SVI362. 
There is some evidence that using carbon dioxide rather than air in the foam may 
decrease these adverse events.  A cohort study found no difference with visual 
disturbance (3.1% and 8.2%), but significantly less chest tightness (3.1% and 18%), 
dry cough (1.6% and 16%) and dizziness (3.1% and 12%) in the carbon dioxide 
group compared to the air group.  Overall the incidence of adverse effects was 
reduced from 39% to 11%363.   
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1.4 Aims and Objectives 
When this programme of investigation was embarked upon; evidence for the new 
minimally invasive techniques was limited to case series, offering general support 
for the relative safety and efficacy in the improvement of surrogate outcomes, 
such as reflux on DUS.  There were no randomised studies centred on the QoL 
benefits seen following intervention other than the REACTIV trial50, which 
provided compelling evidence for the effectiveness of conventional surgery when 
compared with conservative management, but gave little insight into the place of 
sclerotherapy and did not study any other modalities.  
Another compounding factor was that the techniques were still to undergo 
significant evolution and there were considerable variations in techniques and 
practise, with little evidence of what were the most efficacious approaches.  The 
technique of EVLA was the clear front-runner in this revolution in terms of both 
popularity and the strength and longevity of its evidence263,332, and therefore it 
was EVLA which was adopted as the minimally invasive treatment to go forward in 
this assessment process.  
The primary aim of the treatment of varicose veins is to improve QoL; this must be 
regarded as the most significant outcome measure, and as such was the key focus 
of the all three studies. 
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Study 1; Procedure Refinement – A randomised clinical trial of 
endovenous laser ablation with concomitant versus selected 
sequential phlebectomy in the treatment of venous insufficiency 
During the planning phase of Study 2; it was noted that the general efficacy of 
EVLA had been established (See Endovenous Laser Ablation p126) but that 
research was required focusing upon procedure refinement.  A fundamental 
question concerned the management of residual varicosities following truncal 
laser ablation.  Debate existed amongst our research group and other authors 
regarding the most efficacious management of residual tributaries following 
truncal laser ablation.  Options included sclerotherapy or ambulatory phlebectomy 
under tumescent local anaesthesia, both of which could be performed as a 
concomitant or sequential procedure.  Review of the literature seemed to support 
phlebectomy over sclerotherapy due to the complications associated with the 
latter (See Sclerotherapy p131).  However, there was no evidence on which to 
base the timing of the ambulatory phlebectomy, and therefore, following a pilot 
study which confirmed the feasibility and acceptability of laser therapy with 
concomitant phlebectomy under tumescent anaesthesia364, we embarked on a 
randomised clinical trial to compare concomitant and sequential expectant 
phlebectomies. 
The aim of this randomized clinical trial was to assess the advantages of 
performing ambulatory phlebectomy as a concomitant procedure to truncal laser 
ablation, with the primary outcomes based upon patient reported QoL. 
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Study 2; Technique evaluation – A randomised clinical trial of 
endovenous laser ablation versus conventional surgery in the 
treatment of venous insufficiency 
Once the optimum procedure had been established, the next study was directed 
towards a comparison of EVLA with the then current gold standard: conventional 
surgery; featuring SFJ ligation, above knee stripping and phlebectomy.  The aim 
was to firstly establish whether treatment with EVLA results in the same enviable 
improvements in patient QoL as seen in the REACTIV trial following surgery 50.  The 
second and perhaps more important aim was the exploration of whether EVLA 
could address any of the limitations seen with conventional surgery (See The 
Limitations of Conventional Surgery p117) and challenge the century long 
dominance of this technique in the management of SVI. 
 
Study 3; Procedure refinement – Energy delivery during 810nm 
endovenous laser ablation of superficial venous insufficiency 
and post-procedural morbidity 
A meta-analysis suggested that EVLA produces significantly better saphenous 
ablation rates on DUS up to 5 years than conventional surgery, foam sclerotherapy 
and RFA332.  There was however still room for improvement as treatment failure 
on DUS was still occurring in 1 of 20 saphenous trunks treated.  Residual and 
recurrent disease negates some of the quality of life benefit of treatment and is 
unpopular with patients.  It is known that 71% of patients want full treatment of 
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their varicose veins in a single visit and over 90% are concerned about the risk of 
recurrence365. 
During the lifetime of this research programme, several independent research 
groups established that the magnitude of energy delivery was the most important 
predictor of success366-368 and increasing energy delivery has resulted in improved 
occlusion rates369,370.  At this time energy deliveries of around 20-40 Jcm-1 or 
equivalent fluence calculations were being used327, but this new best evidence 
pointed to improved results at energies higher than this and many providers 
started to use 60-80 Jcm-1.  Despite this, 100% success remained an elusive goal. 
The reluctance to increase energy delivery further was most likely due to concerns 
that this may result in increased morbidity and complications from the procedure.  
There was however, no evidence that this is the case, when EVLA is performed 
using tumescent anaesthetic solution.  Surgeons within this research group were 
gradually increasing the energy density utilised since the advent of EVLA and 
deliveries of greater than 100 Jcm-1 became common. 
The aim of this study was to establish whether there was any evidence that this 
increase in the energy density has had any effect upon post-procedural pain, 
quality of life or complication rates. 
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Chapter 2 – Patients and Methods 
 
Study 1; Procedure Refinement – A randomised clinical 
trial of endovenous laser ablation with concomitant 
versus selected sequential phlebectomy in the 
treatment of venous insufficiency 
 
2.1 Patients 
The setting for this non-blinded parallel-group randomised clinical trial was a 
tertiary referral vascular surgical unit, offering specialist dedicated vascular 
services to a population of approximately 1.2 million.  All consecutive patients 
presenting to a single consultant vascular surgeon were evaluated for eligibility 
according to predetermined inclusion and exclusion criteria.  Assessment was 
performed by a consultant vascular surgeon or research registrar with a special 
interest in the management of venous disease.  Clinical assessment included a full 
history and examination including classification of the clinical severity of disease 
using the clinical grading element of the CEAP classification25 and the VCSS 
system186.  This was followed by a detailed duplex ultrasound assessment 
according to a standardised protocol.  All ultrasound scans were performed by 
surgeons who were fully formally accredited in the performance of diagnostic 
vascular ultrasound.  The details of DUS assessment are outlined on p145. 
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Inclusion Criteria 
Clinical 
 The presence of primary, unilateral, symptomatic venous disease of the 
lower limb; classifiable as C2-5 on the clinical grading element of the CEAP 
classification system25 
 Willingness to accept a local anaesthetic EVLA procedure, including 
ambulatory phlebectomy (as outlined in Section 2.3 Interventions, p141) 
 Willingness and ability to participate in a clinical trial, including the 
attendance of additional clinical assessments, completion of 
questionnaires, duplex follow-up and the analysis and publication of this 
data 
 Both patient and surgeon occupy a position of equipoise over the relative 
merits of either intervention  
 
Duplex  
 Greater than, or equal to 1 second of retrograde flow of blood from the 
common femoral vein through the SFJ into the GSV on pulse wave spectral 
Doppler 
 Greater than, or equal to 1 second of retrograde flow of blood in the GSV 
on spectral Doppler in at least the above knee segment 
139 
 
Exclusion Criteria 
Clinical 
 Age less than 18 years 
 Previous intervention aiming to address junction, perforator or superficial 
axial insufficiency 
 Active venous ulceration (C6 classification) 
 Inability or unwillingness to give informed consent to trial participation 
 Pregnancy 
 Symptoms or clinical evidence of arterial disease (including an ankle-
brachial pressure index of less than 0.8)  
 Previous groin surgery 
 Known thrombophilic state 
 Known malignancy 
 Allergy to local anaesthetic medications 
 
Duplex 
 Deep venous disease (including obstruction or insufficiency) 
 Sapheno-popliteal insufficiency 
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 Superficial axis insufficiency other than the GSV (which in the surgeon’s 
view would be optimally treated with ablation or stripping rather than 
phlebectomy) 
 GSV less than 4 millimetre (mm) in antero-posterior diameter at the 
proposed cannulation point 
 
2.2 Randomisation 
Following informed written consent, eligible patients were randomised equally 
into to one of two parallel groups: 
 
Control Group  
Isolated truncal GSV EVLA, with sequential ambulatory phlebectomy of residual 
varicosities after 6 weeks if required 
 
EVLTAP Group   
Truncal GSV EVLA with concomitant ambulatory phlebectomy of varicosities 
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Randomisation was performed at the screening visit immediately following signing 
of the consent form.  Patients were invited to select any opaque envelope, from 
those available whilst under supervision.  No block randomisation was used.  
 
Sample Size   
A sample size calculation was performed, based upon the primary outcome 
measure.  This was informed by data from the literature, giving an estimated 
AVVQ score of 3.94 in the controls371 compared with 0.6 in the EVLTAP group372 
(with a standard deviation of 4).  For 80% power and a two sided significance of 
5%, with a 10% loss to follow up, the estimated sample size was 25 patients per 
group.   
 
2.3 Interventions 
All procedures were performed under local tumescent anaesthesia in a dedicated 
procedure room within the outpatients department.  No sedation was used.  
Patients were preoperatively marked in the procedure room using a portable 
MicroMaxx® ultrasound system (Sonosite Ltd, Hichin, UK).  The course of the GSV 
was marked on the skin using a permanent marker pen from the proposed point of 
cannulation to the SFJ.  If ambulatory phlebectomy was to be performed then the 
sites were also marked preoperatively.   
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The skin was prepared with 10% Povidone-Iodine in water (Betadine®, Purdue 
Pharma L.P, CT, USA).  In the case of iodine allergy, 2% Chlorhexidine Gluconate in 
70% Isopropyl Alcohol (ChoraPrep® Insight Health Ltd, Wembley, UK) was used.  
Sterile draping of the leg was performed prior to percutaneous perigenicular 
cannulation of the GSV with the patient in the reverse Trendelenburg position.  A 5 
French catheter was introduced into the vein using the Seldinger technique, and 
its tip accurately positioned at the SFJ using ultrasound.  The patient was then put 
in the Trendelenburg position, and perivenous local anaesthetic (40 millilitres (ml) 
of 2% Lignocaine with 1:200,000 Adrenaline in 1 litre (l) of 0.9% Sodium chloride 
solution) was infiltrated along the vein.  Total local anaesthetic did not exceed the 
recommended maximum safe dose per patient.  A sterile bare-tipped 600 
nanometre (nm) laser fibre was introduced via the catheter for laser ablation of 
the GSV.  Endovenous laser energy was delivered using an 810 nm diode laser 
generator (Diomed® / Angiodynamics®, Cambridge, UK) at 14 Watts (W) power, 
continuous mode and withdrawal of the catheter was performed; aiming for a 
target energy delivery of 60-80 Joules per centimetre (Jcm-1). 
In the EVLTAP group, tumescent anaesthetic was also infiltrated around varicose 
tributaries and stab incisions were made, allowing avulsion of the veins using a 
Kocherised mosquito clip or vein hook.  In both groups, stab incisions were closed 
with Steri-strips™ (3M, MN, USA), cotton wool, gauze and Panelast® (Lohmann & 
Rauscher International GmbH & Co. KG, Rengsdorf, DE) elastic adhesive bandage 
was applied to the limb.  This remained in situ for 1 week, when it was replaced by 
a thigh length T.E.D™ anti-embolism stocking (Tyco Healthcare, Gosport, UK), 
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which patients were advised to wear for a total of 6 weeks.  All patients were 
discharged with Diclofenac 50 milligrams (mg) ter die sumendus (tds) to be taken 
orally regularly for 1 week and Paracetamol 1 gram (g) quater die sumendus (qds) 
orally for breakthrough pain.   
All patients were seen immediately pre and post procedure by the same research 
nurse, who provided the same instructions: elevation of the leg whilst at rest, 
mobilise as much as possible and return to work as soon as they feel able to do so, 
avoid driving, returning only when they can safely perform emergency 
manoeuvres and after discussion with their insurers.   A 24 hour contact number 
was also given for advice or help.  
 
2.4 Outcomes 
Clinical Outcomes 
Peri-procedural Outcomes 
 Successful completion of the planned procedure 
 Technical success – successful closure of the treated vein segment on 
DUS at 1 week 
 Procedure duration – The time in minutes from the commencement of 
skin preparation until the patient leaves the procedure room 
 Procedural complications 
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 Post-procedural pain scores – These were recorded by patients in a diary.  
Diaries contained 7 unmarked 10 cm visual analogue scales, representing 
day 0 (day of procedure to day 6 post-procedure.  One end of the scale is 
marked “no pain at all” (representing 0.0) the other end is marked “worst 
imaginable pain” (representing 10.0).  Patients were invited to place a 
cross on each line where they feel that their average pain for that day is 
best represented.  These were collected at 1 week and each cross was 
measured to the nearest mm using a ruler 
 Recovery – Time to return to normal activities and work.  These were also 
recorded by patients in a diary and were measured in days 
 
Late Outcomes 
 Objective clinical assessment of venous disease – The VCSS score was 
assessed pre-procedurally and at 3 and 12 months by the same vascular 
research nurse 
 The need for secondary procedures – The treatment of residual and 
recurrent disease.  These were only offered from 6 weeks to patients with 
symptomatic perforator reflux, symptomatic or unsightly surface 
varicosities following a full and frank discussion between the patient and 
surgeon.  These were only undertaken if both parties believed that further 
treatment would likely benefit the patient. 
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 Evidence of recurrence – on clinical or DUS examination 
 Complications – assessed at 1 week, 6 weeks, 3 months and 1 year 
 
Health Related Quality of Life Outcomes 
All QoL instruments below were measured at baseline and 1 week, 6 weeks, 3 
months and 1 year post-procedure.  These questionnaires were completed 
independently by the patients, free from investigator influence and prior to their 
clinical and duplex assessments.  They were then assessed for completeness and in 
the presence of missing responses; patients were prompted to complete these 
sections.  The following instruments were used:   
 Disease specific QoL – AVVQ.  This was the primary outcome measure used in 
this study 
 Generic QoL – SF-36 
 Index utility QoL - EQ5D 
 
Duplex Assessment 
All screening and follow-up duplex assessments were performed using the same 
device; Toshiba Aplio XV® (Toshiba medical systems Crawley, UK) with a 6 Mega 
Hertz linear broadband transducer array, using the same initial default settings.  
The protocol was based upon international consensus, with some minor 
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modifications227 and all sonograms were performed by investigators appropriately 
qualified in the technique. 
 
B-Mode Settings 
In order to clearly and accurately demonstrate the venous anatomy in both 
transverse and longitudinal views; the focal zone was set to the depth of the veins 
under interrogation.  The gain and dynamic gain control were tailored to optimise 
the image in each case.  Tissue harmonic and compound imaging was used to 
further enhance image quality and allow accurate measurements to be recorded. 
 
Doppler Settings 
In both colour duplex and pulse wave spectral Doppler; low flow settings, typically 
5-10 centimetres per second (cms-1) were used to capture venous flow data.  
Filters were reduced and colour gain optimised to enhance sensitivity, whilst 
avoiding artefact and “colour leaking”. 
 
Sonographic Protocol 
Patients were assessed whilst standing in a warm room, with the subject leg 
slightly flexed at the knee and the patients weight transferred onto the other leg.  
Initially the patient faced the sonographers with the subject leg externally rotated 
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at the hip.  The study commenced with identification of the SFJ in transverse 
section.  Assessment for incompetence was performed using manual flow 
augmentation with sudden release, greater than 10 cm distal to the region of 
insonation or the foot; when interrogating the distal calf.  Incompetence was 
defined as retrograde flow greater than or equal to 1 second on spectral Doppler 
(this criteria was used for both superficial and deep venous systems throughout 
this study).  The groin was then assessed for possible sources of reflux including 
the SFJ, abdominal or pelvic veins, aberrant groin tributaries and perforators.  
During detailed mapping, the entire GSV and its tributaries were assessed from 
groin to ankle, followed by any other incompetent veins emanating from the groin, 
thigh or calf.  Any required antero-posterior measurements were made using the 
system’s electronic calipers positioned at the most anterior echo of the anterior 
wall and the most posterior echo of the posterior wall of the vein.  These were 
measured to the nearest 0.1 mm.  The patency of the superficial system was 
assessed using colour duplex and compression. 
The deep system was then assessed from the groin to the knee, continuous flow, 
pulsatile flow, obstruction, thrombosis, or incompetence involving the common 
femoral vein were indications to extend the examination to include the iliac veins 
and inferior vena cava and lead to consideration of other modalities of imaging (as 
did the presence of incompetence in the groin emanating from abdominal or 
pelvic tributaries).  
The patient was then repositioned with their back towards the sonographers and 
their hip was returned to the anatomical position for assessment of the sapheno-
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popliteal system and the deep veins of the calf.  Initially the SSV was identified at 
the ankle and then assessed and traced back to the sapheno-popliteal junction.  
The position of the junction was noted and the examination went on to assess the 
other proximal and distal tributaries including the Giacomini vein, which, where 
present; was followed to its termination.  Again a search was made for any 
incompetent perforators, before finally the popliteal and crural veins were 
assessed for patency and reflux. 
 
Duplex Outcomes  
The post-procedural DUS outcomes used in this study were: 
 Technical success – Successful completion of the planned procedure, i.e. 
successful initial occlusion of the treated segment of GSV 
 Complications – Particularly looking for deep vein thrombosis/heat 
induced thrombosis 
  Recanalisation – Recurrent flow within a previously occluded GSV 
 Progression of disease – with further sites of incompetence 
 
Patient Satisfaction  
This was assessed at 3 months and 1 year by asking if patients would be happy to 
undergo the same procedure again, if necessary, or recommend it to a friend. 
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Data Analysis 
This will be detailed in Section 2.12 Data handling and statistical analysis (p170). 
 
Study 2; Technique evaluation – A randomised clinical 
trial of endovenous laser ablation versus conventional 
surgery in the treatment of venous insufficiency 
 
2.5 Patients  
The setting for this non-blinded parallel-group randomised clinical trial was the 
same tertiary referral vascular surgical unit featured in Study 1.  Larger numbers of 
patients were required in this study.  In an attempt to make substantial 
improvements in the convenience and efficiency of the service to patients, clinical 
and research staff; a dedicated one-stop venous clinic was established.  New 
patients, referred to the service with venous disorders were given information 
regarding the trial prior to being their clinic appointment.  They were then 
assessed clinically by a consultant vascular surgeon or research registrar with a 
special interest in the management of venous disease.  Clinical assessment 
included a full history and examination including classification of the clinical 
severity of disease using the clinical grading element of the CEAP classification25 
and the VCSS system186.  This was followed immediately by a detailed duplex 
ultrasound assessment according to a standardised protocol (as outlined in Duplex 
Assessment, p145).  All ultrasound scans were performed by surgeons who were 
formally accredited in the performance of diagnostic vascular ultrasound.  Patients 
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were assessed for eligibility of trial participation according to predetermined 
inclusion and exclusion criteria.  Patients recruited into the trial were randomised 
and their baseline outcomes measured (as detailed below).  Patients were then 
given a date for their treatment before leaving the clinic.  
 
Inclusion Criteria 
Clinical 
 The presence of primary, unilateral, symptomatic venous disease of the 
lower limb classifiable as C2-6 on the clinical grading element of the CEAP 
classification system25 
 Willingness to accept a local anaesthetic EVLA procedure, including 
ambulatory phlebectomy (as outlined in Section 2.7 Interventions, p154) 
 Willingness to accept a general anaesthetic conventional surgical 
procedure (as outlined in Section 2.7 Interventions, p154) 
 Willingness and ability to participate in a clinical trial, including the 
attendance of additional clinical assessments, completion of 
questionnaires, duplex follow-up and the analysis and publication of this 
data 
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 Both patient and surgeon occupy a position of equipoise over the relative 
merits of either intervention (including an acceptance that general 
anaesthesia will not hold significant additional risks for individual patients) 
 
Duplex  
 Greater than, or equal to 1 second of retrograde flow of blood from the 
common femoral vein through the SFJ into the GSV on pulse wave spectral 
Doppler 
 Greater than, or equal to 1 second of retrograde flow of blood in the GSV 
on spectral Doppler in at least in the above knee segment 
 
Exclusion Criteria 
Clinical 
 Age less than 18 years 
 Previous intervention aiming to address junction, perforator or superficial 
axial insufficiency 
 Inability or unwillingness to give informed consent to trial participation 
 Pregnancy 
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 Symptoms or clinical evidence of arterial disease (including an ankle-
brachial pressure index of less than 0.8)  
 Previous groin surgery 
 Known thrombophilic state 
 Known malignancy 
 Allergy to local anaesthetic medications 
 
Duplex 
 Deep venous disease (including obstruction or insufficiency) 
 Sapheno-popliteal insufficiency 
 Superficial axis insufficiency other than the GSV (which in the surgeon’s 
view would be optimally treated with ablation or stripping rather than 
phlebectomy) 
 GSV less than 3 mm in antero-posterior diameter at the proposed 
cannulation point 
 
2.6 Randomisation 
Following informed written consent, eligible patients were randomised equally 
into to one of two parallel groups: 
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Conventional Surgery Group 
SFJ ligation, stripping of the GSV to the perigenicular segment and phlebectomy 
under general anaesthesia 
 
EVLA Group  
Truncal GSV EVLA with concomitant ambulatory phlebectomy using local 
anaesthesia 
 
Randomisation was performed at the screening visit immediately following signing 
of the consent form.  Patients were invited to select any opaque envelope, from 
those available, whilst under supervision.  No block randomisation was used.    
 
Sample Size 
A sample size calculation was performed, based upon the primary outcome 
measures which were the physical domains of SF-36.  Up to 120 patients per group 
are required to detect a moderate (5-10 point) difference in physical domains 
between two groups, with a power of 80% and a significance of 5%51.  Assuming 
that the differences in the pilot study were reproduced372, this figure would be 
sufficient giving a target recruitment of 140 per group allowing for drop out. 
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2.7 Interventions 
 
Conventional Surgery Group 
All procedures were performed under a general anaesthetic in either a day-case or 
dedicated vascular surgical theatre.  Patients received a single dose of 
preoperative antibiotics according to an RCT based protocol279.  Placed in the 
Trendelenburg position, the skin was prepared with 10% Povidone-Iodine in water 
(Betadine®, Purdue Pharma L.P, CT, USA).  In the case of iodine allergy, 2% 
Chlorhexidine Gluconate in 70% Isopropyl Alcohol (ChoraPrep® Insight Health Ltd, 
Wembley, UK) was used.  Sterile draping was applied prior to performing an 
oblique groin crease skin incision, parallel to the inguinal ligament and centred 
over the SFJ.  The dissection was continued through the superficial fascia to 
identify the groin tributaries and GSV.  All tributaries were ligated back to the 
second junction.  A flush ligation of the SFJ was performed, followed by inversion 
stripping of the GSV to the perigenicular segment.  2-0 uncoated Polyglactin 910 
(Vicryl® Ethicon, Cincinnati OH, USA) was the ligature material used.   The same 
suture was used to suture the cribiform fascia and superficial fascia, following 
evacuation of any blood or thrombus from the GSV strip tract.  The skin was closed 
using subcuticular 3-0 Poliglecaprone 25 (Monocryl® Ethicon, Cincinnati OH, USA) 
following infiltration of 0.5% Levobupivacaine into the wounds.  No additional 
barrier or over-sewing techniques were employed in an attempt to deter 
neorevascularisation.   
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EVLA Group 
All procedures were performed under local tumescent anaesthesia in a dedicated 
procedure room within the outpatients department.  No sedation was used.  
Patients were preoperatively marked in the procedure room using a portable 
MicroMaxx® ultrasound system (Sonosite Ltd, Hichin, UK).  The course of the GSV 
was marked on the skin using a permanent marker pen from the proposed point of 
cannulation to the SFJ.  If ambulatory phlebectomy was to be performed then the 
sites were also marked preoperatively.   
The skin was prepared with 10% Povidone-Iodine in water (Betadine®, Purdue 
Pharma L.P, CT, USA).  In the case of iodine allergy, 2% Chlorhexidine Gluconate in 
70% Isopropyl Alcohol (ChoraPrep® Insight Health Ltd, Wembley, UK) was used.  
Sterile draping of the leg was performed prior to percutaneous cannulation of the 
GSV with the patient in the reverse Trendelenburg position.  The initial aim was to 
cannulate the perigenicular GSV, but the technique evolved during the trial and 
cannulation was performed at the lowest point of demonstrable reflux above the 
medial malleolus.  A 5 French catheter was introduced into the vein using the 
Seldinger technique, and its tip accurately positioned at the SFJ using ultrasound.  
The patient was then put in the Trendelenburg position and perivenous local 
anaesthetic (20 millilitres of 2% Lignocaine with 1:200,000 Adrenaline and 20 ml of 
0.5% Levobupivacaine in 1 l of 0.9% Sodium Chloride solution) was infiltrated 
along the vein.  Total local anaesthetic did not exceed the recommended 
maximum safe dose per patient.  A sterile bare-tipped 600 nm laser fibre was 
introduced via the catheter for laser ablation of the GSV.  Endovenous laser energy 
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was delivered using an 810 nm diode laser generator (Diomed® / Angiodynamics®, 
Cambridge, UK) at 14 W power, continuous mode and withdrawal of the catheter 
was performed; aiming for a specified target energy delivery.  Again during the 
trial this policy evolved.  The initial aim was 60-80 Jcm-1, but by the end of the 
study, 100-120 Jcm-1 was the target. 
 
In both groups, surface varicosities and incompetent perforators were marked 
pre-operatively in the dependant position and concomitant phlebectomies were 
performed via stab incisions made over varicose tributaries, which were avulsed 
using a Kocherised mosquito clip or vein hook.  Perforators not ablated during the 
truncal procedure; were divided and ligated through a 1.5 cm incision, which was 
then closed with a subcuticular monofilament suture.  Stab incisions were closed 
with Steri-strips™ (3M, MN, USA), cotton wool, gauze and elastic compression 
dressings applied.  This was later replaced by a thigh length T.E.D™ anti-embolism 
stocking (Tyco Healthcare, Gosport, UK), which patients were advised to wear for a 
total of 6 weeks. All patients were discharged with Diclofenac 50 mg tds to be 
taken regularly for 1 week and Paracetamol 1 g qds for breakthrough pain.   
All patients were seen immediately pre and post procedure by the same research 
nurse, who provided the same instructions: elevation of the leg whilst at rest, 
mobilise as much as possible and return to work as soon as they feel able to do so, 
avoid driving, returning only when they can safely perform emergency 
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manoeuvres and after discussion with their insurers.   A 24 hour contact number 
was also given for advice or help. 
  
2.8 Outcomes 
Clinical Outcomes 
Peri-procedural Outcomes 
 Strip length – During surgical procedures, the length of GSV that was 
successfully stripped and removed was measured to the nearest cm using 
a ruler 
 Energy delivery – During EVLA procedures, the length of ablated vein was 
measured to the nearest 0.5 cm using the marks on the catheter.  This 
information, along with the total laser energy used was measured to the 
nearest J, allowing an average laser energy delivery in Jcm-1 to be 
calculated  
 Procedure duration – The time in minutes from the commencement of 
skin preparation until the patient leaves the procedure room 
 The need for overnight stay – post procedure 
 Successful completion of the planned procedure 
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 Technical success – Successful completion of the planned procedure, i.e. 
successful disconnection of all groin tributaries and stripping of the GSV 
to the perigenicular segment in the conventional surgery group and initial 
occlusion of the treated segment of GSV in the EVLA group (irrespective 
of the status of the groin tributaries) – established using DUS 
 Post-procedural pain scores – These were recorded by patients in a diary.  
Diaries contained 7 unmarked 10 cm visual analogue scales, representing 
day 0 (day of procedure) to 6.  One end of the scale is marked “no pain at 
all” (representing 0.0) the other end is marked “worst imaginable pain” 
(representing 10.0).  Patients were invited to place a cross on each line 
where they feel that their average pain for that day is best represented.  
These were collected at 1 week and each cross was measured to the 
nearest mm using a ruler 
 Supplementary analgesia – This was reported by patients in the same 
diary as the pain scales.  For days 0-6, each patient indicated whether 
they required any supplementary analgesia, for break-through pain 
 Procedural complications 
 Recovery – Time to return to normal activities and work.  These were also 
recorded by patients in a diary and were measured in days 
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Late Outcomes 
 Objective clinical assessment of venous disease – The VCSS score was 
assessed pre-procedurally and at 3 and 12 months by the same vascular 
research nurse 
 Residual varicose veins – defined as: clinically evident varicose veins 
greater than or equal to 3 mm in diameter present at week 1 and 6 
(irrespective of the existence of reported symptoms) 
 Clinical recurrence - defined as: clinically evident varicose veins greater 
than or equal to 3 mm in diameter, not present at week 1 and 6, but 
becoming apparent during subsequent follow up (irrespective of the 
existence of reported symptoms) 
 The need for secondary procedures – The treatment of residual and 
recurrent disease.  This were only offered after 6 weeks post-procedure to 
patients with symptomatic perforator reflux, symptomatic or unsightly 
surface varicosities following a full and frank discussion between the 
patient and surgeon as to the risks and benefits of further intervention.  
These were only undertaken if both parties believed that further treatment 
were likely to benefit the patient 
 Late complications 
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Health Related Quality of Life Outcomes 
All QoL instruments below were measured at baseline and 1 week, 6 weeks, 3 
months and 1 year post-procedure.  These questionnaires were completed 
independently by the patients, free from investigator influence and prior to their 
clinical and duplex assessments.  They were then assessed for completeness and in 
the presence of missing responses; patients were prompted to complete these 
sections.  The following instruments were used:   
 Disease specific QoL – AVVQ 
 Generic QoL – SF-36.  This was the primary outcome measure used in this 
study 
 Index utility QoL – SF6D 
 Index utility QoL - EQ5D 
 
Duplex Assessment 
Duplex assessment was performed according to the same protocol as used in 
Study 1 (See Duplex Assessment p145). 
 
Duplex Outcomes   
The post-procedural duplex outcomes used in this study were: 
 Technical success – as defined above 
161 
 
 Complications – Particularly deep vein thrombosis/heat induced 
thrombosis  
 The patterns of insufficiency associated with clinical recurrence – 
including recanalisation (defined as recurrent flow within a previously 
occluded GSV) 
 
Patient Satisfaction 
Patients were invited to place a cross on a 10 cm unmarked visual analogue scale 
representing satisfaction with the cosmetic outcome of the procedure and 
satisfaction with the overall treatment, including the process and outcome.  One 
end of the scales was marked “Completely unsatisfied” (representing 0.0) the 
other end is marked “Completely satisfied” (representing 10.0).  These were then 
measured to the nearest mm using a ruler.  This was assessed at 3 months and 1 
year. 
 
Data Analysis 
This will be detailed in Section 2.12 Data handling and statistical analysis (p170). 
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Study 3; Procedure refinement – Energy delivery 
during 810nm endovenous laser ablation of superficial 
venous insufficiency and post-procedural morbidity 
 
2.9 Patients 
The setting for this prospective observational study was the same tertiary referral 
vascular surgical unit hosting Study 1 and 2.  All consecutive patients presenting 
were evaluated for eligibility in a series of trials according to predetermined 
inclusion and exclusion criteria.  These trials included Study 1 and 2 above, the 
non-randomised pilot study for Study 2372 and an RCT of EVLA versus conventional 
surgery for sapheno-popliteal incompetence (follow-up currently on-going).  In 
addition some patients were suitable for inclusion in these studies, except had a 
very strong preference for EVLA.  In this case, consent was taken to observe their 
outcomes, using the same follow-up protocol as for Study 2.  All available data 
from patients undergoing EVLA with concomitant phlebectomy was used in this 
analysis.   
Assessment of each patient was performed by a consultant vascular surgeon or 
research registrar with a special interest in the management of venous disease.  
Clinical assessment included a full history and examination including classification 
of the clinical severity of disease using the clinical grading element of the CEAP 
classification25 and the VCSS system186.  This was followed by a detailed duplex 
ultrasound assessment according to a standardised protocol.  All ultrasound scans 
were performed by surgeons who were formally accredited in the performance of 
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diagnostic vascular ultrasound.  The details of duplex assessment are outlined in 
Section Duplex Assessment, p145. 
 
Inclusion criteria 
Clinical 
 The presence of primary, unilateral, symptomatic venous disease of the 
lower limb; classifiable as C2-5 on the clinical grading element of the CEAP 
classification system25 
 Willingness to accept a local anaesthetic EVLA procedure, including 
ambulatory phlebectomy (as outlined in Section 2.10 Interventions, p165) 
 Willingness and ability to participate in a clinical trial, including the 
attendance of additional clinical assessments, completion of 
questionnaires, duplex follow-up and the analysis and publication of this 
data 
 
Duplex  
 Greater than, or equal to 1 second of retrograde flow of blood from the 
common femoral vein through the SFJ into the GSV or from the deep vein 
through the sapheno-popliteal junction into the SSV on pulse wave spectral 
Doppler 
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 Greater than, or equal to 1 second of retrograde flow of blood in the GSV 
or in the SSV on spectral Doppler 
 
Exclusion Criteria 
Clinical 
 Age less than 18 years 
 Previous intervention aiming to address junction, perforator or superficial 
axial insufficiency 
 Inability or unwillingness to give informed consent to study participation 
 Pregnancy 
 Symptoms or clinical evidence of arterial disease (including an ankle-
brachial pressure index of less than 0.8)  
 Known thrombophilic state 
 Known malignancy 
 Allergy to local anaesthetic medications 
 
Duplex 
 Deep venous disease (including obstruction or insufficiency) 
165 
 
 More than 1 superficial axis of insufficiency (which in the surgeon’s view 
would be optimally treated with ablation or stripping rather than 
phlebectomy) 
 GSV  or SSV less than 3 millimetres in antero-posterior diameter at the 
proposed cannulation point 
 
Sample Size 
A sample size calculation was performed for the regression analyses planned (See 
Section 2.12 Data handling and statistical analysis, p170).  As 11 predictor 
variables were to be studied, the required sample size to test each individual 
predictor is 115, whilst the required sample size to test the models is 138373.  This 
was regarded as the minimum accepted sample size, in order to reduce the risk of 
missing any significant relationships. 
 
2.10 Interventions 
All procedures were performed under local tumescent anaesthesia in a dedicated 
procedure room within the outpatients department.  No sedation was used.  
Patients were preoperatively marked in the procedure room using a portable 
MicroMaxx® ultrasound system (Sonosite Ltd, Hichin, UK).  The course of the 
target vein was marked on the skin using a permanent marker pen from the 
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proposed point of cannulation to the junction.  The sites for ambulatory 
phlebectomy were also marked preoperatively.   
The skin was prepared with 10% Povidone-Iodine in water (Betadine®, Purdue 
Pharma L.P, CT, USA).  In the case of iodine allergy, 2% Chlorhexidine Gluconate in 
70% Isopropyl Alcohol (ChoraPrep® Insight Health Ltd, Wembley, UK) was used.  
Sterile draping of the leg was performed prior to percutaneous cannulation of the 
target vein with the patient in the reverse Trendelenburg position.  A 5 French 
catheter was introduced into the vein using the Seldinger technique, and its tip 
accurately positioned at the junction using ultrasound.  The patient was then put 
in the Trendelenburg position, and perivenous local anaesthetic was infiltrated 
along the vein.  Total local anaesthetic did not exceed the recommended 
maximum safe dose per patient.  A sterile bare-tipped 600 nm laser fibre was 
introduced via the catheter for laser ablation of the GSV.  Endovenous laser energy 
was delivered using an 810 nm diode laser generator (Diomed® / Angiodynamics®, 
Cambridge, UK) at 14 W power, continuous mode and withdrawal of the catheter 
was performed. 
Tumescent local anaesthetic was also infiltrated around varicose tributaries and 
stab incisions were made, allowing avulsion of the veins using a Kocherised 
mosquito clip or vein hook.  These incisions were closed with Steri-strips™ (3M, 
MN, USA), cotton wool, gauze and Panelast® (Lohmann & Rauscher International 
GmbH & Co. KG, Rengsdorf, DE) elastic adhesive bandage was applied to the limb.  
This remained in situ for 1 week, when it was replaced by a thigh length T.E.D™ 
anti-embolism stocking (Tyco Healthcare, Gosport, UK), which patients were 
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advised to wear for a total of 6 weeks. All patients were discharged with 
Diclofenac 50 mg tds to be taken regularly for 1 week and Paracetamol 1 g qds for 
breakthrough pain.   
All patients were seen immediately pre and post op by the same research nurse, 
who provided the same instructions: elevation of the leg whilst at rest, mobilise as 
much as possible and return to work as soon as they feel able to do so, avoid 
driving, returning only when they can safely perform emergency manoeuvres and 
after discussion with their insurers.   A 24 hour contact number was also given for 
advice or help.  
 
2.11 Outcomes 
Clinical Outcomes 
Peri-procedural Outcomes 
 Energy delivery – During EVLA procedures, the length of ablated vein was 
measured to the nearest 0.5 centimetre using the marks on the catheter.  
This information, along with the total laser energy used was measured to 
the nearest J, allowing an average laser energy delivery in Jcm-1 to be 
calculated  
 The need for overnight stay – post procedure 
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 Post-procedural pain scores – These were recorded by patients in a diary.  
Diaries contained 7 unmarked 10 cm visual analogue scales, representing 
day 0 (day of procedure) to 6.  One end of the scale is marked “no pain at 
all” (representing 0.0) the other end is marked “worst imaginable pain” 
(representing 10.0).  Patients were invited to place a cross on each line 
where they feel that their average pain for that day is best represented.  
These were collected at 1 week and each cross was measured to the 
nearest mm using a ruler 
 Supplementary analgesia – This was reported by patients in their pain 
diary.  For days 0-6, each patient indicated whether they took any 
supplementary analgesia, for break-through pain 
 Time to return to normal activities and work – These were also recorded 
by patients in a diary and were measured in days 
 Procedural complications 
 
Health Related Quality of Life Outcomes 
All QoL instruments below were measured at baseline, 1 week and 6 weeks post-
procedure.  These questionnaires were completed independently by the patients, 
free from investigator influence and prior to their clinical and DUS assessments.  
They were then assessed for completeness and in the presence of missing 
responses; patients were prompted to complete these sections.  The following 
instruments were used:   
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 Disease specific QoL – AVVQ. 
 Generic QoL – SF36 physical domains 
 Index utility QoL - EQ5D 
 
Duplex Assessment 
Duplex assessment was performed according to the same protocol as used in 
study 1 (See Duplex Assessment p145). 
 
Duplex outcomes 
The post-procedural duplex outcomes used in this study were: 
 Complications – Particularly deep vein thrombosis/heat induced 
thrombosis 
 
Data Analysis 
This will be detailed in Section 2.12 Data handling and statistical analysis.  
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2.12 Data handling and statistical analysis 
All data was transcribed and recorded into a secure dedicated database (Microsoft 
Access®, Redmond, WA, USA).  All analysis was performed utilising SPSS (Chicago, 
IL, USA). 
The statistical analysis was performed according to a standardised prospectively 
determined protocol according to the principle of intention to treat.  No 
assumptions were made at any time as to the direction of any relationships and no 
imputation of missing data was attempted.  Any key assumptions of the statistical 
techniques used were tested as appropriately. 
 
Continuous data 
Description 
Normally distributed data was quoted as mean (95% confidence interval) (for 
dependant variables) or mean (standard deviation) or mean (range) (for 
independent variables).  If data was not normally distributed, it is quoted as 
median (inter-quartile range).  
Continuous data is presented using standard statistical notation in box and 
whisker plots.  The box indicates the inter-quartile range and the median 
represented by a line within the box.  The whiskers represent the range of data 
within 1.5 times the inter-quartile range below the 1st quartile and above the 3rd 
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quartile.  Data points outside of this are considered outliers and represented by 
dots. 
 
Analysis 
Prior to any further analysis of continuous data, its distribution was explored using 
histogram analysis.  Any data which appeared to be normally distributed 
underwent hypothesis testing using the Shapiro-Wilk test (SW)374 to establish the 
degree of certainty of this assumption.  For the purposes of the following studies; 
significance values greater than 0.050 were assumed to be normally distributed.   
Intragroup comparisons, featured the analysis of paired data (ie before and after 
in the same patient) and intergroup comparisons used unpaired data (ie from 
different patients).  Hypothesis testing was performed comparing groups 
according to the data distribution and whether it was paired or unpaired.   The 
quoted “P-value” represents the probability of having observed the data if the null 
hypothesis were true375 (ie there is no actual differences between the data).  “P-
values” are quoted to three decimal places and a value of less than 0.050 was 
regarded as “significant” and led to rejection of the null hypothesis.  These 
statistically significant differences were then examined to establish whether they 
represented clinically significant findings in the context of this research and the 
existing evidence base. 
The following hypothesis tests were used according to the nature of the data 
under interrogation:  
172 
 
Normally distributed data: 
 Paired – paired Student t-test (t test)376 (2 samples), ANOVA377 (multiple 
related samples) 
 Unpaired – unpaired Student t-test (t test)376 
 
Non-normally distributed data:  
 Paired – Wilcoxon signed rank test (WSR test)378 (2 samples), Friedman 
ANOVA (F-A)379  (multiple related samples) 
 Unpaired – Mann-Whitney U test (MWU test)380 
 
Categorical data 
Description 
Simple categorical data is presented as percentages (x/y) where x represents the 
number of cases in a category and y represents the total number of cases under 
consideration.  When required, relative risk (RR), risk differences (RD) and number 
needed to treat (NNT) is also quoted along with 95 confidence intervals.   
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Analysis 
The primary hypothesis test used in categorical analysis is Pearson’s Chi-square 
test (χ2 test)381.  If greater than 20% of expected frequencies are less than 5 or any 
are below 1, then Fisher’s exact test (FET) 382 was used.  In order to account for 
censored data Kaplan-Meier analysis383 was conducted featuring intergroup Log 
Rank significance testing. 
 
Linear regression analysis (Study 3) 
In order to test the null hypothesis that increasing linear energy delivery had no 
effect upon post-procedural pain, QoL and recovery rates in Study 3, linear 
regression models were used. 
 
Model detail: Predictor variables 
The primary predictor variable of interest was the linear energy delivery in Jcm-1.  
The other independent predictor variables were age, gender, BMI, the radius and 
length of the treated vein and pre-operative QoL (AVVQ, EQ5D and physical 
domains of SF-36).  These were included within the models, so their effect could 
be controlled and the effect of the primary predictor studied in isolation. 
Some surgeons calculate energy delivery taking into account both length and 
diameter.  Controlling for the radius within these models allows these results to be 
comparable.  Although the QoL outcomes are the change in scores, rather than 
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the absolute scores post-procedure, baseline scores were entered into the model. 
This is because it was unknown whether differing scores at baseline would 
respond with differing magnitudes to treatment.  For example would a patient 
with chronic back pain notice a similar incremental change in their total bodily 
pain score as someone with no pain at all before EVLA?  This effect, where 
present, was therefore also controlled. 
 
Model detail: Outcome variables 
The outcome variables of interest were all independently reported by the patient.  
They were post-procedural pain (as measured daily for the first week on visual 
analogue scale), changes in QoL from baseline by week 1 and week 6 (AVVQ, EQ5D 
and physical domains of SF-36) and recovery rates (the time taken to return to 
normal activity and the time taken to return to work). 
 
Model detail: Model technique and testing of assumptions 
The aim of the models was to test the effect of the primary predictor variable 
upon the outcome variables, whilst controlling for the other independent 
predictors.  In order to fulfil this aim, linear regression models were produced for 
these continuous outcomes.  
If the continuous outcomes were not normally distributed, they were transformed 
using standard mathematical techniques.  Statistical significance was set at less 
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than 0.050 (α = 0.05).  T-tests of the estimated b values allowed significance level 
calculation of the contribution of an individual predictor to the model’s predictive 
ability.  Effect sizes and the proportion of variance in the outcome due to the 
energy delivery alone were calculated.  The models were produced via the method 
of “forced entry.”  This allows the retention of methodological control of the 
modal and is thought to reduce the effect of random sampling variation within the 
data and produce replicable results384.   
All predictor variables were continuous, with a variance greater than 0.  All 
outcomes were continuous, independent and not unduly constrained.  Correlation 
statistics were performed and no significant multicollinearity was observed, 
additionally the variance inflation factor was less than 10 in each model.  There 
are no known important correlations between these predictors and external 
variables, which will have a significant effect upon the models.  Residual values 
were plotted to establish linearity and homoscedastiscity.  Residual value 
histograms were drawn confirming normal distribution.  Finally the independence 
of errors was established using the Durbin-Watson test.  This test statistic was 
between 1 and 3 in each model; this was taken to confirm the independence of 
errors. 
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Logistic regression analysis (Study 3) 
In order to test the null hypothesis that increasing linear energy delivery had no 
effect upon supplementary analgesia for breakthrough pain or the incidence of 
complications in Study 3, logistic regression models were used. 
 
Model detail: Predictor variables 
As for the linear regression models, the primary predictor variable of interest was 
the linear energy delivery in Jcm-1.  The other independent predictor variables 
were age, gender, body mass index, the radius and length of the treated vein and 
pre-operative QoL (AVVQ, EQ5D and physical domains of SF-36).   
 
Model detail: Outcome variables 
The outcome variables of interest were binary in nature.  The first was the patient 
reported requirement of supplementary analgesia (daily for the first week) the 
second was the incidence of all patient reported or clinically observed 
complications (including during standardised duplex assessment).  
 
Model detail: Model technique and testing of assumptions 
The aim of the models was to test the effect of the primary predictor variable 
upon the probability of the outcome variables occurring, whilst controlling for the 
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other independent predictors.  In order to fulfil this aim, logistic regression models 
were produced for these binary outcomes.  
The “forced entry” method was again used in model construction.  The individual 
contribution of the predictors was assessed by Chi square testing of the Wald 
statistic.  Again statistical significance was set at less than 0.050 (α = 0.05).  The 
Odds ratio (95% confidence interval) was calculated for the effect of the primary 
predictor in isolation upon the outcome. 
All predictor variables were continuous, with a variance greater than 0.  
Correlation statistics were performed and no significant multicollinearity was 
observed, additionally the variance inflation factor was less than 10 in each model.  
There are no known significant correlations between these predictors and external 
variables, which will have a significant effect upon the models.  Linearity of the 
logit and the independence of errors were confirmed.  Sufficient data was 
available for all combinations of variables.  
 
2.13 Ethics 
The conduct of these studies, along with dissemination of findings and the drafting 
of this thesis has been performed with the principles of the declaration of Helsinki 
at their heart385.  In particular, the health of each individual patient included and 
considered for inclusion was seen as the primary concern of each individual 
involved with this research.   
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In the context of this research; patients were only offered an intervention if both 
patient and surgeon felt that on balance this would result in a significant benefit to 
that individual, with the potential risks being taken into account.  Inclusion in 
randomised studies was only entertained if both surgeon and patient occupied a 
position of equipoise over the optimal procedure to be undertaken.  All patients 
were made aware of the additional burden of the assessments associated with the 
research and were aware that they could withdraw at any stage of the research 
process, without any cost or prejudice to their existing, on-going or future care.  
Dynamic solutions were sought and found to decrease such burdens, such as the 
integration of services resulting from the one-stop venous clinics.  It was 
innovations such as this, the institution of routine duplex assessment and tailored 
treatment in every case, alongside the increased contact and support offered by 
the research team that led to improvements in patient care and outcomes and 
very high levels of patient satisfaction. 
All interventions were approved for routine use within the context of the NHS, in 
particular EVLA was accepted as a treatment provided that “the normal 
arrangements are in place for consent, audit and clinical governance”386. 
The fundamental aim of this body of work was to improve patient care and 
outcomes by providing reliable information of the risks, benefits and efficacy of 
these new technologies to the management of superficial venous insufficiency 
when compared to the gold standard treatment: conventional surgery.  
Conventional Surgery was established as the gold standard after undergoing 
rigorous assessment in comparison with conservative management50. 
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The design of the studies was intended to conform to what is regarded as gold 
standard methodology.  Protocols were prospectively designed and approval 
sought and secured from both independent ethics committees and the 
institutional review board.  These trials were then registered in a freely available 
public registry, as per current recommendations387.  Where possible, the design 
was that of a RCT, offering level-1 evidence.  The nature of the techniques limited 
the possibility of blinding in the main part, but every effort was made to be even-
handed regarding the surrounding package of information and care, and many of 
the key outcomes, including the primary outcomes were independently reported 
by patients themselves using validated instruments.  These were completed prior 
to clinical and duplex assessment, limiting any investigator induced bias and are 
validated in the role of assessing a patient’s quality of life.  The fact that quality of 
life plays such a prominent central role in the evaluation of these technologies, 
testifies to the great emphasis placed upon patient perspectives and patient-
centred end-points, rather than the technical physician-chosen (surrogate) 
outcomes pervading the literature in this area prior to this work.  In order to avoid 
the wastage and redundancy associated with under-powered, possibly misleading 
studies; this work was based upon realistic and feasible sample-size calculations, 
based upon detecting clinically meaningful differences.  All statistical analysis was 
performed using standard, widely accepted techniques, and no imputation of data 
was performed, reducing unnecessary assumptions having an impact upon the 
conclusions. 
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All eligible patients were offered an opportunity to participate, according to their 
free will.  Upon choosing to participate, patients were required to indicate their 
informed consent by signing a standardised form.  Children and vulnerable adults 
were excluded, to help to ensure that all participants had the true capacity to give, 
or perhaps later withhold, their consent to participation.  All hard copy data is kept 
in a locked room at the Academic Vascular Surgical Unit (based within Hull Royal 
Infirmary).  All electronic data was held on a secure server hosted jointly by the 
University of Hull and Hull and East Yorkshire Hospitals NHS Trust.  This data has 
an identified Caldicott guardian, and has not been disseminated in any way, such 
that individual patient’s data or involvement in the studies can be identified.   
All investigators had undergone formal training in “Good Clinical Practice” with 
regards to the undertaking of clinical research and all investigators involved in the 
delivery of clinical care were appropriately qualified and experienced in the 
delivery of that care, in particular all duplex assessments were performed by 
surgeons who had completed (with distinction) a full University-based, post-
graduate ultrasound course, designed for the accreditation of full-time vascular 
sonographers. 
The research team did receive some industry support towards research costs; 
namely Diomed® / Angiodynamics® (Cambridge, UK) provided 50% of a research 
nurse’s salary over a 12 month period to facilitate these studies.  The motivation 
of this support was directed towards the investigators occasionally acting in a 
teaching / mentoring capacity facilitating uptake of these new technologies.  With 
regard to research; the support was unconditional and this company had no 
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involvement or influence in the design, data collection, data analysis, or 
dissemination of this research.  In addition the company had no access to any of 
the documentation, data or analysis that is not available in the public domain.  
This relationship has been made clear whenever this work has been disseminated. 
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Chapter 3 – Results 
 
Study 1; Procedure Refinement – A randomised clinical 
trial of endovenous laser ablation with concomitant 
versus selected sequential phlebectomy in the 
treatment of venous insufficiency 
 
3.1 Patient Recruitment and Baseline Analysis 
Figure 21 outlines the recruitment and the number of patients involved in analysis 
at each stage. 
Some 50 patients were randomised, as planned; with attention to the inclusion 
and exclusion criteria specified in the protocol.  All patients randomised to EVLTAP 
received the allocated treatment as per protocol.  One patient allocated to the 
Control group decided that they would prefer concomitant phlebectomy and 
withdrew from the trial in order to receive their preferred treatment.  They 
declined to continue to participate in follow-up and so were excluded from 
analysis beyond baseline.  Attrition to follow-up was comparable between the two 
groups and occurred mainly between week 6 and 52.  There were no protocol 
violations. 
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Figure 21:  CONSORT diagram showing flow of patients through the trial (Study 1). SPJ, saphenopopliteal junction; SSV - short saphenous vein; EVLT - 
endovenous laser therapy; EVLTAP - EVLT with concomitant ambulatory phlebectomy
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The two groups were analysed in terms of age, gender, baseline VCSS and quality 
of life (Table 15).  The results for age and AVVQ were found to be normally 
distributed (P=0.235-0.804 SW) and therefore parametric hypothesis testing was 
performed to ascertain the significance of any observed differences. The other 
continuous variables differed significantly from a normal distribution and 
differences were analysed using non-parametric hypothesis testing.  No significant 
differences were observed as is to be expected from this randomised data. 
Table 15 illustrates that the methodology has resulted in the recruitment of a 
cohort of patients typical of those seen in routine practice.  Approximately three 
quarters are women with a mean age in their early 50s.  The median VCSS score is 
4, which corresponds to uncomplicated symptomatic varicose veins, which are 
causing a significant perceived impact upon QoL; as evidenced by a median AVVQ 
of 13 to 14.   
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  EVLTAP EVLT alone 
(Control) 
P Value 
Age (yrs): Mean 
(Standard Deviation) 
51 (14) 53 (16) 0.738* 
Gender: Male : Female 8:17 4:21 0.321† 
Venous Clinical Severity 
Score 
4 (3-5) 4 (2-5) 0.507 
SF
-3
6
 D
o
m
ai
n
s 
Physical Function 85 (70-99) 93 (80-100) 0.407 
Role – Physical 100 (57-100) 100 (17-100) 0.947 
Bodily Pain 74 (51-84) 79 (55-100) 0.538 
General Health 71 (58-87) 77 (56-91) 0.455 
Vitality 70 (41-75) 68 (60-75) 0.853 
Social Function 100 (63-100) 100 (78-100) 0.517 
Role- Emotional 100 100 0.678 
Mental Health 84 (66-92) 80 (67-88) 0.592 
Aberdeen Varicose Vein 
Questionnaire:  
Mean (95% Confidence 
Interval) 
13.29 (11.09-15.50) 13.75 (11.67-15.82) 0.728* 
Euroqol Health Index 
Score 
0.796 (0.769-1.000) 0.796 (0.778-1.000) 0.325 
Table 15: Baseline comparison of the groups (Study 1).  Figures are quoted as median (inter-
quartile range) and the P values are derived from the MWU test unless otherwise stated: 
*
 - t 
test, 
†
 - χ
2
 test   
 
 
3.2 Clinical Outcomes 
Peri–procedural Outcomes 
Procedural success:  All attempted procedures were successfully completed as 
per-protocol.  At 1 week all treated vein segments were occluded on examination 
with DUS, giving an initial technical success rate of 100%.   
 
186 
 
Procedure duration:  The median procedural times were 20 minutes longer for 
EVLTAP compared to  the Control group (65 (50-70) and 45 (40-55) minutes 
p=0.002 - MWU). 
 
Procedural complications:  There were no statistical differences in the 
complications observed between the two groups.  One patient suffered phlebitis 
of the GSV in the Control group, this settled within 2 weeks following continuing 
treatment with Diclofenac 50mg tds and topical 0.3% heparinoid gel.  One patient 
developed a small area of pressure necrosis secondary to the dressings, this 
settled spontaneously.  Two patients in the EVLTAP group noticed some 
pigmentation over the GSV and one patient had neuralgia in their thigh, all of 
which were self limiting.   
 
Pain:  Post procedural pain scores were fairly low in both groups. There was no 
statistical difference between the groups in terms of perceived pain scores on day 
0 to 6 (Table 16, Figure 22): 
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Day EVLTAP EVLT Alone (Control) P Value 
0 3.2 (0.2-6.0) 1.9 (0.3 - 4.6) 0.288 
1 3.0 (0.1-4.4) 1.6 (0.6 - 3.0) 0.514 
2 1.7 (0.0-3.2) 1.5 (0.0 - 3.0) 0.808 
3 1.3 (0.0-2.6) 0.6 (0.0 - 1.4) 0.641 
4 1.0 (0.0-2.4) 0.5 (0.0 - 1.2) 0.433 
5 1.1 (0.0-2.4) 0.2 (0.0 - 2.1) 0.466 
6 0.0 (0.0-2.9) 0.3 (0.0 - 1.2) 0.959 
Table 16: Post-procedural pain scores (Study 1).  Values indicate the med (IQR) scores reported 
on an unmarked visual analogue scale from 0 (“no pain at all”) to 10 (“worst imaginable pain”).  
The P-values are derived from the MWU test 
 
 
 
Figure 22: Post-procedural pain scores from the day of the procedure (day 0) until day 6 (Study 1).  
The visual analogue scale runs from 0 (“no pain at all”) to 10 (“worst imaginable pain”) 
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Recovery:  There was no statistically significant difference in the number of days 
taken to return to work (EVLTAP group – 10 (4-21) days, Control group - 3 (1-14) 
days P = 0.054 MWU) or return to normal activities (EVLTAP - 8 (1-14) days, 
Control - 2 (1-5) days p=0.166 MWU). 
 
Late Outcomes 
Objective clinical assessment of venous disease:  Both groups saw a significant 
decrease (improvement) in VCSS scores over the study period following treatment 
(p<0.001 – F-A, Table 17, Figure 23), however when the groups are compared; 
there was a significant difference of median 2 points between the groups at 3 
months (P<0.001 MWU).  The EVLTAP group score significantly lower (better) at 
this time.  By 1 year, this gap had closed again and the groups were once more 
indistinguishable.    
 
Week EVLTAP EVLT Alone (Control) P-Value 
0 4 (3-5) 4 (2-5)   0.817 
12 0 (0-1) 2 (0-2) <0.001 
52    0 (0-1) *    0 (0-1) *   0.738 
Table 17: Venous Clinical severity scores, over time by group (Study 1).  The P-values represent 
the intergroup comparison at each time point (MWU). 
*
 - Intragroup comparison over time 
P<0.001 (F-A).  
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Figure 23: Clinical Severity of Venous Disease, using the Venous Clinical severity score, over time, 
by group (Study 1) 
 
 
Secondary procedures:  In the Control group 16 of 25 patients (64%) required 
subsequent perforator surgery or ambulatory phlebectomy, compared with only 1 
of 25 in the EVLTAP group (4%, p<0.001 χ2).  The RR (95% CI) was 0.06 (0.01-0.44) 
and the NNT (95% CI) with EVLTAP rather than EVLT alone to avoid the 
requirement for 1 subsequent procedure is 1.7 (1.3-2.5).  All were planned and 
performed close to 6 weeks. No further interventions were required at 3 or 12 
months. 
Complications:  There were no late complications which became apparent during 
the 1 year follow-up period. 
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Recurrence:  There were no cases of clinical recurrence evident by 1 year in either 
group.  On DUS at 1 year, one SFJ demonstrated reflux in the EVLTAP and two in 
the Control group.  Three patients had a partially re-canalised GSV (two showed 
reflux) in the EVLTAP group and one in the Control group. No patients required 
further treatment to the GSV or SFJ. 
 
 
3.3 Quality of Life Outcomes 
Disease Specific Quality of Life 
This was the primary outcome for the trial (See Figure 24).  Both groups saw a 
significant decrease (improvement) in AVVQ scores over the study period (Control 
- P=0.031, EVLTAP – P<0.001 – F-A).  Detailed analysis using WSR test clearly shows 
that the EVLTAP group saw a significant improvement from baseline by 6 weeks 
(P=0.008), but this was not true of the Control group (P=1.000), who did not see an 
improvement until 3 months post procedure (P=0.018).   
When comparing the groups; AVVQ scores were significantly lower (better) in the 
EVLTAP group at both 6 weeks (P<0.001 MWU) and 3 months (P=0.015 MWU) 
respectively.  However there is no difference at 1 week or 1 year. 
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Figure 24: Disease Specific Quality of Life Impairment using the Aberdeen Varicose Veins 
Questionnaire, over time, by group (Study 1) 
 
 
Generic Quality of Life 
There were no statistically significant changes in any of the SF-36 domains over 
time in either group (Figure 25 - Figure 32), however the index utility score 
increased (improved) over time in the EVLTAP group (P<0.001 – F-A, Figure 33) 
and this improvement was observed from 6 weeks (P=0.002 WSR). This 
improvement was not demonstrated in the Control group over the study period 
(P=0.112 F-A). 
When comparing the two groups at each time point for each variable, there are no 
clinically significant differences observed.  There is a statistically significant 
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difference in MH at 6 weeks; with patients in the Control group scoring lower 
(worse) (med (IQR) EVLTAP – 88 (76-92), Control – 76 (60-84) (P=0.030 MWU).  
This difference however is not of a sufficient magnitude to be regarded as a 
clinically significant difference in this domain51,388,389.  There were no other 
statistical differences between the groups across all time points (P>0.050) in 
generic QoL measures. 
   
 
Figure 25: SF-36 Physical Function, over time, by group (Study 1) 
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Figure 26: SF-36 Role Limitation due to Physical Disability, over time, by group (Study 1) 
 
 
Figure 27: SF-36 Bodily Pain, over time, by group (Study 1) 
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Figure 28: SF-36 General Health, over time, by group (Study 1) 
 
Figure 29: SF-36 Vitality, over time, by group (Study 1) 
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Figure 30: SF-36 Social Function, over time, by group (Study 1) 
 
Figure 31: SF-36 Role Limitation due to Emotional Problems, over time, by group (Study 1) 
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Figure 32: SF-36 Mental Health, over time, by group (Study 1) 
 
 
Figure 33: Euroqol Utility Index Scores, over time, by group (Study 1) 
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3.4 Patient Satisfaction 
100% (20/20) of EVLTAP patients and 90% (19/21) of Control patients stated that 
they would have EVLA again if necessary or recommend it to a friend at 1 year 
(P=0.342 - FET). 
 
 
Study 2; Technique evaluation – A randomised clinical 
trial of endovenous laser ablation versus conventional 
surgery in the treatment of venous insufficiency 
 
3.5 Patient Recruitment and Baseline Analysis  
Figure 34 outlines the recruitment and the number of patients involved in analysis 
at each stage. 
Some 280 patients were randomised, as planned; with attention to the inclusion 
and exclusion criteria specified in the protocol.  All but one patient randomised to 
EVLA received the allocated treatment as per protocol.  This single patient decided 
that they did not wish to undergo any treatment for their venous disease at this 
time and withdrew from the trial.  Three of the patients randomised to surgery 
withdrew from the trial.  They stated that after consideration; they were no longer 
in a position of equipoise and would prefer endovenous ablative treatment 
instead, hence withdrawing from the study.  These four patients declined to 
continue to participate in follow-up and so were excluded from analysis beyond 
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baseline.  There was no difference between the groups in terms of the numbers 
lost or the length of successful follow-up (Log rank p=0.081).  Considering the 
patients who progressed to treatment within the trial, there were no protocol 
violations. 
 
 
Figure 34: CONSORT diagram showing flow of patients through the trial (Study 2). EVLA - 
endovenous laser ablation; Surgery – conventional SFJ ligation and GSV stripping 
 
 
The two groups were analysed in terms of age, gender, laterality, smoking status, 
employment status, antiplatelet/anticoagulant usage, height, BMI, baseline vein 
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diameter, baseline CEAP clinical grade, baseline VCSS and QoL (Table 18).  No 
continuous variable was found to be normally distributed for both groups and 
therefore non-parametric hypothesis testing was performed to ascertain the 
significance of any observed differences.  There was a statistically significant 
difference in Mental Health, but this is not of a sufficient magnitude to be 
regarded as a clinically significant difference51,388,389.  Therefore no significant 
differences were observed; as is to be expected from this randomised data. 
These patients are typical of those presenting with venous disease in this region.  
Mean age is around 50 years with just over 60% women.  65% are in employment 
and 50% have a positive smoking history.  Approximately 28% are Ex-smokers and 
25% are active smokers, compared with a national average of 25% and 22% 
respectively390.   The mean height and BMI are comparable to the national 
average390.  Around 70% of patients have uncomplicated superficial venous 
insufficiency, which is causing a significant impairment in QoL, as evidenced by the 
AVVQ scores.  This is typical of such a group and is comparable to that observed in 
Study 1.  
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  Surgery EVLA P-Value 
Age (yrs) 49 (37-58) 51 (39-58) 0.601 
Female Gender 65.7% 61.2% 0.433† 
Left leg 54.0% 52.5% 0.803† 
Smoking 
Status 
Ex-Smoker 28.5% 26.5% 
0.805† 
Current Smoker 23.1% 26.5% 
Employed 62.0% 66.9% 0.399† 
Antiplatelet / Anticoagulant 
use 8.8% 6.5% 0.474† 
Height (m) 1.7 (1.6-1.8) 1.7 (1.6-1.8) 0.274 
Body Mass Index (kgm-2) 25.9 (23.1-28.9) 25.3 (23.1-29.1) 0.583 
Diameter GSV (mm): 
Groin 7.5 (6.5-9.6) 8.3 (6.9-10.0) 0.101 
Knee 6.4 (5.4-7.5) 6.3 (5.4-7.7) 0.841 
Venous Clinical Severity Score 4 (3-5) 4 (3-5) 0.919 
CEAP Clinical Grade 
C2 70.1% 68.8% 
0.824† 
C3-C6 29.9% 31.2% 
Aberdeen Varicose Vein 
Questionnaire 
13.7 (9.9-18.2) 12.6 (9.6-17.2) 0.177 
SF
-3
6
 D
o
m
ai
n
s 
 Physical Function 90 (80-100) 90 (75-100) 0.644 
Role-Physical 100 (75-100) 100 (50-100) 0.170 
Bodily Pain 74 (52-100) 74 (52-100) 0.609 
General Health 77 (67-87) 77 (62-92) 0.377 
Vitality 70 (53-80) 70 (55-80) 0.616 
Social Function 100 (75-100) 100 (75-100) 0.242 
Role-Emotional 100 100 0.553 
Mental Health 80 (68-90) 84 (68-92) 0.027 
Euroqol Health Index Score 
0.841 (0.796-
1.000) 
0.848 (0.796-
1.000) 0.954 
SF6D Health Index Score 
0.795 (0.717-
0.847) 
0.804 (0.744-
0.856) 
0.172 
Table 18: Baseline comparison of the groups (Study 2).  SF-36 – UK Short Form-36 V1, Role-
Physical – Role limitation due to physical disability, Role- Emotional – Role limitation due to 
emotional problems, SF6D – Single index utility score derived from SF-36.  Figures are quoted as 
median (inter-quartile range) and the P values are derived from the MWU test unless otherwise 
stated: 
†
 - χ
2
 test   
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3.6 Clinical Outcomes 
Peri-procedural Outcomes 
Procedural details:  In the surgical group the mean (SD) strip length was 33 (11) 
cm.  In the EVLA group the mean (SD) energy density was 95 (15) Jcm-1.  EVLA had 
a marginally longer procedural duration than surgery (mean (SD): 67 (16) versus 61 
(14) minutes – P=0.002 t test).   
 
Procedural setting:  Whilst all EVLA procedures were performed under outpatient 
conditions, unsuitability for day-case general anaesthetic surgery necessitated in-
patient treatment in a proportion of the surgical group and 21% required an 
overnight in-patient stay (P<0.001 χ2). 
 
Technical Success:  Clinical assessment and DUS data was collected within 6 weeks 
of intervention for 96.3% (132/137) of patients post Surgery and 98.6% (137/139) 
post EVLA.  Initial technical success was significantly higher following EVLA 99.3% 
(136/137) versus 92.4% (122/132) (P=0.005 χ2).  The RR of success with EVLA 
compared to Surgery was 1.07 (1.02-1.07), giving a RD of 0.07 (0.02-0.12).  The 
NNT with EVLA rather than Surgery to avoid one failure to complete the planned 
procedure was 14.3 (8.3-50.0). 
The most common failure in the Surgery group was an inability to fully strip the 
incompetent GSV in the thigh due to the vein snapping (6/10).  One of these 
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patients required subsequent EVLA to this remnant by 1 year.  Two of the 10 
Surgery failures were attributable to failed groin dissection secondary to 
significant scarring in patients reporting previous intravenous narcotic use.  One of 
these patients underwent subsequent EVLA.  Finally two patients had a single 
residual groin tributary emanating from the posterior aspect of the common 
femoral vein, this would be difficult to address with a standard surgical approach 
and of doubtful significance: none of these patients required further treatment.  
The technical failure seen in the EVLA group resulted from an inability to cannulate 
the GSV due to spasm.  This patient was happy with the results of their 
phlebectomy alone and has had no further treatment to date.  
 
Pain scores:  EVLA patients reported less post procedural pain than those 
following Surgery.  This was evident from day 1 and maintained until at least day 6 
(P=0.004 - P<0.001 MWU, Table 19, Figure 35). 
 
Day Surgery EVLA P-Value 
0 2.7 (0.9-5.9) 2.0 (0.1-4.9) 0.097 
1 2.2 (0.6-5.0) 1.1 (0.0-3.0) 0.004 
2 1.7 (0.3-4.0) 0.6 (0.0-2.3) <0.001 
3 1.3 (0.2-3.2) 0.2 (0.0-1.5) <0.001 
4 1.4 (0.0-2.8) 0.3 (0.0-1.4) 0.001 
5 1.0 (0.0-2.6) 0.2 (0.0-1.6) 0.001 
6 0.9 (0.0-2.4) 0.0 (0.0-1.0) <0.001 
Table 19: Post-procedural pain scores (Study 2).  Values indicate the med (IQR) scores reported 
on an unmarked visual analogue scale from 0 (“no pain at all”) to 10 (“worst imaginable pain”).  
The P-values are derived from the MWU test 
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Figure 35: Post-procedural pain scores from the day of the procedure (day 0) until day 6 (Study 2).  
The visual analogue scale runs from 0 (“no pain at all”) to 10 (“worst imaginable pain”) 
 
 
Analgesia requirement:  As expected from the pain scores; the Surgical group had 
higher analgesia requirements than the EVLA group over the first week post-
procedure, again evident from day 1 until at least day 6 (P=0.012-P=0.001 – χ2, 
Table 20, Figure 36). 
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Day Surgery EVLA P-Value 
0 68.0% 68.7% 0.904 
1 61.1% 45.4% 0.012 
2 49.2% 33.1% 0.009 
3 41.8% 26.6% 0.011 
4 40.2% 23.4% 0.004 
5 37.7% 21.3% 0.004 
6 35.0% 17.2% 0.001 
Table 20: The percentage of patients requiring supplementary analgesia to control their pain 
over the first post-procedural week, by group (Study 2). Significance testing is with χ
2 
 
 
 
Figure 36: The proportion of patients requiring supplementary analgesia to control their pain in 
the first post-procedural week (Study 2) 
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Complications:  Complications were relatively rare in both groups.  However the 
rates of sensory disturbance, haematoma and infection rates were significantly 
higher in the Surgical group than the EVLA group (Table 21).   
 
  Surgery EVLA P-Value 
Sensory Disturbance 9.8% 2.9% 0.020 
Haematoma 8.3% 0.7% 0.003 
Infection 6.0% 1.5% 0.048 
Phlebitis 4.5% 2.9% 0.536 
Persistent Pain 3.8% 0.7% 0.116 
Pigmentation 0.8% 2.9% 0.371 
GA complications 2.3% 0.0% 0.118 
Persistent Bruising 1.5% 0.7% 0.618 
Allergy 0.8% 0.0% 0.493 
Thromboembolism 0.0% 0.0% N/A 
Table 21: Complications following Treatment (Study 2). Significance testing is with χ
2.
 
 
 
Recovery:  The Surgical group also took longer to return to normal activities than 
the EVLA group; 14 (7-25) versus 3 (1-10) days (P<0.001 MWU).  The same pattern 
was seen in the time taken for employed individuals to return to work 14 (13-28) 
versus 4 (2-14) days (P<0.001 MWU, Figure 37). 
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Figure 37: Time taken to return to work and normal activities post procedure (Study 2) 
 
 
Late Outcomes 
Objective clinical assessment of venous disease:  Both groups saw the same 
significant decrease (improvement) in VCSS scores over the study period from med 
(IQR) 4 (3-5) to 1 (0-1) by 3 months (P<0.001 MWU, Figure 38).  This was 
maintained up to 1 year.  There was no difference between either group at any 
time point. 
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Figure 38: Clinical Severity of Venous Disease, using the Venous Clinical severity score, over time, 
by group (Study 2) 
 
 
Clinical Recurrence:  Clinical recurrence by 1 year was significantly more common 
in the Surgery group than the EVLA group: 20.4% (23/113) versus 4.0% (5/124) 
(P<0.001 χ2, Table 22).  The NNT with EVLA to avoid one clinical recurrence post 
Surgery was approximately 6.  This analysis is based upon those successfully 
followed up and undergoing DUS at 1 year.  A sensitivity analysis was performed 
based upon different assumptions regarding the outcomes of those not followed 
up.  With the exception of the assumption that all EVLA patients lost to follow-up 
underwent clinical recurrence and none of those lost following Surgery did; 
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recurrence remained significantly higher following Surgery, resulting in an 
estimated NNT of approximately between 3 and 8. 
 
Group 
Proportion of 
patients with 
recurrence 
(%) 
P value RR (95%CI) RD (95%CI) NNT (95% CI) 
Surgery 23/113 (20.4) 
<0.001 
0.20 (0.08-
0.50) 
0.16 (0.08-
0.25) 
6.3 (4.0-
12.5) EVLA 5/124 (4.0) 
Assume no lost patients have 
recurred 
0.21 (0.08-
0.55) 
0.13 (0.06-
0.20) 
7.7 (5.0-
16.7) 
Assume all lost patients have 
recurred 
0.42 (0.26-
0.67) 
0.20 (0.10-
0.30) 
5.0 (3.3-
10.0) 
Assume all EVLA lost have 
recurred but no Surgery lost 
recurred 
0.86 (0.49-
1.49) 
0.02 (-0.06- 
0.11) 
N/A 
Assume all Surgery Lost have 
recurred but no EVLA lost 
recurred 
0.10 (0.04-
0.26) 
0.31 (0.22-
0.39) 
3.2 (2.6-4.5) 
Table 22: The proportion of patients by group with clinical recurrence at 1 year (Study 2). The top 
row represents the actual data collected. The bottom half of the table contains a sensitivity 
analysis testing the effect of differing extreme assumptions regarding those lost to follow up 
upon clinical recurrence.  The P value relates to the null hypothesis test that there is no 
significant difference between the groups and is derived using χ
2
. RR is relative risk of clinical 
recurrence following endovenous laser (EVLA) compared to Surgery, RD is risk difference and 
NNT is the number needed to treat with EVLA to avoid 1 case of clinical recurrence at 1 year 
following Surgery 
 
 
Patterns of recurrence:  Up to 1 year, patients regarded as initial technical failures 
in either group have not been shown to suffer a significantly higher incidence of 
clinical recurrence than the technical successes (P=0.427 - P=1.000 χ2); however 
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technical failure was rare in this study and the power to detect this difference is 
consequently low (Table 23).   
Following Surgery, clinical recurrence was most commonly seen in association with 
an incompetent below knee GSV, followed by recurrence from the groin and new 
incompetent perforators.  Of those with recurrence secondary to an incompetent 
below knee GSV, 83% (10/12) of these incompetent segments were amenable to 
EVLA preoperatively and 75% (9/12) were amenable at the time of recurrence; as 
judged by an experienced endovenous surgeon (in one case the vein became too 
tortuous to treat with an endothermal ablative technique during follow-up). 
Recurrence emanating from the groin following successful Surgery was related to 
neovascularisation leading to neoreflux (reflux not evident pre or immediately 
post procedure) in the superficial veins of the thigh, most commonly the ASV.  In 
many cases these incompetent veins were seen to lead back into the perigenicular 
GSV.  Evidence of neovascularisation in the groin was noted from as early as 3 
months following Surgery and seen in 15% (17/113) of cases by 1 year.  53% (9/17) 
of patients with neovascularisation on DUS at 1 year were yet to show evidence of 
clinical recurrence at this time.  
 
The most common feature associated with clinical recurrence following EVLA was 
from disease progression at the groin; this was mainly in the form of neoreflux in 
the ASV.  This pattern appears similar to that associated with groin recurrence 
following Surgery, although no patients demonstrated convincing evidence of 
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neovascularisation.  Three patients showed some evidence of partial 
recanalisation of the treated GSV.  They had received an energy density of 85, 87 
and 112 Jcm-1.  This was compared to the overall mean (SD) of 95 (15) Jcm-1.  Two 
of these cases were yet to result in clinical recurrence by 1 year. 
 
There was no convincing evidence of cross groin or supra-inguinal incompetence 
contributing to any of the observed cases of clinical recurrence.  
 
Group Source of recurrence on DUS Proportion of recurrent cases (%) 
Su
rg
er
y 
Below knee GSV 12/23 (52.2) 
Groin 10/23 (43.5) 
Perforator 9/23 (39.1) 
Saphenopopliteal junction 3/23 (13.0) 
Non-axial branches alone 3/23 (13.0) 
   
EV
LA
 
Groin 2/5 (40.0) 
Below knee GSV 1/5 (20.0) 
Saphenopopliteal junction 1/5 (20.0) 
Recanalisation 1/5 (20.0) 
Non-axial branches alone 1/5 (20.0) 
Table 23: The association of patterns of reflux on DUS with clinical recurrence (Study 2).  Some of 
these patterns (other than “Non-axial branches alone”) coexisted, leading to the total incidence 
of all patterns being higher than the actual number of recurrent cases seen 
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Secondary procedures:  There was no difference between EVLA and Surgery in 
terms of the number, timing or type of additional procedures performed by 1 year 
(P=0.357 – P=0.901 LR, χ2).  18 patients in total had additional procedures.  12 had 
additional procedures for residual disease or technical failure in the absence of 
recurrence.  A greater proportion of patients with clinical recurrence at 1 year 
underwent additional procedures than those without 21.4% (6/28) versus 5.7% 
(12/209, p=0.011 χ2).   
Ten Surgery and seven EVLA patients underwent additional phlebectomy with or 
without additional perforator ligation under local anaesthetic.  Two Surgery 
patients underwent GSV EVLA. One Surgery patient underwent treatment for 
saphenopopliteal insufficiency. 
 
Late Complications:  No further complications were observed in either group up to 
1 year follow-up. 
 
 
3.7 Quality of Life Outcomes 
Generic Quality of Life 
SF-36 profile intragroup analysis  
At 1 week, the Surgical group demonstrated significant deterioration in five of the 
eight SF-36 domains: Physical Function (P<0.001 WSR), Role-Physical (P<0.001 
WSR), Bodily Pain (P<0.001 WSR), Social Function (P=0.001 WSR) and Role-
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Emotional (P=0.029 WSR).  EVLA demonstrated significant deterioration in only 
two of the eight SF-36 domains: Physical Function (P=0.018 WSR) and Role-
Physical (P<0.001 WSR), with preservation of pre-operative scores in the domains 
of Bodily Pain, Social Function and Role-Emotional when compared with Surgery 
(See Table 24, Figure 39 - Figure 46).   
After this initial deterioration, both treatments resulted in significant overall 
improvements in five of the eight domains: Surgery: Physical Function (P<0.001 F-
A), Role-Physical (P=0.040 F-A), Bodily Pain (P<0.001 F-A), General Health (P=0.001 
F-A) and Vitality (P=0.003 F-A).  EVLA: Physical Function (P<0.001 F-A), Role-
Physical (P=0.001 F-A), Bodily Pain (P<0.001 F-A), General Health (P=0.030 F-A) and 
Vitality (P<0.001 F-A). 
 
SF-36 profile intergroup analysis  
The relative preservation of QoL seen in the EVLA group at 1 week resulted in 
significantly higher (better) scores in six of the eight domains than those observed 
in the Surgical group: Physical Function (P=0.012 MWU), Role-Physical (P=0.005 
MWU), Bodily Pain (P=0.031 MWU), Vitality (P=0.049 MWU), Social Function 
(P=0.004 MWU) and Role-Emotional (P=0.027 MWU).  From 6 weeks onwards 
there were no differences between the groups (See Table 24, Figure 39 - Figure 
46).   
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Figure 39: SF-36 Physical Function, over time, by group (Study 2) 
 
Figure 40: SF-36 Role Limitation due to Physical Disability, over time, by group (Study 2) 
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Figure 41: SF-36 Bodily Pain, over time, by group (Study 2) 
 
Figure 42: SF-36 General Health, over time, by group (Study 2) 
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Figure 43: SF-36 Vitality, over time, by group (Study 2) 
 
Figure 44: SF-36 Social Function, over time, by group (Study 2) 
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Figure 45: SF-36 Role Limitation due to Emotional Problems, over time, by group (Study 2) 
 
 
Figure 46: SF-36 Mental Health, over time, by group (Study 2) 
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Week Surgery EVLA 
SF
-3
6
 D
o
m
ai
n
s 
Physical 
Function 
0 90 (80-100) 90 (75-100) 
1 80 (65-90) 88 (70-95) 
52 95 (80-100) 95 (85-100) 
Role-Physical 
0 100 (75-100) 100 (50-100) 
1 50 (0-100) 100 (25-100) 
52 100 100 
Bodily Pain 
0 74 (52-100) 74 (52-100) 
1 62 (41-74) 74 (54-84) 
52 94 (72-100) 100 (72-100) 
General Health 
0 77 (67-87) 77 (62-92) 
1 82 (72-92) 81 (67-92) 
52 82 (72-92) 82 (67-92) 
Vitality 
0 70 (53-80) 70 (55-80) 
1 65 (55-80) 70 (60-80) 
52 75 (65-85) 75 (60-85) 
Social Function 
0 100 (75-100) 100 (75-100) 
1 75 (63-100) 100 (75-100) 
52 100 (75-100) 100 (88-100) 
Role-Emotional 
0 100 100 
1 100 (67-100) 100 
52 100 100 
Mental Health 
0 80 (68-90) 84 (68-92) 
1 84 (68-92) 88 (76-92) 
52 88 (76-92) 88 (74-92) 
Aberdeen Varicose Veins 
Questionnaire 
0 13.7 (9.9-18.2) 12.6 (9.6-17.2) 
1 16.5 (12.2-22.7) 16.6 (12.4-21.1) 
52 2.0 (0-5.3) 2.0 (0-5.3) 
Euroqol Health Index 
Score 
0 0.841 (0.796-1.000) 0.848 (0.796-1.000) 
1 0.801 (0.691-0.895) 0.796 (0.760-1.000) 
52 1.000 (0.841-1.000) 1.000 (0.877-1.000) 
SF6D Health Index Score 
0 0.795 (0.717-0.847) 0.804 (0.744-0.856) 
1 0.759 (0.672-0.830) 0.796 (0.735-0.838) 
52 0.835 (0.777-0.878) 0.843 (0.773-0.876) 
Table 24: Observed health related quality of life (Study 2). SF-36 – UK Short Form-36 V1, Role-
Physical – Role limitation due to physical disability, Role- Emotional – Role limitation due to 
emotional problems, SF6D – Single index utility score derived from SF-36.  Figures are quoted as 
median (inter-quartile range) 
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EQ5D index scores  
Both groups saw a significant decrease (worsening) of EQ5D scores at 1 week 
(Surgery P=0.003 WSR, EVLA P=0.024 WSR).  Again following this there was an 
increase (improvement) in scores over the study period (P<0.001 F-A). There was 
no significant difference between the groups at any time (See Table 24, Figure 47).   
 
 
Figure 47: Euroqol Utility Index Scores, over time, by group (Study 2) 
 
 
SF6D index scores 
A different story was seen with SF6D scores, where deterioration was only evident 
in the Surgical group at 1 week (P<0.001 WSR); scores were preserved in the EVLA 
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group, with no difference from baseline (P=0.141 WSR).  As with EQ5D both 
groups saw significant improvements overall (P<0.001 F-A).  This lack of 
deterioration from pre-operative health status at 1 week in the EVLA group 
resulted in significantly higher (better) scores when compared to patients 
receiving Surgery (P=0.003 MWU) (See Table 24, Figure 48).   
 
 
Figure 48: SF6D Utility Index Scores, over time, by group (Study 2) 
 
 
Disease Specific Quality of Life  
Both groups saw the same significant increase (worsening) in AVVQ scores at 1 
week (P<0.001 WSR).  This in turn was followed by a decrease (improvement) in 
AVVQ scores over the study period from baseline (P<0.001 F-A).  There was no 
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significant difference in AVVQ scores between the groups at any time point (Table 
24, Figure 49). 
Patients with clinical recurrence at 1 year reported significantly higher (worse) 
AVVQ scores than those who did not -  4.6 (1.7-9.4) versus 2.0 (0.0-4.9) (P<0.001 
MWU, Figure 50); demonstrating that although this recurrence is early and 
relatively minor at this stage, there is some early impact upon QoL. 
 
 
Figure 49: Disease Specific Quality of Life Impairment using the Aberdeen Varicose Veins 
Questionnaire, over time, by group (Study 2) 
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Figure 50: Aberdeen Varicose veins Questionnaire results at 1 year for patients with and without 
clinical recurrence at 1 year (Study 2) 
 
 
All of the observed longitudinal and cross sectional changes in QoL instrument 
scores reaching statistical significance in this trial are independently accepted as 
being clinically significant and of a meaningful magnitude (unless otherwise 
stated)49,51,388,389,391. 
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3.8 Patient Satisfaction  
EVLA patients reported slightly higher satisfaction with the cosmetic outcome of 
the procedure at 1 year (P=0.034 MWU), however there was no significant 
difference in satisfaction with the overall treatment (Figure 51). 
Patients with early evidence of clinical recurrence reported lower satisfaction in 
terms of cosmesis - 8.0 (7.0-9.7) versus 9.8 (9.0-10.0) (P<0.001 MWU) and overall 
satisfaction - 9.9 (8.2-10) versus 10 (9.5-10) (P=0.016 MWU, Figure 52).   
 
 
Figure 51: Patient reported satisfaction with the cosmetic outcome and the overall treatment by 
treatment group (Study 2). Values indicate the reported on an unmarked visual analogue scale 
from 0 (“Completely unsatisfied”) to 10 (“Completely satisfied”) 
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Figure 52: Patient reported satisfaction with the cosmetic outcome and the overall treatment in 
those with and without clinical recurrence at 1 year (Study 2). Values indicate the reported on an 
unmarked visual analogue scale from 0 (“Completely unsatisfied”) to 10 (“Completely satisfied”) 
 
 
Study 3; Procedure refinement – Energy delivery 
during 810nm endovenous laser ablation of superficial 
venous insufficiency and post-procedural morbidity 
 
3.9 Patient Recruitment and Baseline Analysis 
Some 232 patients were included in this analysis with attention to the inclusion 
and exclusion criteria outlined for the study.  The mean (range) age was 50 (18-83) 
years.  63% were women.  The mean diameter for each treated vein was 
calculated by dividing the sum of the diameter 1cm distal to the junction and the 
diameter at the point of cannulation by 2.  The mean (range) diameter of the vein 
224 
 
segments treated was therefore 7.4 (3.0-16.4) mm (assuming uniformity).  There 
was no statistical difference between the energy given to men or women (P=0.404 
t test) and therefore no further gender-specific analysis was performed.  Baseline 
clinical severity scores and quality of life are shown in Table 25.  No further 
analysis was performed of baseline data as its inclusion in the models themselves 
controls for any variation, precluding the necessity. 
 
 
Baseline 1 Week 6 Weeks 
Venous Clinical 
Severity Score  
4 (3-5) N/A N/A 
Aberdeen Varicose 
Vein Questionnaire 
12.9 (9.9-17.8) 16.8 (12.8-21.8) 8.1 (4.7-12.9) 
Euroqol Health Index 
Score 
0.796 (0.760-
1.000) 
0.796 (0.708-
1.000) 
1.000 (0.796-
1.000) 
SF
-3
6
 D
o
m
ai
n
s 
Physical 
Function 
90 (75-100) 85 (70-95) 95 (80-100) 
Role- Physical 100 (50-100) 75 (0-100) 100 (75-100) 
Bodily Pain 74 (51-84) 74 (51-84) 84 (62-100) 
General Health 77 (60-90) 77 (67-92) 82 (67-92 
Table 25: Clinical and quality of life measures at baseline, 1 week and 6 weeks post-procedure 
(Study 3).  SF-36 – UK Short Form-36 V1, Role-Physical – Role limitation due to physical disability.  
Figures are quoted as median (inter-quartile range) 
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3.10 Clinical Outcomes 
Energy delivery:  The mean (range) energy delivery used was 89.8 (44.5-158.4) 
Jcm-1. 
 
Setting:  All procedures were performed under local anaesthetic in an outpatient 
setting.  No patients required sedation or an overnight stay.   
 
Pain scores:  There was no statistically significant relationship between the energy 
delivered and the magnitude of post-procedural pain reported by patients (Table 
26). 
 
Day Pain Score Effect size Proportion of Variance (R2) P-Value 
0 1.7 (0.3-4.9) -0.16 2.7% 0.087 
1 1.2 (0.0-3.0) -0.15 2.2% 0.154 
2 0.6 (0.0-2.1) 0.06 0.4% 0.570 
3 0.2 (0.0-1.5) 0.05 0.3% 0.649 
4 0.3 (0.0-1.3) 0.03 0.1% 0.821 
5 0.2 (0.0-1.5) 0.07 0.5% 0.559 
6 0.0 (0.0-1.0) 0.08 0.6% 0.562 
Table 26: Results of a linear regression model analysing the effect of linear energy delivery (Jcm
-1
) 
on patient reported post-procedural pain scores (Study 3).  Pain score values indicate the med 
(IQR) scores reported on an unmarked visual analogue scale from 0 (“no pain at all”) to 10 
(“worst imaginable pain”).  The effects of age, gender, body mass index, vein dimensions and 
pre-procedural quality of life are controlled 
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Analgesia requirement:  There was no statistically significant relationship between 
the energy delivered and the requirement for supplementary analgesia during the 
first post-procedural week (Table 27). 
 
Day Percentage of Patients Odds Ratio (95% CI) P-Value 
0 64.6 1.002 (0.995-1.031) 0.154 
1 45.5 1.016 (0.998-1.033) 0.078 
2 32.1 1.002 (0.984-1.021) 0.805 
3 21.5 1.009 (0.986-1.032) 0.461 
4 17.2 1.005 (0.981-1.030) 0.669 
5 18.7 1.010 (0.987-1.034) 0.405 
6 14.4 1.005 (0.979-1.032) 0.693 
Table 27: Results of a logistic regression model analysing the effect of linear energy delivery (Jcm
-
1
) on the proportion of patients requiring supplementary analgesia to control their pain (Study 3). 
The effects of age, gender, body mass index, vein dimensions and pre-procedural quality of life 
are controlled 
 
 
Recovery:  Increasing energy delivery also had no demonstrable effect upon the 
number of days taken to return to work or to other activities (Table 28). 
 
 
 
 
227 
 
 
 
Recovery Time 
in Days 
Effect size 
Proportion of 
Variance (R2) 
P-Value 
 Work 4 (1-11) -0.18 3.4% 0.088 
 Normal activity 3 (1-14) -0.11 1.2% 0.210 
Table 28: Results of a linear regression model analysing the effect of linear energy delivery (Jcm
-1
) 
on the time taken by patients to return to work and return to normal activities (Study 3).  
Recovery time values indicate the med (IQR) number of days reported.  The effects of age, 
gender, body mass index, vein dimensions and pre-procedural quality of life are controlled 
 
 
Complications:  Complications were uncommon and therefore were insufficient to 
allow meaningful further detailed analysis (Table 29). 
 
 
 
Sensory Disturbance 3.7% 
Phlebitis 2.1% 
Pigmentation 1.7% 
Infection 1.2% 
Haematoma 0.4% 
DVT 0.0% 
Table 29: Percentage of patients with complications (Study 3) 
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3.11 Health Related Quality of Life Outcomes 
The QoL data at each time point is summarized in Table 25.  Increasing energy 
delivery had no statistically significant effect upon generic QoL outcomes or 
disease specific AVVQ scores at 1 week (Table 30).  At 6 weeks, there was a weak 
association between increasing energy delivery and higher (worse) AVVQ scores.  
This was of borderline statistical significance and accounted for only 3.1% of the 
variance at this time point.  This brings into doubt the clinical significance of this 
finding. 
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Week Effect Size 
Proportion of 
Variance (R2) 
P-Value 
SF
-3
6
 D
o
m
ai
n
s 
Physical Function 
1 
0.06 0.4% 0.451 
Role-Physical 0.05 0.3% 0.536 
Bodily Pain 0.08 0.6% 0.344 
General Health 0.13 1.8% 0.111 
Physical Function 
6 
0.16 2.6% 0.072 
Role-Physical 0.16 2.6% 0.073 
Bodily Pain 0.13 1.6% 0.162 
General Health 0.12 1.4% 0.203 
Aberdeen Varicose Vein 
Questionnaire 
1 0.06 0.4% 0.464 
6 -0.18 3.1% 0.050 
Euroqol Health Index 
Score 
1 0.06 0.4% 0.484 
6 0.08 0.6% 0.402 
Table 30: Results of the linear regression model charting the effect of linear energy delivery (Jcm
-
1
) on post-procedural quality of life (Study 3). SF-36 – UK Short Form-36 V1, Role-Physical – Role 
limitation due to physical disability.  The effects of age, gender, body mass index, vein 
dimensions and pre-procedural quality of life are controlled 
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Chapter 4 - Discussion 
 
These three studies all provide a significant contribution to the evolving literature 
focused upon the use of minimally invasive interventions for the treatment of SVI.  
Study 1 was the first trial designed to explore the impact of different treatment 
approaches in the management of tributaries aiming to establish the optimal 
treatment of non axial SVI.   
Study 2 was not the first randomised trial to present its findings of a comparison of 
minimally invasive treatment with the gold standard of conventional surgery.  
However, it was the first to focus upon the true outcome of interest in venous 
intervention; namely health related quality of life.  It was the first trial with 
sufficient power to allow in-depth analysis of health-related quality of life; 
powered to detect small, but significant differences in quality of life and the first 
to clearly elicit the benefits of this new technology.   
Finally Study 3 was the first to explore the link between the safety and morbidity 
of the EVLA procedure with the magnitude of energy applied to the target vein; 
aiming to shed light onto the debate regarding the optimum energy delivery to 
balance recanalisation and potential harm.  
Previous studies have centred on technical and safety outcomes, and have shown 
new endothermal ablative techniques in particular to be safe336 and result in 
better duplex derived outcomes than conventional surgery332.  The hope is that 
recurrence rates will be reduced in the long term, although a clear understanding 
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of the impact of the milder degrees of recurrent veins on QoL has yet to be 
ascertained.  Until now, there has been little hard evidence to show that EVLA, or 
the other technologies, demonstrates measurable QoL benefits over conventional 
surgery. 
What has been shown clearly is that successful treatment of venous insufficiency 
results in significant QoL improvements50.  Minimally invasive techniques have 
been demonstrated to result in less post-procedural pain than surgery312,372,392-394, 
and allow an earlier return to work and normal activities392-395, although this has 
not been a unanimous finding312,396. 
 
 
4.1 Effectiveness 
Study 1 illustrates that EVLA with or without concomitant phlebectomy is a 
popular, effective and well tolerated procedure.  EVLA improves objective clinical 
venous severity, resulting in significant benefits in QoL.  Study 2 confirms that both 
surgery and EVLA are popular and equally highly efficacious interventions.  Both 
treatments result in significant improvements in the objective severity of venous 
disease, with lower VCSS values after treatment.  This subsequently produced a 
decrease in AVVQ scores, signifying a reduction in the impact of venous disease on 
QoL, which in turn had a positive effect on generic QoL.  Primarily the physical, 
rather than emotional and psychological, attributes of health were improved, 
enhancing overall QoL, as evidenced by QALY gains.  This is in agreement with the 
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findings of a study modelling the quality of life impairment seen in association 
with SVI, where the reported morbidity was centred on physical domains44.  It has 
been shown that cosmetic concern is most closely associated with mental health46, 
highlighting the dominance of physical rather than cosmetic concerns of sufferers. 
Patient satisfaction is known to be low following venous surgery298 and it is 
reassuring to see such high rates following either treatment.  There is a trend that 
fewer patients are being referred for treatment of varicose veins in the UK265.  The 
data from this and other studies43,50,268,397 suggest that treatment results in 
significant, durable improvement in QoL. 
Study 1 indicates that concomitant ambulatory phlebectomy alongside EVLA is 
feasible under local anaesthetic as an outpatient procedure.  It is well tolerated, 
with no significant increase in postoperative pain detected.  There was a trend 
towards faster recovery in those who had EVLA alone, but this did not reach 
statistical significance owing to the small sample size and the additional recovery 
period following any subsequent procedures was not accounted for in this 
comparison.  EVLTAP took a median of 20 minutes longer to perform, but to 
counter this; two-thirds of patients in the Control group returned for subsequent 
phlebectomy, which was reflected in significantly worse VCSS values at 3 months.   
This inconvenience and morbidity of subsequent procedures resulted in a 
demonstrably poorer disease specific QoL at 6 weeks and 3 months.  If patients do 
not undergo phlebectomy at the time of initial treatment, it takes up to a year to 
see the same QoL benefit as in those who have EVLTAP. 
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One question that cannot be answered is whether the patients who had not 
undergone phlebectomy by 1 year would have benefited from it, or whether it 
would have been an unnecessary procedure.  The Control group continued to have 
higher AVVQ scores at 1 year, although this did not reach statistical significance.  It 
seems unlikely that patients undergoing phlebectomy after 6 weeks would have 
been significantly worse than those in the EVLTAP group at 1 year.  It is therefore 
possible that that those who did not have phlebectomy account for this difference 
at 1 year, although this involved only eight patients.  The lack of significant 
difference in any of the psychological domains of SF-36 suggests that the observed 
differences in AVVQ scores were due to the specific venous symptoms and not to 
the negative psychological effect of having residual veins. 
Although the EVLTAP group showed a significant improvement in EQ-5D scores 
from 6 weeks, there was no improvement in the Control group.  This would 
suggest a generic QoL benefit in favour of EVLTAP, but this was not proven on 
intergroup analysis.  It is possible that this represents a type II error, as the 
sensitivity of the EQ-5D is relatively low and the study was not powered to analyse 
intragroup EQ-5D scores. 
Comparison of studies which utilise laser therapy alone, or in combination with 
concomitant phlebectomy, but do not directly compare the two approaches, is 
difficult due to variation in study design.  However, we can be certain that 
combining laser therapy with concomitant phlebectomy significantly reduces the 
requirement for subsequent interventions in this randomised clinical trial from 
67% to 4%.  In other studies the requirement for secondary procedures following 
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isolated laser therapy varies considerably from 17% to 95%393,398,399.  Secondary 
procedures are unpopular with patients; with 71% wanting full treatment of their 
varicose veins in a single visit365.  This one stop, single treatment seems attractive 
to both patients and surgeons who appear to be voting with their feet400-402.   
On the basis of the Study 1 findings; it was decided that the EVLA group in Study 2 
should receive concomitant ambulatory phlebectomy.  As discussed above; Study 
2 confirmed equivalent improvements in objective disease severity and quality of 
life up to 1 year following both EVLA and surgery.  In a trial with the power of 
Study 2 and given the differences observed in Study 1; if concomitant 
phlebectomy had not been employed in the EVLA arm, it seems likely that there 
would have been a significant deficit in clinical and symptomatic improvement 
when compared with surgery.   
The next issue to explore was whether EVLA addresses any of the limitations of 
conventional surgery (See p117).  
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4.2 Post-procedural Morbidity  
Any invasive procedure will have some negative short-term impact on QoL, but 
this was minimized in the group receiving EVLA.  The surgery group had a 
significant deterioration in early QoL, whereas QoL was relatively preserved 
following EVLA.  Patients who had EVLA saw less disruption in their activities of 
daily living, and returned to normal within less time.  The time taken to return to 
work is known to be influenced by multiple factors403,404.  However, the groups in 
this study were well matched at baseline, and efforts were made to give the same 
advice regarding the expected convalescence.  Thus the difference of 10 days 
reported here is likely to be real.   
It is important to note that despite any concerns regarding additional pain and 
prolonged healing following concomitant phlebectomy; this study clearly shows 
that EVLA with concomitant phlebectomy is superior to what was widely regarded 
as current best practice. 
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4.3 Recurrence 
Analysis of 64 prospective studies of endovenous treatments for varicose veins 
suggested that freedom from incompetence on duplex ultrasound examination 
was more likely at 5 years after EVLA than following surgery (95.4 versus 
75.7%)332.  However this paper was criticised for compiling data from hetrogenous 
case series with hetrogenous outcomes.  Study 2 has clearly confirmed the higher 
rates of early clinical recurrence following surgery compared with EVLA.  The fear 
of recurrence is significantly high amongst patients (90%)365 making this a 
significant issue irrespective of the uncertainty surrounding the degree of 
associated quality of life impairment.  It has been claimed that the observed high 
recurrence rates following surgery for varicose veins are related to the technical 
inadequacy of the initial procedure299,405-407.  This has been challenged; recurrence 
after surgery is progressive from as early as 3 months, at sites that had undergone 
proven technically adequate surgery296.  This was shown again here, as 
postoperative duplex imaging confirmed the adequacy of standard groin surgery in 
all but two patients; yet almost half of recurrences were related to recurrent groin 
incompetence and 15.0% overall had convincing evidence of neovascularisation by 
1 year.  Another large duplex ultrasound study of 264 legs with symptomatic 
recurrent veins found that 70.8% had groin recurrence (20.4% due to an intact SFJ, 
leaving 50.4% due to neovascularisation) and 57.2% had residual incompetent 
GSVs408.  About half of the patients in Study 2 with neovascularisation have not yet 
suffered a clinical recurrence.  Given the evidence to date, if they do; the gap 
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between EVLA and surgery may be widened further, even in the absence of the 
development of more sources of neoreflux. 
Neovascularisation has been implicated as the leading cause of surgical recurrence 
in several studies294,302,408-410 with rates as high as 52% at 2 years294,305 and 79% at 
5 years291,296; evidence of neovascularisation on duplex imaging at 1 year has 
shown a positive predictive value for clinical recurrence of 70–100%411.  This is 
ultimately linked to the need for reintervention297.  Barrier techniques aiming to 
reduce the rates of neovascularisation have shown mixed results291,304-309,412 and 
are not in widespread routine use.  Neovascularisation is thought to be the result 
of angiogenesis following the tissue trauma of surgical dissection410, whereas it is 
speculated that extra venous inflammation does not occur following EVLA.  It has 
also been suggested that the preservation of groin tributaries during EVLA avoids 
the stimulus for angiogenesis348; some surgeons even preserve groin tributaries 
during saphenofemoral ligation on this basis413.  It seems naive to believe that 
EVLA causes no extra venous inflammation.  Anecdotally groin dissections 
following EVLA recurrence secondary to groin tributaries has found evidence of 
fibrosis.  Irrespective of these arguments, neovascularisation appears rare 
following EVLA.   
This trial also demonstrated a flaw in the widely practised principle of only 
stripping the GSV to the knee.  Below knee GSV reflux is especially significant, due 
to its association with CVI (See Table 3, p39) and therefore it can be argued that 
this mandates particular attention during treatment.  The largest number of 
recurrences were also associated with incompetence in the below-knee GSV408,409 
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and on detailed analysis there is some suggestion that the occurrence of above-
knee neoreflux may be associated with residual below knee disease.  If proven 
definitively, this would clearly lend some support to the ascending theory of 
venous insufficiency (See The Pathogenesis of Primary Venous Insufficiency p49).  
It has been argued that the length of GSV stripping should be dictated by the 
length of refluxing vein and not concerns over injury to the saphenous nerve285-287; 
full-length stripping remains controversial.  Below-knee EVLA, in contrast, is safe 
and effective as shown in this study and others399,414 and many of the incompetent 
below knee segments in the surgical arm would have been amenable to treatment 
with EVLA initially. 
Several independent research groups have established that the magnitude of 
energy delivery during EVLA is the most important predictor of success366-368 and 
increasing energy delivery has resulted in improved occlusion rates369,370. 
Commonly energy deliveries of around 20-40 Jcm-1 or equivalent fluence 
calculations have been used, but the current best evidence points to improved 
results at energies higher than this and many providers now use 80-100 Jcm-1. 
Despite this, 100% success remains an elusive goal.  The reluctance to increase 
energy delivery further is most likely due to concerns that this may result in 
increased morbidity and complications from the procedure.  There is however, no 
evidence that this is the case, when EVLA is performed using tumescent 
anaesthetic solution. 
Early recurrence is uncommon following EVLA in Study 2 and all but one of those 
observed were associated with the development of new incompetence, including 
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in the groin tributaries, which occurs despite a policy of placing the fibre tip at the 
SFJ.  This has been observed previously415, although some claim that such 
tributaries are insignificant416.  It is difficult to suggest how this can be prevented 
and it seems likely that, alongside neoreflux in the saphenopopliteal junction, 
perforators and non-axial branches, it represents natural background disease 
progression.  All three patients who had recanalisation after EVLA in this trial were 
treated above the previously recommended 810nm energy density threshold of 60 
Jcm-1 367, suggesting that this threshold may be too low.  No recanalisation was 
seen when energy densities above 115 Jcm-1 were used. 
One would expect that increasing the magnitude of energy delivery to the vein 
would increase the magnitude of tissue damage created, increasing both pain and 
swelling, alongside analgesia requirement.  This should then have a detectable 
impact upon quality of life, reducing mobility and general health perception.  
Patients would take longer to recover.  Moreover, transmission of thermal energy 
beyond the vein should, in theory damage surrounding structures resulting in 
higher complication rates.  Study 3 does not support this proposed theorem 
(within the range of energy utilized).  Increasing energy had no effect upon pain or 
analgesia requirements.  The effect of energy upon AVVQ scores at 6 weeks is of 
borderline statistical significance and doubtful clinical significance; energy 
accounts for just 3.1% of the variation.  It has been previously found that generic 
QoL analysis is more sensitive to the QoL changes associated with periprocedural 
morbidity than AVVQ417 and yet there was no difference seen in either of the 
instruments analysed.  It follows therefore that there was no effect upon recovery 
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times and complication rates were low, adding further support to the evidence 
that EVLA is a very safe procedure332,333,336.  The sample size used in this analysis is 
double that required for testing the significance of an individual predictor, and so 
it is unlikely that any significant relationship has been missed.   
It seems likely that these results are explained by the use of tumescent local 
anaesthetic.  Accurate and meticulous infiltration of local anaesthetic around the 
vein causes hydro-dissection of the surrounding tissues away from the vein and 
the laser fibre.  This fluid collapses the vein around the fibre and acts as a heat 
sink, reducing the transmission of thermal energy by convection and conduction 
beyond the vein wall.  The 810nm photons from this laser are primarily absorbed 
by haemoglobin within the blood327, minimizing the transmission of radiant energy 
beyond the vein, also trapping the heat where it is needed: inside the vein.  This 
may not be the case with longer wavelengths, which are primarily absorbed by 
water, and may therefore be transmitted to the heat sink and possibly beyond. 
The early benefits of concomitant phlebectomy and treatment of incompetent 
perforators upon effectiveness has been discussed above, however it is possible 
that they could have a favourable impact upon disease recurrence also.  The 
ascending theory of venous insufficiency (See The Pathogenesis of Primary Venous 
Insufficiency p49) would suggest that unaddressed tributary incompetence will 
gradually result in the development of further disease more proximally.  It is 
therefore uncertain whether these results can be applied to the simple treatment 
of isolated superficial axes with EVLA alone, either in terms of early efficacy or 
later recurrence.  These studies do not at present provide clear evidence on this 
241 
 
issue and Study 1 is clearly not powered to look at recurrence; only a handful of 
patients got to 1 year without requesting further intervention.  
 
 
4.4 Additional Findings 
Cost utility analysis in economic evaluation requires the use of utility scoring 
systems to estimate the QALY value associated with differing health states.  The 
different utility scoring systems, lead to different results, therefore 
standardisation is required.  In the UK, NICE recommends that cost utility analysis 
should utilise EQ5D190 and it is also the chosen generic instrument for the routine 
collection of patient-reported outcome measures in the UK191.  However the 
newer SF6D has shown some relative advantages.  Firstly it can be derived from 
previous studies using SF36 or SF12, when no dedicated utility scoring system was 
utilised.  Additionally, the theoretical basis at the heart of SF6D is the standard 
gamble and the principle of decision making with uncertainty.  This is felt by 
purists to be the optimum method for valuing health states (See Index utility p95).  
Finally Study 2 highlights the increased sensitivity of SF6D, allowing it to detect 
differences missed by EQ5D.   
It has been noted previously that EQ-5D is a relatively insensitive instrument, 
particularly when used in situations such as Study 250,222,418.  These findings 
challenge the place of EQ5D in this context; however despite the drawbacks of 
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QALY league tables when comparing different healthcare programmes212, analyses 
must be made using broadly similar units.  This is because the principle of rational 
economic decision making under a fixed budgetary constraint relies upon the 
adoption of an economically favourable programme by the sacrifice of the least 
favourable programme(s), thus freeing the required resources.  This process 
clearly cannot be undertaken with any certainty if programmes are not valued in 
the same units.  The adoption of a new index system would therefore require a 
“currency exchange” across the entire healthcare landscape.  
 
 
4.5 Critique 
In common with most comparative trials of SVI treatment, neither the patients nor 
the assessors could be blinded to the techniques used.  The risk of observer bias 
was reduced, however, as the majority of key outcomes reported (including the 
primary outcomes) were reported independently by the patient.  Those observed 
by an assessor were registered using objective and validated instruments.  
Furthermore specific imaging protocols and definitions were also used to minimize 
the possibility of bias.   
As with all trials of venous interventions; continued and complete follow-up is 
challenging.  This did not have a critical effect on the power of the trials for 
example, in Study 2; a sensitivity analysis explored the confidence of the results 
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given extreme assumptions regarding those lost to follow-up.  EVLA reliably had 
lower recurrence rates at all sensible assumptions.  Follow-up on the whole was 
relatively short following venous intervention and data acquisition must continue.   
The inclusion and exclusion criteria were fairly specific.  In designing these trials, 
the aim was to produce studies which gave clarity in the outcome and 
interpretation, while being a true reflection of clinical practice in the UK.  QoL data 
are subject to significant degrees of unsystematic variation, leading to problems 
with statistical interpretation.  Therefore, it was felt important to minimize 
variation and allow meaningful differences to be uncovered.  
A criticism of Study 2 is that patients in the surgery arm underwent conventional 
inversion stripping under general anaesthesia.  This reflects the predominant 
practice in the UK.  Newer techniques such as cryostripping, or the use of 
tumescent anaesthesia for surgical stripping are described, but there is little 
convincing evidence to date that these will significantly improve short-term 
outcomes following surgery312,315,393. 
A criticism of Study 3 is that although all patients underwent some concomitant 
treatment (phlebectomy and/or perforator ligation), the extent of these 
procedures could not be controlled between individuals. However; these 
procedures maximize the quality of life benefits of treatment (as per the findings 
of Study 1) and achieve the much desired aim of one-stop treatment419-421.  This 
study therefore aimed to reflect true clinical practice with the aim of allowing the 
results to be generalized. 
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4.6 Further Avenues of Research 
The popularity of minimally invasive techniques for the treatment of superficial 
venous insufficiency has led to a series of studies aiming to establish which is 
optimal.  A large industry has developed centred around these technologies, and 
with a market of such considerable size, financial backing has found its way in the 
form of industry sponsored studies.  Some question the quality and validity of 
some of the resultant findings and it is difficult to make any firm conclusions at 
present.  A detailed discussion of the evidence to date is beyond the scope of this 
thesis, which was designed to establish the relationship of one of these 
technologies with the gold standard.  There is little conclusive evidence to date 
that one approach is an obvious leader, but each has its advocates and each has 
comparative strengths and weaknesses in different situations.  This has led to a 
number of surgeons using differing techniques in different situations and the 
mixed use of technology in the same patient, particularly in the treatment of 
recurrence is not uncommon. 
Presently there is much debate around the use of higher wavelength lasers and 
specialised fibre-tips.  To date there is no conclusive evidence supporting 
improved results and care must be taken in this area.  The thermodynamic and 
absorption profile of different wavelengths of laser are different.  The hope is that 
this will lead to improved morbidity and side-effect profiles, but this could go the 
other way344 and using water specific wavelengths could see greater quantities of 
energy being transferred to the tumescent anaesthetic attenuating its effect as a 
“heat shield”.  It is also incorrect to assume that the recanalisation rates for short 
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wavelength lasers at specific energy densities can simply be applied to the new 
wavelengths or fibre tips altering the density of laser delivery, in the same way 
that the long term results of direct RFA cannot be applied to the ClosureFAST® 
device.     
Economic analysis is a critical component of health technology assessment, more 
so now than ever.  Economic modelling is an established technique, but the 
validity of its findings is entirely dependant upon the credible valuation of the 
QALY associated with each health state and the probability of transition between 
states.  This process has clearly established the superiority of conventional surgery 
when compared with conservative management in the REACTIV trial50.  To date 
there has been only one detailed attempt at this for the modern management of 
SVI422.  This was a high quality Markov model analysis, finding EVLA under 
tumescent anaesthetic to have the highest probability of all treatments of being 
cost effective at the commonly quoted UK NHS threshold of £20 000 per QALY.  
Below this came day-case surgery (under GA) and then RFA (under tumescent 
anaesthetic).  Foam sclerotherapy was dominated due to the assumption of high 
recurrence and re-intervention rates.  An additional finding was that EVLA and RFA 
with concomitant phlebectomy under a GA was less likely to be cost effective than 
simple day-case surgery under GA.  There were however flaws in the analysis:  QoL 
following successful intervention was assumed to be the same for all groups 
(Study 2 disproves this).  It was assumed that a GA would be required to perform 
concomitant phlebectomy (Study 1 disproves this).  Some authors would also 
object to the high levels of recurrence assumed following foam 
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sclerotherapy358,359.  This paper therefore highlighted some of the issues with the 
current literature which need addressing to take such an analysis forward.  
Another such issue is the nature of recurrence.  Little is known of the QoL impact 
of early recurrence.  There is no doubt that by the time such cases present in clinic 
requesting treatment, there is little difference between them and those with no 
history of intervention, however it is impossible to draw firm conclusions 
regarding the significance and natural history of early recurrence seen on intensive 
follow-up such as that seen in Study 2.  Further work in this area and upon the 
natural history of venous disease in general, will improve patient selection and 
inform economic models, allowing the extrapolation of such analyses over the 
appropriate time frame: a patient’s lifetime.  This area of economic analysis also 
highlights a methodological debate.  Conventionally health economic analysis is 
performed from the perspective of the healthcare system; often (possibly 
erroneously) labelled as the “third party payer”.  Whilst from an international 
perspective this allows information transfer between differing models of 
healthcare provision, in the UK (where society is the third party payer); a societal 
perspective is arguably a more appropriate viewpoint.  This would then consider 
the impact of minimally invasive treatments upon lost productivity and time spent 
away from employment.   
A further area requiring additional study is the treatment of venous ulceration.  
Most cases of venous ulceration involve SVI (See Patterns of Reflux, p36) and the 
degree of venous hypertension is therefore amenable to reduction by the 
treatment of SVI.  Whilst surgery for SVI is yet to be shown to improve ulcer 
247 
 
healing, it does decrease recurrence256,257.  A significant proportion of patients 
with venous ulcers are elderly, with significant co-morbidities making them less 
suitable for treatment under GA.  In addition around 25% of patients refuse 
conventional surgery, when offered256,423 .  The potential advantages of minimally 
invasive intervention are clear and research in this area is required. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
248 
 
4.7 Conclusions 
SVI is a very common disease and results in significant impairment in health 
related QoL.  The treatment of SVI has been demonstrated to be highly effective; 
improving QoL with an extremely competitive economic profile. 
Endothermal ablation with EVLA of SVI is a popular, safe and effective treatment 
resulting in equivalent health benefits over time to those seen following 
conventional open surgery.  Additionally EVLA addresses the limitations of 
conventional surgery; minimising the disruption in sufferer’s lives and careers; 
resulting in superior post-procedural QoL and reducing early recurrence rates. 
Concomitant phlebectomy with EVLA is feasible and acceptable to patients under 
local anaesthetic.  The use of general anaesthesia negates some of the benefits 
and in particular has been shown to be economically non-viable.  The application 
of concomitant phlebectomy virtually eliminates the need for any subsequent 
interventions and results in superior QoL benefits for at least the first year.  There 
is no clear associated increase in post-procedural pain or time to recovery and 
patient satisfaction is very high.  The only discernable disadvantage seems to be a 
small increase in operative time and the vast reduction in secondary procedures 
more than compensates for this. 
In experienced hands 810 nm EVLA is safe and effective, with no evidence of 
increased complications or morbidity associated with increasing energy delivery in 
the range studied.  This confidence in the safety of EVLA has allowed the increase 
in applied energy density to result in enviably low recanalisation rates, but the 
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optimal energy required to result in 100% closure rates is yet unknown.  It is likely 
that the aim of durable one-stop treatment, first time, and every time is possible. 
The benefits of minimally invasive intervention with EVLA and concomitant 
phlebectomy mandate the consideration of adoption of this technology as the 
gold standard treatment for SVI. 
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